

Multi-organ Proteomic Landscape of COVID-19 Autopsies

Xiu Nie ^{1#}, Liuja Qian ^{2,3#}, Rui Sun ^{2,3#}, Bo Huang ^{1#}, Xiaochuan Dong ^{1#}, Qi Xiao ^{2,3#}, Qiushi Zhang ^{2,3#}, Tian Lu ^{2,3}, Liang Yue ^{2,3}, Shuo Chen ¹, Xiang Li ¹, Yaoting Sun ^{2,3}, Lu Li ^{2,3}, Luang Xu ^{2,3}, Yan Li ¹, Ming Yang ¹, Zhangzhi Xue ^{2,3}, Shuang Liang ^{2,3}, Xuan Ding ^{2,3}, Chunhui Yuan ^{2,3}, Li Peng ¹, Wei Liu ^{2,3}, Xiao Yi ^{2,3}, Mengge Lyu ^{2,3}, Guixiang Xiao ¹, Xia Xu ¹, Weigang Ge ^{2,3}, Jiale He ^{2,3}, Jun Fan ¹, Junhua Wu ¹, Meng Luo ^{2,3,4}, Xiaona Chang ¹, Huaxiong Pan ¹, Xue Cai ^{2,3}, Junjie Zhou ¹, Jing Yu ^{2,3}, Huanhuan Gao ^{2,3}, Mingxing Xie ⁵, Sihua Wang ⁶, Guan Ruan ^{2,3}, Hao Chen ^{2,3}, Hua Su ⁷, Heng Mei ⁸, Danju Luo ¹, Dashi Zhao ¹, Fei Xu ⁴, Yan Li ¹⁰, Yi Zhu ^{2,3*}, Jiahong Xia ^{9*}, Yu Hu ^{8*}, Tiannan Guo ^{2,3,11*}

¹ Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

² Zhejiang Provincial Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China

³ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China

⁴ Department of Anatomy, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China

⁵ Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁶ Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁷ Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁸ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁹ Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

¹⁰ Department of Anatomy and Physiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, 200025, China

¹¹ Lead contact

These authors contribute equally

* Correspondence: zhuyi@westlake.edu.cn (Y.Z.); jiahong.xia@hust.edu.cn (H.X.); dr_huyu@126.com (Y.H.); guotiannan@westlake.edu.cn (T.G.).

40 **HIGHLIGHTS**

41

- 42 • Characterization of 5336 regulated proteins out of 11,394 quantified proteins
43 in the lung, spleen, liver, kidney, heart, thyroid and testis autopsies from 19
44 patients died from COVID-19.
- 45 • CTSL, rather than ACE2, was significantly upregulated in the lung from
46 COVID-19 patients.
- 47 • Evidence for suppression of glucose metabolism in the spleen, liver and
48 kidney; suppression of fatty acid metabolism in the kidney; enhanced fatty
49 acid metabolism in the lung, spleen, liver, heart and thyroid from COVID-19
50 patients; enhanced protein translation initiation in the lung, liver, renal medulla
51 and thyroid.
- 52 • Tentative model for multi-organ injuries in patients died from COVID-19:
53 SARS-CoV-2 infection triggers hyperinflammatory which in turn induces
54 damage of gas exchange barrier in the lung, leading to hypoxia, angiogenesis,
55 coagulation and fibrosis in the lung, kidney, spleen, liver, heart, kidney and
56 thyroid.
- 57 • Testicular injuries in COVID-19 patients included reduced Leydig cells,
58 suppressed cholesterol biosynthesis and sperm mobility.

59

60 ABSTRACT

61
62 The molecular pathology of multi-organ injuries in COVID-19 patients remains
63 unclear, preventing effective therapeutics development. Here, we report an in-depth
64 multi-organ proteomic landscape of COVID-19 patient autopsy samples. By
65 integrative analysis of proteomes of seven organs, namely lung, spleen, liver, heart,
66 kidney, thyroid and testis, we characterized 11,394 proteins, in which 5336 were
67 perturbed in COVID-19 patients compared to controls. Our data showed that CTSL,
68 rather than ACE2, was significantly upregulated in the lung from COVID-19 patients.
69 Dysregulation of protein translation, glucose metabolism, fatty acid metabolism was
70 detected in multiple organs. Our data suggested upon SARS-CoV-2 infection,
71 hyperinflammation might be triggered which in turn induces damage of gas exchange
72 barrier in the lung, leading to hypoxia, angiogenesis, coagulation and fibrosis in the
73 lung, kidney, spleen, liver, heart and thyroid. Evidence for testicular injuries included
74 reduced Leydig cells, suppressed cholesterol biosynthesis and sperm mobility. In
75 summary, this study depicts the multi-organ proteomic landscape of COVID-19
76 autopsies, and uncovered dysregulated proteins and biological processes, offering
77 novel therapeutic clues.

79 INTRODUCTION

80 The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome
81 coronavirus 2 (SARS-CoV-2), has led to more than 20 million infected individuals
82 and over 700,000 deaths by the middle of August 2020. Morphological
83 characterization of autopsies, mainly focused on the pulmonary lesions, has greatly
84 advanced our understanding of COVID-19-caused deaths (Carsana et al., 2020; Su et
85 al., 2020a; Wichmann et al., 2020; Wu et al., 2020; Xu et al., 2020; Yao et al., 2020).
86 Mechanistic studies of SARS-CoV-2 infected cell line models (Bojkova et al., 2020;
87 Bouhaddou et al., 2020; Gordon et al., 2020) offer new insights into virus-perturbed
88 biochemical processes of COVID-19 and suggest potentially novel therapies. SARS-
89 CoV-2 infected mouse models (Bao et al., 2020; Hassan et al., 2020; Jiang et al.,
90 2020) and rhesus macaque models (Chandrashekar et al., 2020; Deng et al., 2020)
91 generated by adenovirus transduction of human ACE2 have been established for
92 preclinical selection of antiviral therapeutic agents and vaccines as well as for
93 investigating pathogenesis. Few studies have characterized host responses at
94 molecular level from clinical specimens. We and others have studied the host
95 responses by proteomic and metabolomic analysis of patient sera (Messner et al.,
96 2020; Shen et al., 2020a), but molecular changes in infected tissues and
97 consequentially affected organs remain elusive. To date, little knowledge has been
98 obtained concerning how SARS-CoV-2 virus induces injuries in multiple organs
99 (Bian, 2020; Tian et al., 2020; Wichmann et al., 2020) including lung, kidney (Kudose
100 et al., 2020), liver, heart, spleen, thyroid and testis (Yang et al., 2020), and how to
101 prevent and revert them.

102 Maximilian et. al analyzed the mRNA expression of autopsies of seven lungs

103 from COVID-19 patients and reported intussusceptive angiogenesis which may be
104 induced by hypoxemia (Ackermann et al., 2020). Latest advances of proteomics
105 technologies allow effective and robust analysis of formalin-fixed tissue samples (Gao
106 et al., 2020; Zhu et al., 2019). Comparative analysis of mRNA and protein expression
107 in tissue samples showed that proteins measured by mass spectrometry was much
108 more stable than transcripts (Shao et al., 2019). Here, we report a multi-organ
109 proteomic profiling of 144 autopsy tissue samples collected from the lung, spleen,
110 liver, heart, kidney, thyroid and testis of 19 patients died from COVID-19 and 74
111 control tissue samples from 56 non-COVID-19 patients. Using TMT-based shotgun
112 proteomics, we quantified 11,394 proteins, out of which 5336 were significantly
113 dysregulated proteins in at least one organ in COVID-19 patients. This data resource
114 offers a unique channel to understand multi-organ injuries in the COVID-19 patients,
115 and nominates potential therapeutics.

116

117 **RESULTS AND DISCUSSION**

118 **Generation and characterization of proteomic landscape**

119 We first performed proteomic profiling of 144 autopsy tissue samples from seven
120 types of organs, namely lung (N=15, n=30; N represents the patient number, n
121 represents sample number), spleen (N=9, n=9 from white pulp and N=8, n=8 from
122 red pulp), liver (N=10, n=24), kidney (N=10, n=18 from renal cortex and N=9, n=16
123 from renal medulla), heart (N=9, n=19), testis (N=5, n=5) and thyroid (N=15, n=15).
124 The samples were from 19 COVID-19 cases, ten of which have been described
125 previously (Wu et al., 2020), compared with 74 control samples from 56 non-COVID-
126 19 cases with other diseases via surgeries (Figure 1A, Tables S1,2). All 19 COVID-19
127 patients died from SARS-CoV-2 pneumonia or respiratory failure, among whom
128 seven also developed terminal multi-organ failure. Detailed information of patients
129 including medication history during hospitalization, laboratory test data, pathological
130 changes, and cause of death are summarized in Tables S1, 5 and Figure S1, 2.

131 Altogether we quantified 11,394 proteins from the above samples with a false
132 discovery rate (FDR) less than 1% at both peptide and protein levels (Table S3, Figure
133 1A). The number of identified proteins ranged from 5828 (heart) to 9544 (kidney)
134 across seven types of organs. We included 37 technical replicates of randomly
135 selected tissue samples, as well as 18 pooled controls for each TMT batch (Figure
136 S3A, Table S2). Proteins quantified in these technical replicates and control samples
137 showed relatively low median coefficient of variance (CV) of 6.88% and 2.47%,
138 respectively (Figure S3B, C). A total of 5336 dysregulated proteins were characterized
139 from the seven types of organs between COVID-19 and control groups (Benjamini &
140 Hochberg (B-H) adjusted p value < 0.05 and $|\log_2(\text{fold change})| > \log_2(1.2)$, Table S4,
141 Figure 1A). Splenic red pulp samples were excluded from downstream analysis since
142 they did not show statistically significant proteomic regulations changes (Figure 1A).
143 Hierarchical clustering of the differentially expressed proteins from each organ type
144 (Figure S3D) showed that these proteins well separated COVID-19 samples and
145 controls. The t-distributed stochastic neighbor embedding shows that dysregulated

146 proteomes of each organ type clustered tightly apart from each other (Figure S3E),
147 consolidating that these selected proteins well resolved different tissue types. Except
148 testis, the other six tissue types shared only 27 dysregulated proteins, suggesting
149 different organs responded via diverse pathways. Among them, the acute
150 inflammatory protein, C-reactive protein (CRP), and the M2 type macrophage highly
151 expressed marker (Etzerodt and Moestrup, 2013), scavenger receptor cysteine-rich
152 type 1 protein M130 (CD163) were the most upregulated proteins (Figure 1B),
153 probably reflecting both the hyperinflammatory and repairing state in patients died
154 from COVID-19.

155 **Six clusters of proteins relevant to SARS-CoV-2 infection**

156 We then focused on six clusters of proteins including viral receptors and
157 proteases, transcription factors (TFs), cytokines (and their receptors), coagulation
158 system, angiogenesis associated proteins, and fibrosis markers due to their relevance
159 to SARS-CoV-2 infection (Figure 2A, B). After cellular entry mediated by receptors
160 and proteases, SARS-CoV-2 hijacks the host translation machinery and induces host
161 inflammatory response via TFs, leading to hyper-inflammatory state, which might be
162 associated with the clinically observed blood hypercoagulability as measured by
163 blood tests (Figure S2), fibrosis and microthrombosis as examined by pathologists
164 (Figure S1), and enhanced angiogenesis as reported by morphologic and gene
165 expression examination in the lung of COVID-19 (Ackermann et al., 2020).

166 Our data showed substantial regulation of TFs in COVID-19 autopsies. 395 out
167 of 1117 quantified TFs were altered in at least one tissue type (Table S5, Figure S4A),
168 and they were significantly enriched in spliceosome, viral carcinogenesis, among
169 others as shown in Figure S4B. By matching the experiential fold-change with the
170 predicted activation state in IPA, ten of these dysregulated TFs shown the same
171 change trend, which participate in the hyperinflammation, hypoxia state and tissue
172 injury in COVID-19 patients (Figure S4A, Supplementary Discussion).

173 Among the 242 quantified cytokines, 112 were significantly dysregulated and
174 mapped to angiogenesis, response to growth factor and other pathways (Figure S4C,
175 D, Table S5 and Supplementary Discussion). Nicotinamide phosphoribosyl
176 transferase (NAMPT), glucocorticoid receptor (NR3C1) and interferon-gamma
177 receptor 1 (IFNGR1) were dysregulated cytokines in most organs. NAMPT, which
178 participates in multiple signaling pathways, such as IL6-STAT3 and NF- κ B (Garten et
179 al., 2015), was upregulated in the six organs except for testis. NR3C1, which is
180 involved in the anti-inflammatory process (Baschant and Tuckermann, 2010), was
181 downregulated in the five organs except for testis and thyroid. IFNGR1, which
182 triggers host immune responses upon viral infection (Xia et al., 2018), was upregulated
183 in the five organs except for testis and thyroid.

184 **CTSL, rather than ACE2, was upregulated in lungs**

185 Our data identified six reported potential receptors or proteases for virus entry
186 (Figure 2C, Supplementary Discussion), namely angiotensin-converting enzyme 2
187 (ACE2) (Hoffmann et al., 2020), C-type lectin domain family 4 member M
188 (CLEC4M) (Jeffers et al., 2004) and member L (CD209) (Yang et al., 2004), Niemann-

189 Pick C1(NPC1)(Cote et al., 2011), carcinoembryonic antigen-related cell adhesion
190 molecule 1 (CEACAM1)(Tsai et al., 2003) and cathepsin L1 (CTSL)(Liu et al.,
191 2020b). ACE2, the known receptor mediating SARS-CoV-2 entry, did not show
192 significant regulation in lungs, but was downregulated in both kidney and heart in
193 COVID-19 patients (Figure 2C). This observation is supported by the modulatory
194 roles of ACE2 on angiotensin II, including inflammation, vasoconstriction and
195 thrombosis(Liu et al., 2020a). Interestingly, our results showed CTSL, the serine
196 protease of SARS-CoV-2 in the endosomal pathway, was significantly upregulated in
197 the lung (Figure 2C), nominating it as a potential therapeutic target for COVID-19. In
198 the SARS-CoV infection cell model, the inhibitor of CTSL has been proven to be
199 effective for blocking the virus entry (Simmons et al., 2005).

200 **Multi-organ coagulation, angiogenesis and fibrosis**

201 Our data suggested systematic dysregulation of coagulation, angiogenesis and
202 fibrosis in COVID-19 patients, as shown in Figure 3 and Table S5. Microthrombi in
203 the COVID-19 patients were observed in the lungs and kidneys of COVID-19 patients
204 (Figure S1), in agreement with laboratory markers, such as D-dimer (Figure S2),
205 indicating a prothrombotic state. Based on our analysis, the dysregulated proteins
206 participating in coagulation, anticoagulation and fibrinolytic system could contribute
207 to the coagulation disorders in COVID-19 (Figure 3A, Table S5, Supplementary
208 Discussion). Besides, angiogenesis has also been reported in the lung (Ackermann et
209 al., 2020). In our study, a total of 139 angiogenesis-related proteins from the nCounter
210 PanCancer Progression Panel (NanoString Technologies) were significantly
211 dysregulated (Table S5, Figure 3B). Based on our data, multi-organ abnormal
212 angiogenesis (not only in the lung) may have developed due to disordered
213 coagulation, tissue hypoxia and excessive stimulation by cytokines in COVID-19
214 (Supplementary Discussion).

215 As fibrosis has been observed in the lungs of COVID-19 patients (Figure S1,
216 Table S1), we analyzed 29 fibrosis associated proteins in our dataset by matching with
217 the reported potential fibrosis markers (Figure 3C, Table S5, Supplementary
218 Discussion). Serpin family E member 1 (SERPINE1) and Chitinase 3 Like 1
219 (CHI3L1) were upregulated in the most organs of COVID-19 patients (Figure 3C). In
220 the COVID-19 samples, we characterized 179 dysregulated proteins involved in the
221 four stages of fibrosis, namely initiation, inflammation, proliferation and
222 modification, according to nCounter Fibrosis Panel (NanoString Technologies). These
223 proteins formed 447 interactions according to String (Szklarczyk et al., 2019) and
224 Cytoscape (Shannon et al., 2003) in the studied tissue types (Figure S5, Table S5,
225 Supplementary Discussion). The dysregulated proteins associated with the fibrosis
226 process are mostly in the lung, which is consistent with the pathological observation
227 (Figure S1). Along with the fibrosis process, fewer proteins were dysregulated at the
228 modification step compared with the other three stages, suggesting that chronic
229 inflammation and fibrosis process may initiate at the molecular level without obvious
230 pathological changes (Supplementary Discussion). The above observation may be
231 instructive clinically to monitor COVID-19 patients after recovery for delayed

232 development of tissue fibrosis.

233 **Dysregulated protein translation, glucose and fatty acid metabolism**

234 To obtain a systematic understanding of biological processes represented by
235 5336 dysregulated proteins, we performed pathway enrichment in each tissue type
236 using Ingenuity Pathway Analysis. Comparisons of the most enriched or dysregulated
237 pathways ($-\log_{10}(\text{p value}) > 10$ or ratio > 0.35 or absolute (Z-score) > 5) among seven
238 organ types are shown in Figure 4A and Table S6. EIF2 signaling is involved in the
239 regulation of mRNA translation (Roux and Topisirovic, 2018), which has been
240 reported to be affected by virus infection (Bojkova et al., 2020). The lung, liver and
241 thyroid shared a similar pattern of mRNA translation (Figure 4A), though there was
242 little evidence of direct virus infection in the liver or thyroid. Most dysregulated
243 proteins specific to the lung belonged to L13a-mediated translational silencing of
244 ceruloplasmin expression (Figures 4B, 6A), which has been reported as an innate
245 immune mechanism after the virus infection (Mazumder et al., 2014). We observed
246 suppression of multiple metabolic processes including glycogenolysis, galactose
247 degradation and glycolysis (Figure 4A, Table S6). In contrast, fatty acid β oxidation
248 (FAO) and oxidative phosphorylation were activated in most organs, suggesting a
249 switch to high-efficiency energy production mode to support virus replication in the
250 lung and mRNA translation in the liver (Heaton and Randall, 2011). In addition,
251 dysregulated FAO and oxidative phosphorylation also led to excessive generation of
252 reactive oxygen species (ROS) and release of proapoptotic proteins, which induced
253 liver necrosis (Figure S1). In the kidney, FAO was inhibited, which is thought to be a
254 contributor to acute kidney injury (AKI) induced renal fibrogenesis (Kang et al.,
255 2015). Indeed, AKI has been observed in most COVID-19 patients in our study (Table
256 S1).

257 **Inter-organ crosstalk**

258 We next investigated inter-organ crosstalk in COVID-19 patients based on our
259 proteomics data (Figures 5, 6, Figures S7, Supplementary Discussion). The lung is the
260 major target attacked by SARS-CoV-2. In our data, COVID-19 lung proteome showed
261 unique enrichment of pathways which are known to be associated with virus
262 infection, including mRNA decay and translation shutoff (Tanaka et al., 2012) (Figure
263 4C). Further, double-stranded RNA (dsRNA) and uncapped mRNA of the virus act as
264 viral pathogen-associated molecular patterns (PAMPs) which trigger the innate
265 immune response through recognition by pattern recognition receptors (PRRs) in the
266 cytoplasm (Lin and Cao, 2020). By comparing with the SARS-CoV-2 protein
267 interaction map (Gordon et al., 2020), 12 virus-host interacting proteins were
268 dysregulated only in the lung, including stress granule-related factor G3BP1,
269 mitochondrial protein TIM10, transcription regulator eIF4H, RING-type E3 ubiquitin
270 ligase MIB1, pro-inflammatory cytokine receptor IL17RA, and member of Cullin
271 RING E3 ligase 2 complex ZYG11B (Figure 4D). These proteins have been reported
272 to promote virus replication, inhibit host mRNA expression, mediate the delivery of
273 viral DNA through viral nuclear pore complex, participate in pulmonary fibrosis and
274 degrade virus restriction factors (Gordon et al., 2020). G3BP1 was reported to interact

275 with SARS-CoV-2 nucleocapsid (N) protein, which could be sequestered by viruses to
276 promote their replication (Gordon et al., 2020). Mitochondrial proteins known to be
277 targeted by viruses to enhance their replication (Williamson et al., 2012). The
278 interaction between SARS-CoV-2 Nsp9 and eIF4H may indicate the inhibition of host
279 mRNA expression (Gordon et al., 2020). The interaction between Nsp9 and MIB1
280 may mediate the delivery of viral DNA through nuclear pore complex (Gordon et al.,
281 2020). IL17RA is associated with elevation of collagen and pulmonary fibrosis, and
282 its inhibitor has been reported to reduce fibrosis in SARS infection (Mi et al., 2011).
283 The interaction between Orf10 and ZYG11B may be hijacked for degradation of virus
284 restriction factors or be blocked to protect itself from degradation (Gordon et al.,
285 2020).

286 We found that spleen and lung exhibited similar immune response patterns. T
287 cell exhaustion and upregulation of monocytes biomarkers in the spleen (Figures 5A,
288 6B) suggested hyperinflammatory, which may have damaged the integrity of the gas
289 exchange barrier and induced hypoxia. The hypoxia state would further stimulate the
290 inflammatory responses (Eltzschig and Carmeliet, 2011). We further checked multiple
291 markers for various immune cells in the spleen samples using immunohistochemistry
292 (IHC) and found that the number of T and B lymphocytes were significantly reduced
293 by IHC staining of CD3, CD4, CD8 and CD20, especially in the white pulp of
294 COVID-19 patients, while the number of macrophages, M2 macrophages increased in
295 the red pulp of COVID-19 patients by IHC staining of CD68 and CD163 respectively.
296 These findings agreed with our proteomic data (Figure S6). Besides, the cytokines and
297 immune cells in the blood cycling could induce acute phase response and NF- κ B
298 signaling in the liver (Figure 5B) (Alonzi et al., 2001; Israel, 2010), which
299 sequentially leads to vascular hyperpermeability (Nagy et al., 2008) and vasogenic
300 edema in the heart (Figures S1, S7A). In the thyroid and kidney, inflammatory
301 infiltration and activated inflammation associated signals and proteins were also
302 identified (Figures S7B, C, D).

303 **Testicular injuries**

304 Compared with the other organ types, the number of differentially expressed
305 proteins in testes was negligible. Only ten proteins were downregulated (Figure 7A).
306 Insulin like factor 3 (INSL3), the most abundantly expressed proteins in Leydig cells
307 (Uhlen et al., 2015), was the most dramatically decreased protein in COVID-19
308 testicular tissue (Figures 7A, D), suggesting impaired Leydig cell functions or a
309 reduced Leydig cell population. Indeed, the histological examination revealed a
310 reduction of Leydig cells (Figures 7B, C), in consistent with our previous pathological
311 report (Yang et al., 2020). We also found five down-regulated proteins related to
312 cholesterol biosynthesis (Figures 7A, D). All steroid hormones, including
313 testosterone, are derived from cholesterol. Downregulation of dynein regulatory
314 complex subunit 7 (DRC7), a sperm motility factor, suggested impaired sperm
315 mobility (Morohoshi et al., 2020) (Figures 7A, D).

316 **CONCLUSION**

318 In summary, we have quantified 11,394 proteins in seven types of tissue from
319 patients died from COVID-19, and identified 5336 significantly dysregulated proteins
320 compared to non-COVID-19 patients. This proteomic atlas uncovered multiple
321 biological and pathological processes regulated in COVID-19, including immune
322 response, protein translation, coagulation disorder, angiogenesis and profibrotic
323 process. Crosstalk among multiple organs further linked the aforementioned processes
324 by the hyperinflammatory environment with tissue hypoxia after SARS-CoV-2
325 infection. This systematic proteomic investigation provides a rich resource for
326 improving our understanding of the molecular pathogenesis of SARS-CoV-2
327 infection, and offers clues for therapeutics. This study is limited by the sample size. In
328 addition, future in-depth investigation of the perturbed pathways and the nominated
329 therapeutics is needed.

330

331 **ACKNOWLEDGMENTS**

332 This work is supported by grants from Tencent Foundation (2020), National Natural
333 Science Foundation of China (81972492, 21904107, 81672086, 81773022), Zhejiang
334 Provincial Natural Science Foundation for Distinguished Young Scholars
335 (LR19C050001), the Key Special Project of Ministry of Science and Technology,
336 China (No.2020YFC0845700), the Fundamental Research Funds for the Central
337 Universities (No.2020kfyXGYJ101), and Hangzhou Agriculture and Society
338 Advancement Program (20190101A04). We thank Drs D.S. Li, O.L. Kon and the
339 Guomics team for helpful comments to this study, and Westlake University
340 Supercomputer Center and biomedical research core facilities for assistance in data
341 generation and storage.

342

343 **AUTHOR CONTRIBUTIONS**

344 T.G., X.N., Y.Z., Y.H. and J.X. designed and supervised the project. X.N., B.H and
345 X.D summarized the pathological changes and SARS-COV-2 test. L.Q., R.S., Q.X.,
346 Q.Z., T.L., L.Y., W.G., W.L., Y.S., L.L., H.C., X.Y., M.L., S.L., X.D., C.Y., L.X., J.H.,
347 M.L., X.C., H.G., J.Y., Z.X. and G.R. conducted proteomic analysis. X.L., J.Z. and
348 S.W. collected the autopsies. X.L, J.Z, J.F, X.C and D.Z organized the clinical data.
349 H.M., H.S. and M.X. participated in clinical-pathological analysis. S.C, M.Y., L.P.,
350 G.X., X.X., J.W., H.P. performed H&E and IHC analysis. D.L., B.H. and Y.L. (Union
351 Hospital) performed SARS-CoV-2 detection for lungs and analyzed the relevant data.
352 L.Q., R.S., Q.X., T.L, L.Y, X.N., Y.Z., and T.G. interpreted the data with inputs from
353 all co-authors. L.Q., R.S., Q.X., T.L, Y.Z. and T.G. wrote the manuscript with inputs
354 from co-authors.

355

356 **DECLARATION OF INTERESTS**

357 NA

358

359

360

361 **MATERIALS AND METHODS**

362 **Clinical specimens and histological analysis**

363 This study was approved by the Medical Ethics Committee of Union Hospital
364 affiliated to Tongji Medical College of Huazhong University of Science and
365 Technology (No.2020-0043-1) and Medical Ethical Committee of Westlake
366 University (No.20200329GTN001).

367 All COVID-19 patients were from the Union Hospital affiliated to Tongji
368 Medical College of Huazhong University of Science and Technology and met the
369 diagnostic criteria by the National Health Commission of China. With the consent by
370 the fatal COVID-19 patients' families, ultrasound-guided percutaneous multi-point
371 postmortem core biopsies were performed within two hours after death in a negative
372 pressure isolation ward, from February to April 2020. Ultrasound examinations were
373 performed using an ultrasound scanner (EPIQ 7C, Philips Medical Systems, Andover,
374 MA, USA) equipped with an L12-5/S5-1 probe, or a China Mindray portable
375 Ultrasound M9 GD equipped with an L10-3 probe. All autopsies were performed
376 using the large core (14-gauge) needle by the multitask team consisting of
377 pathologists, thoracic surgeons, and ultrasound doctors. Procured tissues were
378 preserved in the 10% neutral formalin immediately after the procedure and fixed for
379 over 24 hours, and then routinely processed for paraffin blocks. Histological slices
380 were prepared using a microtome and stained with hematoxylin and eosin (H&E) as
381 described previously (Su et al., 2020b). Immunohistochemical stains (IHC) were
382 performed for CD3 (Dako, Copenhagen, Denmark), CD4 (Dako), CD8 (Dako), CD20
383 (Roche, Tucson, AZ, USA), CD68 (Dako) and CD163 (Cell Margue) according to the
384 manufacturers' protocols on a Dako Link 48 automated stainer (for CD3, CD4, CD8,
385 CD68 and CD163) or a Roche Benchmark XT Ultra system (for CD20). All slides
386 were examined by at least two senior pathologists independently. A total of 144
387 microscopy-guided dissection samples were analyzed from 73 specimens, including
388 heart (9 specimens), lung (15 specimens), liver (10 specimens), kidney (10
389 specimens), spleen (9 specimens), testis (5 specimens), and thyroid (15 specimens),
390 see Tables S1, S2. We also collected 74 control samples from archived blocks of 56
391 non-COVID-19 patients before December, 2019 (Tables S1, S2).

392
393 **Proteomics data acquisition**

394 Around 1-1.5mg FFPE tissue samples were processed to generate peptide
395 samples using accelerated pressure cycling technology (PCT) assisted sample
396 preparation method as described previously (Gao et al., 2020; Zhu et al., 2019).
397 Briefly, the samples were dewaxed by heptane and rehydrated by ethanol solution of
398 different concentrations; then undergone acidic hydrolysis by 0.1% formic acid, and
399 basic hydrolysis by 0.1 M Tris-HCl (pH 10.0); followed by tissue lysis by 6 M
400 urea/2M thiourea (Sigma) buffer, reduction by Tris(2 carboxyethyl)phosphine (TCEP,
401 Sigma) and alkylation by iodoacetamide (IAA, Sigma) in PCT. Then the lysates were
402 digested using PCT by a mix of LysC and trypsin (Hualishi Tech. Ltd, Beijing, China)
403 and the digestion was quenched by trifluoroacetic acid. After C18 cleaning, 7 µg of

404 peptides from each of the 218 tissue samples, and 37 technical replicates, 34 pooling
405 samples including common pooled samples and tissue specific pooled samples (Table
406 S2) were taken for the following TMTpro 16plex labeling based proteomics analysis.
407 The common pooled samples were prepared by mixing equal amount of peptide from
408 6 different human organs including testis, lung, kidney, spleen, heart and liver. The
409 tissue specific pooled samples were prepared by mixing equal amount of peptides
410 from all samples of a specific organ) were labeled with TMTpro 16plex reagent
411 (Thermo Fisher Scientific™, San Jose, USA)(Li et al., 2020). After quenching the
412 labeling reaction by hydroxylamine, 16 TMT-labeled peptide samples were combined
413 and cleaned by C18 columns (Waters, Sep-Pak Vac tC18 1cc, 50mg). Fractionation
414 was performed on Thermo Ultimate Dinex 3000 (Thermo Fisher Scientific™, San
415 Jose, USA) with an XBridge Peptide BEH C18 column (300Å, 5 µm × 4.6 mm × 250
416 mm) (Waters, Milford, MA, USA). The sample was separated using a 60 min LC
417 gradient from 5% to 35% acetonitrile (ACN) in 10 mM ammonia (pH=10.0) at a flow
418 rate of 1 mL/min to 60 fractions. The fractions were combined using the following
419 strategy: 1) combine the 1st to 12th, 59th and 60th fraction; 2) combine the 13rd, 20th and
420 52nd fraction; 3) combine the 14th, 19th 54th and 55th fraction; 4) combine the 15th, 18th
421 and 58th fraction; 5) combine the 16th, 22nd and 53rd fraction; 6) combine the 17th, 21st,
422 56th and 57th fraction; 7) combine the 23rd and 50th fraction; 8) combine the 24th and
423 48th fraction; 9) combine the 25th and 47th fraction; 10) combine the 26th and 49th
424 fraction; 11) combine the 27th and 51st fraction; 12) no combination for 28th to 46th
425 fraction. Together, we got 30 combinations of fractionates and dried them in vacuum.
426 Dried peptides were re-dissolved in 2% ACN/0.1% formic acid and then analyzed
427 with QE HFX or QE HF with the same LC-MS/MS settings as described in Shen et al
428 (Shen et al., 2020b). The MS raw data were analyzed by Proteome Discoverer
429 (Version 2.4.1.15, Thermo Fisher Scientific) using a combination of the FASTA files
430 of 20,365 reviewed Homo sapiens proteins downloaded from UniProt website on 14
431 April, 2020 and the SARS-CoV-2 virus FASTA of 10 SARS-CoV-2 proteins
432 downloaded from NCBI (version MN908947.3). Precursor ion mass tolerance was set
433 to 10 ppm, and product ion mass tolerance was set to 0.02 Da. Other parameters in
434 Proteome Discoverer analysis are identical to our previous study(Shen et al., 2020b).
435 The grouped abundance ratio of 15 tissue samples to the pooled sample in the same
436 batch was selected as the value of proteins in the protein matrix for the statistical
437 analysis. As for the lung, spleen, liver, heart, kidney and testis samples, the pooled
438 sample for ratio calculation was chosen as the common pooled sample in the
439 corresponding batch. As for the thyroid samples, the pooled sample for ratio
440 calculation was chosen as the tissue specific pooled sample in the corresponding
441 batch.

442

443 **Quality control of proteomics data**

444 The quality control (QC) of proteomics data was similar as described in Shen et
445 al(Shen et al., 2020b). We performed QC in the following levels: i) As to the batch
446 design, one plex of TMTpro 16plex was set as a pooled sample for batch alignment
447 and quantitative accuracy (as calculated in the grouped abundance ratio); ii) During

448 the MS acquisition, we analyzed mouse liver protein digests for MS instrument
449 performance evaluation every two batches, and analyzed MS buffer A (2%
450 ACN/0.1% formic acid) as blanks every six LC-MS/MS injections; iii) We random
451 distributed the peptide samples from every organ of COVID-19 patients and non-
452 COVID-19 patients into each batch; iv) For data analysis, we calculated the median
453 coefficient of variation (CV) of the proteomics data for reproducibility. As for the
454 pooled controls, we calculated the CV by the $\log_2(\text{abundance})$ of quantified proteins
455 in the pooled controls of each organ (Figure S3B). The pooled samples for CV
456 calculation was the same as the ones for grouped ratio calculation. As for the technical
457 replicates, we calculated the CV by expression ratio of quantified proteins in the
458 technical replicates of each sample (Figure S3C). Besides, unsupervised clustering for
459 the proteomics data were performed, including heatmap and tSNE (Figures S3D, E).
460 After the selection of differentially expressed proteins (adjusted p value by B-H
461 correction < 0.05 and $|\log_2(\text{FC})| > \log_2(1.2)$), the heatmap of each organ by the
462 dysregulated proteins was performed and the few samples that couldn't be grouped
463 correctly were excluded for further statistical analysis, probably due to unknown pre-
464 analytical reasons.

465

466 **Statistical analysis**

467 \log_2 fold-change (FC) was calculated by the mean of proteins expression ratio in
468 a specific tissue between COVID-19 and non-COVID-19 patient groups. Student's *t*
469 test was performed for each pair of comparing groups. Adjusted p values were
470 calculated using B-H correction. The criteria for significantly dysregulated proteins
471 selection was that the adjusted p value should be less than 0.05 and $|\log_2\text{FC}|$ should be
472 larger than $\log_2(1.2)$. Statistical analysis was performed using R (version 3.6.3).

473

474 **Pathway/network analysis**

475 The pathway enrichment was analyzed by either ingenuity pathway analysis
476 (IPA)(Kramer et al., 2014) (with p value < 0.05 , Z score > 0 or < 0), or Metascape
477 web-based platform(Zhou et al., 2019) (with p-value < 0.05), or string web-based
478 platform(Szklarczyk et al., 2019). The immunological proteins were mapped against
479 GSEA-immunologic gene sets in Metascape platform with our differentially
480 expressed proteins and then the enriched pathways were distinguished by IPA
481 analysis.

482

483 **REFERENCES**

- 484 Ackermann, M., Verleden, S.E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A.,
485 Werlein, C., Stark, H., Tzankov, A., *et al.* (2020). Pulmonary Vascular Endothelialitis, Thrombosis,
486 and Angiogenesis in Covid-19. *N Engl J Med* *383*, 120-128.
- 487 Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., and Poli, V. (2001). Essential role of
488 STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation
489 [correction of activation] in the liver. *Mol Cell Biol* *21*, 1621-1632.
- 490 Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., *et al.* (2020). The
491 pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature*.
- 492 Baschant, U., and Tuckermann, J. (2010). The role of the glucocorticoid receptor in inflammation
493 and immunity. *J Steroid Biochem Mol Biol* *120*, 69-75.
- 494 Bian, X.-W. (2020). Autopsy of COVID-19 victims in China. *National Science Review*.
- 495 Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., Cinatl, J., and Munch, C. (2020).
496 Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. *Nature* *583*, 469-472.
- 497 Bouhaddou, M., Memon, D., Meyer, B., White, K.M., Rezelj, V.V., Correa Marrero, M., Polacco, B.J.,
498 Melnyk, J.E., Ulferts, S., Kaake, R.M., *et al.* (2020). The Global Phosphorylation Landscape of SARS-
499 CoV-2 Infection. *Cell*.
- 500 Carsana, L., Sonzogni, A., Nasr, A., Rossi, R.S., Pellegrinelli, A., Zerbi, P., Rech, R., Colombo, R.,
501 Antinori, S., Corbellino, M., *et al.* (2020). Pulmonary post-mortem findings in a series of COVID-19
502 cases from northern Italy: a two-centre descriptive study. *Lancet Infect Dis*.
- 503 Chandrashekar, A., Liu, J., Martinot, A.J., McMahan, K., Mercado, N.B., Peter, L., Tostanoski, L.H., Yu,
504 J., Maliga, Z., Nekorchuk, M., *et al.* (2020). SARS-CoV-2 infection protects against rechallenge in
505 rhesus macaques. *Science*.
- 506 Cote, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C.M., Hensley, L., Li, Q., Ory, D., Chandran,
507 K., *et al.* (2011). Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus
508 infection. *Nature* *477*, 344-348.
- 509 Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., *et al.* (2020). Primary
510 exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science*.
- 511 Eltzschig, H.K., and Carmeliet, P. (2011). Hypoxia and inflammation. *N Engl J Med* *364*, 656-665.
- 512 Etzerodt, A., and Moestrup, S.K. (2013). CD163 and inflammation: biological, diagnostic, and
513 therapeutic aspects. *Antioxid Redox Signal* *18*, 2352-2363.
- 514 Gao, H., Zhang, F., Liang, S., Zhang, Q., Lyu, M., Qian, L., Liu, W., Ge, W., Chen, C., Yi, X., *et al.* (2020).
515 Accelerated Lysis and Proteolytic Digestion of Biopsy-Level Fresh-Frozen and FFPE Tissue Samples
516 Using Pressure Cycling Technology. *J Proteome Res* *19*, 1982-1990.
- 517 Garten, A., Schuster, S., Penke, M., Gorski, T., de Giorgis, T., and Kiess, W. (2015). Physiological and
518 pathophysiological roles of NAMPT and NAD metabolism. *Nat Rev Endocrinol* *11*, 535-546.
- 519 Gordon, D.E., Jang, G.M., Bouhaddou, M., Xu, J., Obernier, K., White, K.M., O'Meara, M.J., Rezelj,
520 V.V., Guo, J.Z., Swaney, D.L., *et al.* (2020). A SARS-CoV-2 protein interaction map reveals targets
521 for drug repurposing. *Nature* *583*, 459-468.
- 522 Hassan, A.O., Case, J.B., Winkler, E.S., Thackray, L.B., Kafai, N.M., Bailey, A.L., McCune, B.T., Fox, J.M.,
523 Chen, R.E., Alsoussi, W.B., *et al.* (2020). A SARS-CoV-2 Infection Model in Mice Demonstrates
524 Protection by Neutralizing Antibodies. *Cell*.
- 525 Heaton, N.S., and Randall, G. (2011). Multifaceted roles for lipids in viral infection. *Trends Microbiol*

526 19, 368-375.

527 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S.,
528 Herrler, G., Wu, N.H., Nitsche, A., *et al.* (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and
529 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 181, 271-280 e278.

530 Israel, A. (2010). The IKK complex, a central regulator of NF-kappaB activation. *Cold Spring Harb*
531 *Perspect Biol* 2, a000158.

532 Jeffers, S.A., Tusell, S.M., Gillim-Ross, L., Hemmila, E.M., Achenbach, J.E., Babcock, G.J., Thomas,
533 W.D., Jr., Thackray, L.B., Young, M.D., Mason, R.J., *et al.* (2004). CD209L (L-SIGN) is a receptor for
534 severe acute respiratory syndrome coronavirus. *Proc Natl Acad Sci U S A* 101, 15748-15753.

535 Jiang, R.D., Liu, M.Q., Chen, Y., Shan, C., Zhou, Y.W., Shen, X.R., Li, Q., Zhang, L., Zhu, Y., Si, H.R., *et*
536 *al.* (2020). Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-
537 Converting Enzyme 2. *Cell* 182, 50-58 e58.

538 Kang, H.M., Ahn, S.H., Choi, P., Ko, Y.A., Han, S.H., Chinga, F., Park, A.S., Tao, J., Sharma, K., Pullman,
539 J., *et al.* (2015). Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney
540 fibrosis development. *Nat Med* 21, 37-46.

541 Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches in
542 Ingenuity Pathway Analysis. *Bioinformatics* 30, 523-530.

543 Kudose, S., Batal, I., Santoriello, D., Xu, K., Barasch, J., Peleg, Y., Canetta, P., Ratner, L.E., Marasa, M.,
544 Gharavi, A.G., *et al.* (2020). Kidney Biopsy Findings in Patients with COVID-19. *J Am Soc Nephrol*.

545 Li, J., Van Vranken, J.G., Pontano Vaiteas, L., Schweppe, D.K., Huttlin, E.L., Etienne, C., Nandhikonda,
546 P., Viner, R., Robitaille, A.M., Thompson, A.H., *et al.* (2020). TMTpro reagents: a set of isobaric
547 labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. *Nat*
548 *Methods* 17, 399-404.

549 Lin, H., and Cao, X. (2020). Nuclear innate sensors for nucleic acids in immunity and inflammation.
550 *Immunol Rev*.

551 Liu, P.P., Blet, A., Smyth, D., and Li, H. (2020a). The Science Underlying COVID-19: Implications for
552 the Cardiovascular System. *Circulation* 142, 68-78.

553 Liu, T., Luo, S., Libby, P., and Shi, G.P. (2020b). Cathepsin L-selective inhibitors: A potentially
554 promising treatment for COVID-19 patients. *Pharmacol Ther*, 107587.

555 Mazumder, B., Poddar, D., Basu, A., Kour, R., Verbovetskaya, V., and Barik, S. (2014). Extraribosomal
556 I13a is a specific innate immune factor for antiviral defense. *J Virol* 88, 9100-9110.

557 Messner, C.B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube, K.,
558 Vernardis, S.I., Egger, A.S., Kreidl, M., *et al.* (2020). Ultra-High-Throughput Clinical Proteomics
559 Reveals Classifiers of COVID-19 Infection. *Cell Syst* 11, 11-24 e14.

560 Mi, S., Li, Z., Yang, H.Z., Liu, H., Wang, J.P., Ma, Y.G., Wang, X.X., Liu, H.Z., Sun, W., and Hu, Z.W.
561 (2011). Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-
562 beta1-dependent and -independent mechanisms. *J Immunol* 187, 3003-3014.

563 Morohoshi, A., Miyata, H., Shimada, K., Nozawa, K., Matsumura, T., Yanase, R., Shiba, K., Inaba, K.,
564 and Ikawa, M. (2020). Nexin-Dynein regulatory complex component DRC7 but not FBXL13 is
565 required for sperm flagellum formation and male fertility in mice. *PLoS Genet* 16, e1008585.

566 Nagy, J.A., Benjamin, L., Zeng, H., Dvorak, A.M., and Dvorak, H.F. (2008). Vascular permeability,
567 vascular hyperpermeability and angiogenesis. *Angiogenesis* 11, 109-119.

568 Roux, P.P., and Topisirovic, I. (2018). Signaling Pathways Involved in the Regulation of mRNA
569 Translation. *Mol Cell Biol* 38.

Main text

570 Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B.,
571 and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular
572 interaction networks. *Genome Res* *13*, 2498-2504.

573 Shao, W., Guo, T., Toussaint, N.C., Xue, P., Wagner, U., Li, L., Charmpi, K., Zhu, Y., Wu, J., Buljan, M.,
574 *et al.* (2019). Comparative analysis of mRNA and protein degradation in prostate tissues indicates
575 high stability of proteins. *Nat Commun* *10*, 2524.

576 Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., *et al.* (2020a).
577 Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. *Cell* *182*, 59-72 e15.

578 Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., *et al.* (2020b).
579 Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. medRxiv,
580 2020.2004.2007.20054585.

581 Simmons, G., Gosalia, D.N., Rennekamp, A.J., Reeves, J.D., Diamond, S.L., and Bates, P. (2005).
582 Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc Natl*
583 *Acad Sci U S A* *102*, 11876-11881.

584 Su, H., Yang, M., Wan, C., Yi, L.X., Tang, F., Zhu, H.Y., Yi, F., Yang, H.C., Fogo, A.B., Nie, X., *et al.*
585 (2020a). Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in
586 China. *Kidney Int* *98*, 219-227.

587 Su, H., Yang, M., Wan, C., Yi, L.X., Tang, F., Zhu, H.Y., Yi, F., Yang, H.C., Fogo, A.B., Nie, X., *et al.*
588 (2020b). Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in
589 China. *Kidney Int*.

590 Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva,
591 N.T., Morris, J.H., Bork, P., *et al.* (2019). STRING v11: protein-protein association networks with
592 increased coverage, supporting functional discovery in genome-wide experimental datasets.
593 *Nucleic Acids Res* *47*, D607-D613.

594 Tanaka, T., Kamitani, W., DeDiego, M.L., Enjuanes, L., and Matsuura, Y. (2012). Severe acute
595 respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific
596 translational shutoff of host mRNA. *J Virol* *86*, 11128-11137.

597 Tian, S., Xiong, Y., Liu, H., Niu, L., Guo, J., Liao, M., and Xiao, S.Y. (2020). Pathological study of the
598 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Mod Pathol* *33*,
599 1007-1014.

600 Tsai, J.C., Zelus, B.D., Holmes, K.V., and Weiss, S.R. (2003). The N-terminal domain of the murine
601 coronavirus spike glycoprotein determines the CEACAM1 receptor specificity of the virus strain. *J*
602 *Virology* *77*, 841-850.

603 Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A.,
604 Kampf, C., Sjostedt, E., Asplund, A., *et al.* (2015). Proteomics. Tissue-based map of the human
605 proteome. *Science* *347*, 1260419.

606 Wichmann, D., Sperhake, J.P., Lutgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F.,
607 Mushumba, H., Kniep, I., Schroder, A.S., *et al.* (2020). Autopsy Findings and Venous
608 Thromboembolism in Patients With COVID-19. *Ann Intern Med*.

609 Williamson, C.D., DeBiasi, R.L., and Colberg-Poley, A.M. (2012). Viral product trafficking to
610 mitochondria, mechanisms and roles in pathogenesis. *Infect Disord Drug Targets* *12*, 18-37.

611 Wu, J.H., Li, X., Huang, B., Su, H., Li, Y., Luo, D.J., Chen, S., Ma, L., Wang, S.H., Nie, X., *et al.* (2020).
612 [Pathological changes of fatal coronavirus disease 2019 (COVID-19) in the lungs: report of 10
613 cases by postmortem needle autopsy]. *Zhonghua Bing Li Xue Za Zhi* *49*, 568-575.

Main text

614 Xia, C., Anderson, P., and Hahm, B. (2018). Viral dedication to vigorous destruction of interferon
615 receptors. *Virology* *522*, 19-26.

616 Xu, X., Chang, X.N., Pan, H.X., Su, H., Huang, B., Yang, M., Luo, D.J., Weng, M.X., Ma, L., and Nie, X.
617 (2020). [Pathological changes of the spleen in ten patients with coronavirus disease 2019(COVID-
618 19) by postmortem needle autopsy]. *Zhonghua Bing Li Xue Za Zhi* *49*, 576-582.

619 Yang, M., Chen, S., Huang, B., Zhong, J.M., Su, H., Chen, Y.J., Cao, Q., Ma, L., He, J., Li, X.F., *et al.*
620 (2020). Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications. *Eur Urol*
621 *Focus* *6*, 1124-1129.

622 Yang, Z.Y., Huang, Y., Ganesh, L., Leung, K., Kong, W.P., Schwartz, O., Subbarao, K., and Nabel, G.J.
623 (2004). pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the
624 spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. *J Virol* *78*, 5642-
625 5650.

626 Yao, X.H., Li, T.Y., He, Z.C., Ping, Y.F., Liu, H.W., Yu, S.C., Mou, H.M., Wang, L.H., Zhang, H.R., Fu,
627 W.J., *et al.* (2020). [A pathological report of three COVID-19 cases by minimal invasive autopsies].
628 *Zhonghua Bing Li Xue Za Zhi* *49*, 411-417.

629 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and
630 Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-
631 level datasets. *Nat Commun* *10*, 1523.

632 Zhu, Y., Weiss, T., Zhang, Q., Sun, R., Wang, B., Yi, X., Wu, Z., Gao, H., Cai, X., Ruan, G., *et al.* (2019).
633 High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. *Mol*
634 *Oncol* *13*, 2305-2328.

635

636

637 **FIGURE LEGENDS**

638 **Figure 1. Multi-organ proteomic landscape of COVID-19 autopsies. A.** The
639 quantified and dysregulated proteins across multiple organs. The outermost (first) ring
640 represents the type of samples. The number of samples and patients (n/N) are labeled
641 respectively. The second ring (in blue) refers to the missing/undetected proteins for
642 each organ. The numbers in black represent the quantified protein number in the
643 specific organ. The third ring (in light green) refers to unregulated proteins for each
644 type of organ. The numbers in white represent the significantly dysregulated protein
645 number in specific organ type (B-H adjusted p value < 0.05; fold change (FC):
646 comparing COVID-19 with non-COVID-19 patients; $|\log_2(\text{FC})| > \log_2(1.2)$). The
647 innermost ring refers to the significantly dysregulated proteins for each organ (pink:
648 upregulated; dark green: downregulated). The length of the radius represents the
649 protein number. **B.** Proteins expression of CRP and CD163 across six organs (except
650 testis). The y-axis stands for the protein expression ratio by TMT-based quantitative
651 proteomics. Pair-wise comparison of each protein between COVID-19 patients and
652 non-COVID-19 control groups was performed with student's *t* test. Note: The cutoff
653 of dysregulated proteins has been set at B-H adjusted p value < 0.05 and $|\log_2(\text{FC})| >$
654 $\log_2(1.2)$. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

655
656 **Figure 2. Six functional clusters of dysregulated proteins from seven organs**
657 **between COVID-19 and non-COVID-19 patients. A.** Counts of dysregulated
658 proteins in six clusters of molecules, including potential virus receptors, fibrosis
659 markers, cytokines (or its receptors), transcription factors (TF), coagulation system
660 and angiogenesis associated proteins, were shown in a bar chart. Each column along
661 y-axis represents a type of organ. The number of proteins is shown in x-axis. **B.**
662 Landscape of 5336 significantly dysregulated proteins in seven organs. The
663 dysregulated proteins in the six clusters are labeled as circles (solid: upregulated
664 proteins; hollow: downregulated proteins). The size of circle indicates $|\log_2(\text{FC})|$.
665 Proteins discussed in Supplementary Discussion are labeled. **C.** Protein expression of
666 potential virus receptors across multiple organs. The y-axis stands for the protein
667 expression ratio by TMT-based quantitative proteomics. Pair-wise comparison of each
668 protein between COVID-19 and non-COVID-19 patient groups was performed using
669 student's *t* test. Note: The cutoff of dysregulated proteins has been set at B-H adjusted
670 p value < 0.05 and $|\log_2(\text{FC})| > \log_2(1.2)$. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

671
672 **Figure 3. Coagulation, angiogenesis associated proteins and fibrosis markers**
673 **regulated in multiple organs.** Chord diagrams shows dysregulated and shared
674 proteins in coagulation system (A), angiogenesis associated proteins (B), potential
675 fibrosis markers (C) between COVID-19 and non-COVID-19 patients across multiple
676 organs. The cutoff of dysregulated proteins has been set at B-H adjusted p value <
677 0.05 and $|\log_2(\text{FC})| > \log_2(1.2)$. The length of the brick for each protein corresponds to
678 the sum of $|\log_2(\text{FC})|$ in multiple organs. The length of the brick for each organ
679 corresponds to the sum of $|\log_2(\text{FC})|$ in one or more proteins.

680

681 **Figure 4. Dysregulated pathways in multiple organs. A.** The top pathways
682 dysregulated across multiple organs. Pathway analysis was performed using all
683 dysregulated proteins in the specific organ using IPA. The top enriched pathways
684 among seven organ types were selected by cutoff of either $-\log_{10}(P) > 10$, or ratio $>$
685 0.35 , or absolute (Z-score) > 5 . The size of circle represents the $-\log_{10}(p$ value) and
686 the color represent the Z score by IPA. **B.** Translation-associated pathway comparison
687 across multiple organs. The size of circle represents the $-\log_{10}(p)$ and the color
688 represent the Z score by IPA. **C.** The pathways enriched by Metascape for translation
689 initiation relating proteins that differentially expressed only in lung or liver
690 respectively. **D.** Heatmap of SARS-CoV-2 interacting proteins dysregulated in the
691 lung. The significance ('Sig.' as the short term in figures) was calculated using
692 Student's *t* test (p value: *, <0.05 , **, <0.01 ; *** <0.001). Note: The cutoff of
693 dysregulated proteins has been set at B-H adjusted p value < 0.05 and $|\log_2(FC)| >$
694 $\log_2(1.2)$.

695

696 **Figure 5. The heatmap of key dysregulated proteins in the lung, spleen and liver,**
697 **respectively. A.** The heatmap of key proteins in associated pathways in the lung and
698 spleen model of Figure 6B. **B.** The heatmap of key proteins in associated pathways in
699 the liver model of Figure 6B. Note: The significance (Sig.) of them in lung, spleen
700 and liver was calculated using Student's *t* test (p value: *, <0.05 , **, <0.01 ; ***
701 <0.001).

702

703 **Figure 6. Dysregulated proteins and networks in six organs. A.** Significantly
704 enriched networks from the dysregulated proteins in the six organs. Each protein is
705 depicted with radar chart for the six organs. Different organs are labeled with different
706 colors. The shadow areas covering the circles indicate the FC values for each protein.
707 **B.** A hypothetical systems view of the multiple organs' responses to SARS-CoV-2
708 infection. In the lung, the virus and its released RNA could induce immune response
709 and hijack the host translation mechanism. The innate and adaptive immune cells in
710 the spleen and the cytokine induced acute phase proteins secreted by hepatic cells
711 respond to antiviral defense. Such hyperinflammatory status across the whole body
712 through circulatory system led to multi-organ injuries. More details are discussed in
713 Supplementary information. Red box: upregulated proteins/pathways; green box:
714 downregulated proteins/pathways; blue box, pathology of the organ.

715

716 **Figure 7. Proteomic and histopathological characterization of COVID-19 testes.**
717 **A.** The comparison of ten dysregulated proteins between COVID-19 and control
718 samples. Pair-wise comparison of each protein between COVID-19 patients and
719 control groups was performed with student's *t* test. *, $p < 0.05$; **, $p < 0.01$. **B.** The
720 H&E staining of testis from a control patient. H&E stained seminiferous tubules at
721 high power ($\times 200$) showed normal spermatogenesis. Clusters of Leydig cells are seen
722 in the interstitium (a). **C.** The H&E staining of testis from a COVID-19 patient. In
723 COVID-19 testes, H&E stained seminiferous tubules at high power ($\times 200$) showed

Main text

724 sparse intratubular cells with swollen and vacuolated Sertoli cells (b) and decreased
725 number of Leydig cells in the interstitium (a). **D.** Diagram of the pathology in the
726 COVID-19 testis, with seven dysregulated proteins indicated. The green box with
727 black font inside shows the downregulated protein. The downregulation pathway is in
728 green box with white font.

729 **SUPPLEMENTARY FIGURE LEGENDS**

730 **Figure S1. Comparison of histopathological features of organs between COVID-**
731 **19 and non-COVID-19 patients (H&E ×200).** The left column shows the results of
732 non-COVID-19 patients and the right part shows the results of COVID-19 patients. **A.**
733 Pathological features of lungs from COVID-19 patients. (i) The lung showed diffuse
734 alveolar damage, with the alveolar epithelia being replaced by hyperplastic type II
735 alveolar epithelia and falling of type II alveolar epithelia (a). Alveolar septa were
736 thickened with the proliferation of fibroblasts/myofibroblasts and fibrosis (b).
737 Fibrinous exudation and hyaline membrane formation were found (c), with
738 neutrophils aggregation in the alveolar cavity (d). (ii) There were some
739 macrothrombus in small vessels of the lung (a), and megakaryocytes in the alveolar
740 septal capillaries (b). **B.** Pathological findings of the spleen from COVID-19 patients.
741 (i) The red pulp of the spleen expanded, and splenic sinus extended with hyperemia
742 accompanying with macrophage proliferation. (ii) The white pulp of spleen was
743 appeared atrophy with lymphocytes significantly reduced. **C.** Pathological findings of
744 the liver from COVID-19 patients. (i) Coagulative necrosis of hepatocytes was
745 observed in zone III. (ii) The hepatocytes exhibited prominent steatosis. **D.**
746 Pathological findings of the heart from COVID-19 patients. (i) Atrophic myocardia
747 and scant lymphocytes (a) were present in the edematous cardiac interstitium. (ii) The
748 myocardium showed hydropic degenerative change. **E.** Pathological findings of the
749 kidney from COVID-19 patients. (i) In the renal cortex, the proximal tubules showed
750 prominent acute tubule injury manifested as the loss of brush border and epithelial
751 cells necrosis in the tubular lumens (a). Microthrombi in peritubular capillaries and
752 glomeruli were frequently seen (b). (ii) In the renal medulla, the collecting ducts
753 showed occasional cellular swelling and atrophy (a), and edema without significant
754 inflammation (b). **F.** Pathological findings of the thyroid from COVID-19 patients.
755 Lymphoid infiltration was found in some of interfollicular region. Neither
756 neutrophilic infiltration nor necrosis was present.

757
758 **Figure S2. Laboratory characteristics of multi-organ dysfunction and infection**
759 **indicators with COVID-19.** Boxplots display the blood biochemistry tests based on
760 samples collected from COVID-19 patients on the day of admission (red) and death
761 (green). The dash line represents the normal range of laboratory characteristic. BNP,
762 brain natriuretic peptide; CK-MB, creatine kinase-MB; ALB, albumin; ALT, alanine
763 aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase;
764 TBIL, total bilirubin; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase;
765 WBC, white blood cells; PLT, platelets; RBC, red blood cells; BUN, blood urea
766 nitrogen; PT, prothrombin time; APTT, activated partial thromboplastin time; INR,
767 international normalized ratio; FIB, fibrinogen; TT, thrombin time; CRP, C-reactive
768 protein; IL-6, interleukin-6.

769
770 **Figure S3. Proteomic workflow and quality control of proteome data analysis. A.**
771 The workflow of TMT-labeling based quantitative proteomics analysis employed in

772 our study. 288 peptide samples containing 37 technique replicates, 16 common pooled
773 controls and 17 tissue specific pooled controls were distributed into 18 batches and
774 analyzed by TMT 16-plex labeling based proteomic strategy. FFPE, formalin-fixed
775 and paraffin-embedded; PCT, pressure cycling technology; RP-LC, reversed phase
776 liquid chromatography; LC-MS, liquid chromatography-mass spectrometry. **B.** The
777 median CV of the proteomics data is calculated by the $\log_2(\text{abundance})$ of quantified
778 proteins in the pooled controls of each organ. **C.** The median CV of the proteomics
779 data is calculated by expression ratio of quantified proteins in the technique replicates
780 of each organ. **D.** Heatmap of organ-specific dysregulated proteins for lung (37
781 samples * 1606 proteins), splenic white pulp (17 samples * 1726 proteins), liver (36
782 samples * 1969 proteins), heart (40 samples * 919 proteins), renal cortex (32 samples
783 * 1585 proteins), renal medulla (29 samples * 642 proteins) and thyroid (29 samples *
784 1297 proteins) between COVID-19 patients and control groups were shown. **E.** The t-
785 distributed stochastic neighbor embedding (tSNE) visualization of significantly
786 dysregulated proteins in multi-organ proteomes of COVID-19 (triangle) and non-
787 COVID-19 (circle) patients. The color of triangle or circle represents the organ type.
788 Note: The cutoff of dysregulated proteins has been set at B-H adjusted p value < 0.05
789 and $|\log_2(\text{FC})| > \log_2(1.2)$.

790
791 **Figure S4. Transcription factors and cytokines dysregulated in multiple organs.**

792 **A.** Circular heatmap of dysregulated transcription factors. The selected transcription
793 factors with FC larger than 1.5 from dysregulated proteins are shown. Some of the
794 transcription factors in specific tissue with the same trend of changes, and
795 distinguished out by upstream analysis are highlighted in red frame with red and bold
796 font. **B.** Pathway enrichment analysis of dysregulated transcription factors between
797 COVID-19 patients and control groups. Reactome pathways were enriched by String.
798 FC: fold change; FDR: false discovery rate. **C.** The chord diagram shows the shared
799 cytokines (or their receptors) dysregulated between COVID-19 and non-COVID-19
800 patient groups across multiple organs. **D.** Pathway enrichment analysis of the
801 dysregulated cytokines. Gene ontology (GO) pathways were enriched by Metascape.
802 The cutoff of dysregulated proteins has been set at B-H adjusted p value < 0.05 and
803 $|\log_2(\text{FC})| > \log_2(1.2)$. The color of protein represents the upregulation or
804 downregulation pattern. The length of the brick for each protein corresponds to the
805 sum of $|\log_2(\text{FC})|$ in multiple organs. The length of the brick for each organ
806 corresponds to the sum of $|\log_2(\text{FC})|$ in one or more proteins.

807
808 **Figure S5. The network of fibrosis associated proteins over four fibrosis stages in**

809 **multiple organs.** The network shows the interactions among 179 stage-specific
810 dysregulated proteins between COVID-19 and non-COVID-19 patient groups in each
811 organ over the four fibrosis stages: initiation (green), inflammation (blue),
812 proliferation (orange), and modification (red). The network analysis was performed
813 using String and Cytoscape. The size of the dot represents the value of $|\log_2(\text{FC})|$.
814 Note: The cutoff of dysregulated proteins has been set at B-H adjusted p value < 0.05
815 and $|\log_2(\text{FC})| > \log_2(1.2)$.

816

817 **Figure S6. Representative images of immunohistochemical (IHC) staining for**
818 **immune cells in spleens of COVID-19 and non-COVID-19 patients.** White pulp
819 and red pulp samples were from patient P1 (COVID-19) and patient C57 (non-
820 COVID-19), respectively. The multiple markers for various immune cells in the
821 spleen samples using IHC including CD3 for total T cell, CD4 for CD4 positive T
822 cell, CD8 for CD8 positive T cell, CD20 for B cell, CD68 for macrophage and CD163
823 for M2 macrophage were shown.


824

825 **Figure S7. The key dysregulated proteins in the heart, renal cortex, renal**
826 **medulla and thyroid associated with the enriched pathways by IPA.** The heatmap
827 of key proteins in associated pathways in the heart (**A**), renal cortex (**B**), renal medulla
828 (**C**), and thyroid (**D**). The significance (Sig.) of them in each type of organ was
829 calculated using Student's t test (p value: *, <0.05, **, <0.01; *** <0.001).


Figures and supple Figures

Figure 1

A




B




Figures and suppl Figures

Figure 2




Figures and supple Figures

Figure 3




Figures and supple Figures

Figure 4




Figures and supple Figures

Figure 5




Figures and supple Figures

Figure 6




Figures and supple Figures

Figure 7




Figures and supple Figures

Figure S1




Figures and supple Figures

Figure S2




Figures and suppl Figures

Figure S3




Figures and supple Figures




Figures and suppl Figures

Figure S4




Figures and supple Figures

Figure S5




Figures and supple Figures

Figure S6



Figures and supple Figures

Figure S7



1 **Supplementary information for Figure 2, 3, 6 and 7 in**

2 **Multi-organ Proteomic Landscape of** 3 **COVID-19 Autopsies**

4
5 **Xiu Nie ^{1#}, Liujia Qian ^{2,3#}, Rui Sun ^{2,3#}, Bo Huang ^{1#}, Xiaochuan Dong ^{1#}, Qi**
6 **Xiao ^{2,3#}, Qiushi Zhang ^{2,3#}, Tian Lu ^{2,3}, Liang Yue^{2,3}, Shuo Chen ¹, Xiang Li ¹,**
7 **Yaoting Sun ^{2,3}, Lu Li ^{2,3}, Luang Xu ^{2,3}, Yan Li ¹, Ming Yang ¹, Zhangzhi Xue ^{2,3},**
8 **Shuang Liang ^{2,3}, Xuan Ding ^{2,3}, Chunhui Yuan ^{2,3}, Li Peng ¹, Wei Liu ^{2,3}, Xiao Yi**
9 **^{2,3}, Mengge Lyu ^{2,3}, Guixiang Xiao ¹, Xia Xu ¹, Weigang Ge ^{2,3}, Jiale He ^{2,3}, Jun**
10 **Fan ¹, Junhua Wu ¹, Meng Luo ^{2,3,4}, Xiaona Chang ¹, Huaxiong Pan ¹, Xue Cai ^{2,3},**
11 **Junjie Zhou ¹, Jing Yu ^{2,3}, Huanhuan Gao ^{2,3}, Mingxing Xie ⁵, Sihua Wang ⁶,**
12 **Guan Ruan ^{2,3}, Hao Chen ^{2,3}, Hua Su ⁷, Heng Mei ⁸, Danju Luo ¹, Dashi Zhao ¹,**
13 **Fei Xu ⁴, Yan Li ¹⁰, Yi Zhu ^{2,3*}, Jiahong Xia ^{9*}, Yu Hu ^{8*}, Tiannan Guo ^{2,3,11*}**

14
15 ¹ Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of
16 Science and Technology, Wuhan 430022, China

17 ² Zhejiang Provincial Laboratory of Life Sciences and Biomedicine, Key Laboratory of
18 Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou
19 310024, China

20 ³ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou
21 310024, China

22 ⁴ Department of Anatomy, College of Basic Medical Sciences, Dalian Medical University,
23 Dalian 116044, China

24 ⁵ Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University
25 of Science and Technology, Wuhan 430022, China

26 ⁶ Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong
27 University of Science and Technology, Wuhan 430022, China

28 ⁷ Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University
29 of Science and Technology, Wuhan 430022, China

30 ⁸ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of
31 Science and Technology, Wuhan 430022, China

32 ⁹ Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong
33 University of Science and Technology, Wuhan 430022, China

34 ¹⁰ Department of Anatomy and Physiology, College of Basic Medical Sciences, Shanghai Jiao
35 Tong University, Shanghai, 200025, China

36 ¹¹ Lead contact

37
38 #These authors contribute equally

39 * Correspondence: zhuyi@westlake.edu.cn (Y.Z.); jiahong.xia@hust.edu.cn (H.X.);
40 dr_huyu@126.com (Y.H.); guotiannan@westlake.edu.cn (T.G.).

42	Table of Contents	
43	<i>Multi-organ Proteomic Landscape of COVID-19 Autopsies</i>	1
44	Overview	3
45	Six clusters (supple for Figures 2 and 3)	3
46	Cluster 1: Receptors.....	3
47	Cluster 2: Transcription factors.....	4
48	Cluster 3: Coagulation system.....	6
49	Cluster 4: Cytokines.....	9
50	Cluster 5: Angiogenesis.....	12
51	Cluster 6: Fibrosis.....	15
52	Multi-organs proteomic changes (supple for Figures 6 and 7)	30
53	Lung and spleen.....	30
54	Liver.....	33
55	Heart.....	36
56	Kidney.....	37
57	Thyroid.....	39
58	Testis.....	40
59	References	43
60		
61		
62		
63		

64 Overview

65 In this supplementary file, we discussed in greater details the six clusters in Figure 2 and
66 proteomic changes in the seven organs as briefly discussed in Figure 6 and 7.

67 Six clusters (supple for Figures 2 and 3)

68 Cluster 1: Receptors

69 Known receptors for SARS-CoV-2

70 To investigate the virus induced pathologic features at the protein level, we first focused on
71 the lung proteome. As the entry of the virus, the known ACE2 receptor and cathepsin L1 (CTSL)
72 for SARS-CoV-2¹, known C-type lectin domain family 4 member L(CD209) and member M
73 (CLEC4M) receptors for SARS^{2,3} were identified in the lung proteome in this study. Interestingly,
74 ACE2, CD209 and CLEC4M were not significantly dysregulated in the lung compared with other
75 organs (Figure 2C). This might be associated with the multiple functions of these receptors. ACE2
76 is not only the receptor for SARS-CoV-2, but also regulate the inflammation response. It could
77 directly mediate the macrophage inflammatory function and its angiotensin converting activity
78 may protect the lung from injury by controlling excess inflammation^{4,5}. In this study, no difference
79 of ACE2 in the lung between COVID-19 patients and control groups has been found, indicating
80 that ACE2 inhibitors might not be an ideal therapy in the treatment for COVID-19⁶. On the other
81 hand, we found that the ACE2 was downregulated in the kidney and heart of COVID-19 patients
82 (Figure 2C), which might be associated with its catalytic activity in the local renin-angiotensin
83 system (RAS) in these two organs⁷. CLEC4M is a highly expressed dendritic cell (DC) specific
84 adhesion receptor in the liver, and it recognizes T cells to promote immune response⁸. CLEC4M
85 was found to be downregulated in the liver of COVID-19 patients in this study (Figure 2C). It has
86 been reported that the hepatocyte specific expression of CLEC4M could promote clearance of Von
87 Willebrand factor (vWF) in mouse model⁹, which might be associated with hypercoagulability.
88 CD209, in the same family with CLEC4M, however, showed no differential expression in neither
89 organ. CD209 and CLEC4M are all associated with HCV infection¹⁰. On the contrary, CTSL was
90 upregulated in the lung, spleen and renal medulla of COVID-19 patients, which has been reported
91 to promote the SARS-CoV-2 entry and its inhibitor could suppress virus entry effectively¹¹. The
92 inhibitor of CTSL might be an effective drug for COVID-19 treatment. The above examples
93 indicate that our data might complement the protein interaction data. The proteins which interact
94 directly with virus could also be dysregulated at protein level, which might be potential targets for
95 treatments.

96 Other receptors

97 To search for other potential targets for COVID-19, we reviewed validated virus entry
98 associated receptors and proteases¹² and checked their abundance among the seven organs.
99 Intracellular cholesterol transporter 1 (NPC1) binds to the glycoprotein of Ebola and its inhibitor
100 has been recognized as a potential target for the treatment of Ebola¹³. NPC1 is significantly
101 upregulated in most organs of COVID-19 patients, including the lung, white pulp of spleen, heart

102 and thyroid (Figure 2C). Considering the critical need for lipid and its metabolism during viral
103 replication¹⁴, NPC1 might be a potential drug target for the COVID-19. The carcinoembryonic
104 antigen-related cell adhesion molecule 1 (CEACAM1), which is the major receptor for murine
105 coronavirus on its host cells¹⁵, was significantly upregulated in the lung, liver, kidney, and thyroid
106 (Figure 2C). Its dimerization with the immune checkpoint TIM3 would further suppress adaptive
107 immunity¹⁶, so the inhibitor of CEACAM1 might be a potential target for COVID-19 treatment. In
108 the hepatocytes, CEACAM1 could respond to insulin¹⁷, which may be associated with the
109 hyperglycemia in the COVID-19 patient. In summary, this study might indicate the SARS-CoV-2
110 infection or potential drug target by the differential expression across eight organs between
111 COVID-19 patients and the control group.


112 **Cluster 2: Transcription factors**

113 Remarkably, we identified 1,107 transcription factors (TFs) among seven organs and 396 of
114 them were differentially expressed between COVID-19 and control groups (B-H adjusted p value
115 < 0.05 and $|\log_2(\text{fold-change, FC})| > \log_2(1.2)$, Table S5). By matching the experiential FC with
116 the predicted activation state in upstream regulator analysis using Ingenuity Pathway Analysis
117 (IPA), we found ten transcription factors expressed with the same trend, including nine
118 upregulated proteins and one downregulated protein (SI Figure 1, Table S5).

119 Among the ten upregulated TFs (SI Figure 1), seven of them were involved in the
120 inflammatory response, such as the acute phase response and NF- κ B signaling, reflecting the
121 extensive inflammatory infiltration in these tissues in COVID-19 patients. NF- κ B subunit 2
122 (NFKB2) is expressed in various cell types and plays a key role in proinflammation¹⁸. It functions
123 mainly through Toll-like receptor signaling pathway¹⁹ and NF- κ B signaling pathway²⁰.
124 Transcription factor p65 (RELA) is a proto-oncogene and also encodes an NF- κ B subunit protein.
125 The heterodimeric RELA-NFKB1 complex has been reported to be the most abundant form of
126 NF- κ B, and plays a key role in immune, inflammatory and acute phase responses and affect cell
127 proliferation and apoptosis²¹. In this study, RELA was upregulated in the thyroid and NFKB2 was
128 elevated in the lung, kidney and thyroid (SI Figure 1), indicating a strong immune reaction in
129 these three organs. CCAAT/enhancer-binding protein β (C/EBPB) is a transcription enhancing
130 protein, which plays an important role in liver regeneration²², immune and inflammatory
131 responses²². NF-IL6 is a member of the CCAAT/enhancer-binding protein (C/EBP) family and it
132 is essential to induce G-CSF in macrophages and fibroblasts²³. Upregulation of C/EBPB was
133 detected in the lung, spleen, liver, heart and kidney (SI Figure 1), indicating potential immune
134 dysregulation or liver damage. Signal transducer and activator of transcription 1 and 3 (STAT1/3)
135 encode proteins of the STAT protein family. STAT is regulated and controlled by some cytokines
136 and growth factors²⁴ and then transmit the signal to downstream pathways such as cell growth and
137 apoptosis^{25,26}. STAT3 can contribute to the inflammation activation in tumors by NF- κ B and IL-6-
138 GP130-JAK pathways²⁷. Upregulation of STAT3 was observed in the spleen, liver, heart and
139 kidney, while STAT1 was only observed to be upregulated in the kidney (SI Figure 1). This may
140 indicate potential dysregulation of immune state of COVID-19 patients. Transcription factor jun-B
141 (JUNB) is a proto-oncogene encoding a transcription factor protein. It belongs to activate protein
142 1 (AP-1), which is regulated by varied physiological or pathological stimuli, such as cytokines,
143 growth factors and infections²⁸. It acts as a negative regulator of proliferation by modulating cell-
144 cycle regulators²⁹. Upregulation of JUNB was observed across over the lung, spleen, liver, heart,

145 kidney and thyroid based on our analysis.

146 Other transcription factors either reflect the tissue injury or hypoxia state in COVID-19
 147 patients in this study. The RB transcriptional corepressor 1 (RB1) was upregulated in the liver and
 148 kidney (SI Figure 1), which may negatively modulate the cell cycle³⁰ and induce a higher degree
 149 of mitochondria permeabilization and apoptosis³¹. The La-related protein 1 (LARP1) was
 150 upregulated in the lung, spleen, liver, kidney and thyroid (SI Figure 1). LARP1 can regulate
 151 mRNA translation and is associated with mTOR signaling³², and it has been reported to interact
 152 with SARS-CoV-2³³. The hypoxia-inducible factor 1-alpha (HIF1A) was upregulated in renal
 153 cortex (SI Figure 1) and was also predicted active in the lung, liver, renal cortex and medulla by
 154 upstream regulator analysis, reflecting the systemic hypoxia state³⁴. Hepatocyte nuclear factor 4
 155 alpha (HNF4A) can modulate gene transcription of lipid and bile acid synthesis, gluconeogenesis,
 156 and cytokines³⁵. This function may be associated with the hepatic steatosis in COVID-19 patients
 157 because HNF4A was downregulated in the liver in this study (SI Figure 1).



158
 159 **SI Figure 1| Protein expression of transcription factors with same fold-change trend in**
 160 **experiential FC and the predicted activation state by IPA.** The y-axis stands for the protein
 161 expression ratio by TMT-based quantitative proteomics. Pair-wise comparison of each protein
 162 between COVID-19 patients and control groups was performed with student's *t* test. *, $p < 0.05$;
 163 **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.
 164

165 Cluster 3: Coagulation system

166 Blood coagulation occurred in most patients died from COVID-19 in our study with clotting
167 in lower extremity vein (Table S1), which resulted from the induced coagulation cascade and the
168 imbalance between coagulation, anticoagulation system and the impaired fibrinolytic system³⁶.

169 The activities of inflammatory cells and cytokines following virus infection would result in
170 endothelial injury and the secretion of tissue factors, which could initiate the coagulation
171 cascade^{37,38}. Tissue factor pathway inhibitor (TFPI) could inhibit the activated factor Xa (F10a),
172 tissue factor catalytic complex and then inhibit the subsequent coagulation cascade³⁹. In COVID-
173 19 patients, TFPI was upregulated in the white pulp of the spleen and liver (SI Figure 2), which
174 may occur with coagulation. Meanwhile, some coagulation factors were dysregulated in COVID-
175 19 patients. For example, coagulation factor XII (F12) was downregulated in the heart, renal
176 cortex and thyroid, coagulation factor XI (F11) was decreased in the lung, renal cortex and
177 medulla while plasma kallikrein (KLKB1) was decreased in the lung, renal cortex and thyroid (SI
178 Figure 2). F12 has been reported to be activated by KLKB1 and the activated F12 could catalyze
179 F11. The activated F11 could activate factor IX (F9), which will lead to thrombosis and the
180 formation of fibrin⁴⁰. In COVID-19 patients, F12 was decreased in the heart, renal cortex and
181 thyroid. Coagulation factor XIIIa (F13a) is activated in the last step of coagulation, which would
182 induce hemostasis. In addition, it would stabilize the fibrin clot to avoid fibrinolysis⁴¹. It was
183 increased in the renal cortex and thyroid, which could contribute to the formation of blood
184 clotting. vWF is a glycoprotein, which could bind to the factor VIII (F8) and protect F8 from
185 degradation by Vitamin K-dependent protein C (PROC). Besides, it could mediate the platelet
186 aggregation following the vascular injury⁴². The VWF was increased in the white pulp of the
187 spleen and renal cortex, which indicates the high risk of thrombosis risk. In contrast, it was
188 decreased in the heart and lung of the COVID-19 patients Von Willebrand factor (VWF).
189 Fibrinogen alpha chain, gamma chain and beta chain (FGA, FGG and FGB), which could be
190 cleaved to fibrin and generate the blood clots⁴³, were all increased in the lung and all decreased in
191 the thyroid, while FGA was only increased in the renal cortex (SI Figure 2). The prothrombin (F2)
192 was decreased in the heart (SI Figure 2).


193 The Vitamin K-dependent protein S (PROS1) and PROC belong to the protein C
194 anticoagulant system. PROS1 is the cofactor of PROC, which could degrade factor VIIIa (F8a),
195 factor Va (F5a) and protease-activated receptor 1 (PAR-1) once activated⁴⁴. Alpha-1-antitrypsin
196 (SERPINA1) is an inhibitor of PROC⁴⁵. Plasma serine protease inhibitor (SERPINA5) is also a
197 serine proteinase inhibitor and acts as an inhibitor of protein C and other coagulation enzymes⁴⁶.
198 In the COVID-19 patients, PROC was decreased in the heart and PROS1 was decreased in the
199 kidney (SI Figure 2), which may contribute to the thrombosis. SERPINA1 is also decreased in the
200 heart and thyroid. SERPINA5 is decreased in the liver, heart, renal cortex and thyroid.
201 Antithrombin III (SERPINC1) inhibits thrombin and several serine proteases, such as factors IXa
202 (F9a), Xa (F10a), XIa(F11a), XIIa (F12a), plasmin and kallikrein. It would consume rapidly
203 during disseminated intravascular coagulation (DIC)⁴⁷. In the COVID-19 patients, SERPINC1 was
204 decreased in the heart, renal medulla and thyroid (SI Figure 2). Thrombomodulin (THBD) is also
205 an anticoagulant protein, which could inhibit fibrinogen clotting and FV activation⁴⁸. It is
206 increased in the white pulp of spleen, heart and renal cortex (SI Figure 2). Heparin cofactor 2
207 (SERPIND1) is a serine proteinase inhibitor, which acts as the inhibitor of thrombin⁴⁹ and the
208 cofactor for heparin. In the COVID-19 patients, SERPIND1 significantly decreased in the liver,

Supple Info

209 heart, renal cortex, medulla and thyroid (SI Figure 2), which could lead to the generation of
210 thrombin or the procoagulant state in the body.

211 In the fibrinolytic system, plasminogen (PLG), the zymogen, could convert into serine
212 proteinase plasmin by two serine peptidases, the tissue plasminogen activator (PLAT) and
213 urokinase plasminogen activator (uPA)⁵⁰. Then the plasmin could breakdown the blood clotting. In
214 this study, PLG was downregulated in the heart and thyroid while PLTA was upregulated in the
215 liver of the COVID-19 patients (SI Figure 2). Alpha-2-antiplasmin (SERPINF2) was
216 downregulated in the heart, renal medulla and thyroid of the COVID-19 patients (SI Figure 2),
217 which may indicate the increased fibrinolysis⁵¹. Plasminogen activator inhibitor 1 (SERPINE1) is
218 a serine proteinase inhibitor and acts as a major inhibitor of plasminogen activators. In the
219 COVID-19 patients, SERPINE1 significantly upregulated in the lung, liver, heart, renal cortex and
220 medulla (SI Figure 2), which could increase the risk of thrombosis and fibrosis⁵². Alpha-2-
221 macroglobulin (A2M) could bind to varied proteinases, such as plasmin and kallikrein, and
222 inactive them. And in sepsis, it would decrease because of the formation of complex⁵³. Here, we
223 found A2M was decreased in lung, heart, renal medulla and thyroid (SI Figure 2).

Supple Info



224

225

226

SI Figure 2| Expression of dysregulated proteins in coagulation system. The y-axis stands for the protein expression ratio by TMT-based quantitative proteomics. Pair-wise

227 **comparison of each protein between COVID-19 patients and control groups was performed**
228 **with student's t test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.**
229

230 **Cluster 4: Cytokines**

231 When the SARS-CoV-2 virus enters the lung mediated by ACE2 or other receptors through
232 the superior respiratory system, it induces the secretion of inflammatory cytokines and transmits
233 the information from lesions to the whole body through the circulatory system. Then the
234 inflammation cells are attracted to the infection sites. Meanwhile, the hyperinflammatory state
235 harms the alveolar cells and influences multiple organs. The damage of the integrity of the gas
236 exchange barrier may induce hypoxia, which strengthens inflammation response⁵⁴ in the whole
237 body. The following paragraphs described the significantly dysregulated protein associated with
238 cytokines.

239 Our data showed that nicotinamide phosphoribosyl transferase (NAMPT) was upregulated in
240 the six organs (except for testis) of COVID-19 patients (SI Figure 3). NAMPT is involved in the
241 resistance of cells to oxidative stress and may help immunity cells' survival under stress such as
242 inflammation⁵⁵. Extracellular NAMPT (eNAMPT) was identified as the pre-B cell colony
243 enhancing factor⁵⁶ and an essential factor in granulocyte-colony-stimulating factor-(G-CSF)-
244 induced myeloid differentiation⁵⁷, which also could promote B cell maturation and inhibit
245 neutrophil apoptosis⁵⁸. The overexpression of NAMPT in various organs may indicate that the
246 COVID-19 patients are under activated immune response.

247 Glucocorticoid receptor (NR3C1) was significantly downregulated in five organs (except for
248 testis and thyroid) in our study (SI Figure 3). NR3C1 usually exists in the cytoplasm and would be
249 translocated to the nucleus after binding to its ligand. It could upregulate the anti-inflammatory
250 protein or inhibit the expression of pro-inflammatory protein in the nucleus⁵⁹. The significant
251 downregulation of NR3C1 in the five organs may indicate an increased inflammatory response of
252 various organs after SARS-CoV-2 infection.

253 Our data indicated that interleukin-6 receptor subunit beta (IL6ST) was significantly
254 upregulated in COVID-19 patients' thyroid (SI Figure 3). IL6ST is involved in the signal
255 transduction of IL-6-type cytokines. After binding to its receptor, IL6ST is driven to form a
256 complex by IL6, then activating Janus kinases (JAKs) and STAT3 and participating in acute phase
257 response, T cell differentiation, antibody production and proliferation^{60,61}. IL6 is a key pro-
258 inflammatory factor in the early stage of infection and is associated with prognosis⁶⁰. It has also
259 been reported to be overexpressed in the serum of severe COVID-19 patients⁶².

260 The abundance of angiopoietin like 6 (ANGPTL6) in the thyroid tissue of COVID-19
261 patients was significantly downregulated (SI Figure 3). ANGPTL6 plays a role in angiogenesis,
262 lipid metabolism and glucose metabolism⁶³. It has been reported that in the ANGPTL6 deficient
263 mouse model, obesity, lipid accumulation and insulin resistance were developed. In contrast, the
264 mouse would be more sensitive to insulin by activating the ANGPTL6, which indicates that
265 ANGPTL6 is related to insulin resistance⁶⁴. The downregulation of ANGPTL6 in the thyroid of
266 COVID-19 patients indicates a potential insulin resistance status in COVID-19 patients.

267 Our data showed that the expression of natriuretic peptides A (NPPA) in the heart tissue of
268 COVID-19 patients was significantly downregulated (SI Figure 3). NPPA belongs to the
269 natriuretic peptide family, which regulates the extracellular electrolyte homeostasis. The cardiac

270 natriuretic peptide, also known as vasodilation, is mainly produced, stored, and secreted by atrial
271 cardiomyocytes. When the blood volume increases and the heart or blood vessel wall is stimulated
272 to release atrial natriuretic peptide by a large stretch which causes powerful natriuretic and diuretic
273 effects. The knockout of NPPA receptor (NPR1) in the heart of mice exhibited cardiac
274 hypertrophy⁶⁵ and the knockout of NPPA could cause heart failure and hypertension⁶⁶. The
275 downregulation of NPPA implies potential heart damage in COVID-19 patients.

276 Downregulation of fibroblast growth factor 2 (FGF2) was detected in the liver of COVID-19
277 patients (SI Figure 3). FGF2 is a growth factor that belongs to the heparin-binding (fibroblast)
278 growth factor family. FGF2 can induce angiogenesis by promoting endothelial cell proliferation
279 and transferring its physical organization⁶⁷ and is involved in the regulation of many other
280 important biological processes such as cell survival and cell differentiation⁶⁸. The decrease of
281 FGF2 may contribute to the liver fibrosis of COVID-19 patients.

282 Fibroblast growth factor 17 (FGF17) was significantly overexpressed in the heart of COVID-
283 19 (SI Figure 3). FGF17 belongs to the family of fibroblast growth factor (FGF), which
284 participates in a variety of biological processes, including cell proliferation, cell migration during
285 embryonic development, wound healing immune responses, cell differentiation and angiogenesis
286 ⁶⁷. The upregulation of FGF17 may indicate a repair status of heart damage in the patients.

287 In the renal medulla of COVID-19 patients, IL13RA1 was significantly upregulated (SI
288 Figure 3). IL13RA1 is a subunit of the interleukin 13 receptor, which mainly mediates IL-4 signal
289 transduction. IL-4 and IL-13 both belongs to the profibrogenic cytokines⁶⁹. It has been reported to
290 protect the lung from bleomycin induced injury⁷⁰.

291 Interferon-gamma receptor 1 (IFNGR1) was overexpressed in multiple kinds of organs
292 except for the thyroid and testis (SI Figure 3). IFNGR1 is a ligand-binding chain of heterodimeric
293 gamma interferon receptors on macrophages and is a functional receptor for interferon-gamma⁷¹,
294 which triggers host immunity to virus infection⁷², such as induction of phagocyte oxidase system,
295 NO production and lysosomal enzymes for microbe destruction in macrophages⁷³. The
296 overexpression status of IFNGR1 implies the systemic immune response activated by SARS-CoV-
297 2.

298 Interleukin 1 receptor-like 1 (IL1RL1) was found to be upregulated in the kidney cortex of
299 COVID-19 patients in this study (SI Figure 3). IL1RL1 belongs to the interleukin 1 receptor
300 family, which is a receptor for interleukin-33 (IL-33)⁶⁵. IL-33 signal transduction could lead to the
301 activation of NF- κ B, MAP kinase and induction of Th2 cytokines⁶⁶. It has been reported that
302 IL1RL1 was overexpressed in aged SARS-CoV infected animals, and the overexpression of
303 IL1RL1 indicates that older macaques have a stronger host response upon viral infections than
304 young macaques⁷⁴. This may indicate that a pro-inflammatory status in COVID-19 patients.

305 Eosinophil-derived neurotoxin (RNASE2) was found to be downregulated in the COVID-19
306 patient's kidney cortex (SI Figure 3). RNASE2 is derived from eosinophils and has antiviral
307 activity and selective chemotactic properties to dendritic cells⁷⁵. It can reduce the activity of
308 single-stranded RNA virus through ribonucleolytic enzyme activity and interaction with the
309 extracellular virus by its unique structure⁷⁶. The downregulation of RNASE2 in the renal cortex
310 of COVID-19 patients may indicate dysregulation of the immune system or may be a result of
311 consuming itself to binding with and inhibit extracellular virus in COVID-19 patients.

312 Syndecan-4 (SDC4) was upregulated in the liver of the COVID-19 patients (SI Figure 3).
313 SDC4 is a membrane proteoglycan. It can support exosome biogenesis and engagement of FGF

Supple Info


314 with its receptor, which plays a role in angiogenesis, inflammation and infection⁷⁷.

315 C-X-C motif chemokine 13 (CXCL13) was observed to be upregulated in the spleen of
316 COVID-19 patients (SI Figure 3). CXCL13 is a member of the CXC chemokine family, which
317 interacts with the chemokine receptor CXCR5 to selectively chemotactic for B cells⁷⁸.
318 CXCL13/CXCR5 enhances antigen encounter and BCR-mediated B-cell activation through
319 regulation of actin cytoskeleton and activity of motor protein⁷⁹. The upregulation of CXCL13 may
320 indicate the elevated humoral immune response in the spleen of COVID-19 patients.

321 Cathelicidin antimicrobial peptides (CAMP), an antimicrobial peptide family member, was
322 downregulated in the spleen of the COVID-19 patients (SI Figure 3). When mammals encounter a
323 large number of bacterial invasions, it plays a role in the innate immune defense by inducing
324 leukocyte chemotaxis, degranulation, the response of macrophages and stimulating wound
325 healing⁸⁰. The downregulation of CAMP may indicate the dysregulation of innate immunity in
326 COVID-19 patients.

327 Retinoic acid receptor RXR-alpha (RXRA) was detected to be downregulated in the lung of
328 the COVID-19 patients (SI Figure 3). RXRA is a nuclear receptor for retinoic acid⁸¹ and regulates
329 lipid metabolism and inflammation in macrophages⁸². In response to viral infections, it plays a
330 role in weakening the innate immune system. It has been reported that the downregulation of
331 RXRA would induce the production of type I IFN and antiviral response⁸³. Downregulation of
332 RXRA may indicate a proinflammatory state in the lung of COVID-19 patients.

Supple Info



333

334 **SI Figure 3| Protein expression of dysregulated cytokines. The y-axis stands for the**
 335 **protein expression ratio by TMT-based quantitative proteomics. Pair-wise comparison of**
 336 **each protein between COVID-19 patients and control groups was performed with Student's**
 337 **T test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.**
 338

339 **Cluster 5: Angiogenesis**

340 Angiogenesis is the forming of new blood vessels from existing vessels by sprouting and
 341 splitting. Both types are discovered in almost all the organs in human bodies⁸⁴. The normal
 342 regulation of angiogenesis is governed by a fine balance between factors that induce the formation
 343 of blood vessels, such as pro-angiogenic factors and those that halt or inhibit the process.
 344 Generally, cells activated by hypoxia would release pro-angiogenic molecules, such as hypoxia-
 345 inducible factors (HIF)⁸⁵, vascular endothelial growth factor (VEGF)⁸⁶ and angiotensin (Ang)⁸⁷.
 346 In response to the pro-angiogenic factors, the endothelial cells would proliferate to form the
 347 neighboring blood vessels and secret matrix metalloproteases (MMP) to digest the blood vessel

348 walls for migration. Several protein fragments are produced by the digestion of the blood vessel
349 walls, which would intensify the proliferative and migratory activity of endothelial cells and then
350 form a capillary tube by altering the arrangement of their adherence membrane proteins, such as
351 vascular cell adhesion molecule (VCAM) and integrin⁸⁸. Finally, new blood vessels become
352 mature and stabilized by Ang, PDGF (platelet derived growth factor) and transforming growth
353 factor beta (TGFB), resulting in a continuous blood flow⁸⁹.

354 It is known that hyperbaric oxygen therapy increases the expression of HIF and activates
355 VEGF production⁹⁰. Thereby, we can speculate that severe COVID patients with ARDS after
356 ventilator treatment would be pro-angiogenesis. However, the angiogenesis may not be specific to
357 COVID cases. Recently, a study which compared tissues from seven lung samples obtained from
358 patients who died from COVID-19, tissues from 7 lungs obtained from ARDS secondary to
359 influenza A(H1N1) infected corpses and tissues from 10 age-matched uninfected lungs found that
360 the amount of new vessel generated by intussusceptive angiogenesis was 2.7 times as high as that
361 in the lungs from patients with influenza⁹¹. These results support a more profound evidence of
362 pro-angiogenesis in COVID-19 patients.

363 It is worth noting that 139 proteins involved in seven organs are related to angiogenesis by
364 our proteomic data analysis. It implies that the angiogenesis process has differences between
365 COVID-19 patients and healthy controls.


366 As a supplement to that study, our multi-organ data found a multi-organ angiogenesis
367 process, not merely in the lung. The vascular endothelial growth factors A (VEGFA) was
368 upregulated in the thyroid, and the VCAM1 was upregulated in the kidney (cortex as well as
369 medulla) of COVID-19 (SI Figure 4). The MMP protein 14 were found upregulated in the spleen,
370 lung and thyroid, and the MMP2 were induced in thyroid, lung and renal cortex in COVID-19
371 cases (SI Figure 4). We also quantified transforming growth factor beta related proteins (TGFB1)
372 and angiogenin (ANG) in our proteomics data, while it was not upregulated in all of these COVID
373 organs (SI Figure 4).

374 Besides the proteins that directly participate in angiogenesis, we also detected some potential
375 regulatory ones. Firstly, the upstream hypoxia inducible factor 1 subunit alpha (HIF1A) was
376 found to be increased in the kidney of COVID-19 cases, which activates VEGF production and
377 angiogenesis. In addition, the integrin proteins (ITGA5, ITGB1, and ITGB3) are found up-
378 regulated in the lung, heart, liver or renal cortex (SI Figure 4). Many molecules participate in the
379 processes of angiogenesis, endothelial cells proliferation and invasive signal. Integrins are the
380 principle adhesion receptors in forming extracellular microenvironment, and integrin-mediated
381 interactions mainly regulate cell proliferation, migration, and survival⁹². The chemokine CX3CL1
382 could induce the monocytes accumulation and angiogenesis during inflammation⁹³. Our data also
383 found the overexpression of CX3CL1 in COVID-19 patients' thyroid (SI Figure 4), which may
384 indicate the angiogenesis potential in thyroid. It is found that SERPIN family is anti-angiogenesis.
385 In the rat, blockage of SERPIN family would mediate the process of angiogenesis by interleukin 8
386 (IL-8) and VEGF. In assays of cellular events in angiogenesis, SERPIN family blocked the
387 processes of invasion, migration and tube formation⁹⁴. Our results showed a downregulation
388 pattern of SERPIN family proteins in multiple organs of COVID-19 cases. The SERPINA1,
389 SERPINF1, and SERPING1 are significantly reduced in heart (SI Figure 4). Besides, SERPINA1
390 was also found downregulated in the thyroid, and SERPING1 are found downregulated in the
391 renal medulla and liver (SI Figure 4). Transmembrane Protein 100 (TME100) is an intracellular

Supple Info

392 transmembrane protein. It is involved in the differentiation of arterial endothelium and vascular
 393 morphogenesis, which can be activated by AKT1 receptor⁹⁵. In addition, TME100 plays a vital
 394 role in maintaining vascular integrity and vascular genesis⁹⁶. In our proteomic data, TME100
 395 were downregulated in the lung of COVID-19 patients (SI Figure 4). It hints that the blood vessels
 396 of the lung in COVID patients might have poor stability, resulting in increased risk of
 397 angiogenesis in the lung under weak vascular integrity.

398 In conclusion, we suspected that the balance of angiogenesis is dysregulated in COVID-19
 399 patients, which results in pathological angiogenesis and causes an increased blood-vessel
 400 formation.



401
 402 **SI Figure 4| Expression of dysregulated proteins involved in angiogenesis. The y-axis**
 403 **stands for the protein expression ratio by TMT-based quantitative proteomics. Pair-wise**
 404 **comparison of each protein between COVID-19 patients and control groups was performed**

405 with Student's T test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

406

407 Cluster 6: Fibrosis

408 Fibrosis markers

409 The fibrosis process is associated with the overexpressed extracellular matrix, collagen
410 proteins and proliferation of fibroblasts⁹⁷. COL1A1 and COL1A2 are pro-alpha 1 and 2 chains of
411 type I collagen, and COL3A1 is collagen type III alpha 1 chain. All of them belong to fibril-
412 forming collagens, which are produced by fibroblasts and act as the essential components of the
413 myocardial interstitial matrix. These three proteins were downregulated in heart tissue samples
414 from COVID-19 patients (SI Figure 5). It is reported that an increased expression of collagen type
415 I and III are believed to be related to fibrosis^{98,99}. Our control samples of heart were collected
416 from patients with dilated cardiomyopathy (DCM), in which interstitial fibrosis is one of the major
417 characteristics¹⁰⁰. It is also reported that collagen type I and III were both elevated in patients with
418 DCM¹⁰¹. Due to the potential fibrosis status in our control groups, minor heart fibrosis can be
419 missed even if it exists in COVID-19 patients.


420 LAMB1, LAMB2 and LAMC1 are laminin subunits. Laminins are found in basement
421 membrane as ECM associated glycoproteins. It is reported that laminins are good prognostic
422 markers for liver fibrosis^{102,103}. Though no significant change of expression level of laminins was
423 observed in the liver, we noticed upregulated LAMB1 and LAMC1 in the white pulp of spleen,
424 and downregulated LAMB2 and LAMC1 in renal medulla (SI Figure 5). It is reported that
425 increased matrix metalloproteinase 7 and 9 (MMP7 and MMP9) are closely related to the
426 development of fibrotic kidneys, and laminins are the substrate of MMP7¹⁰⁴ and MMP9¹⁰⁵.
427 Although we didn't find significant upregulation of MMP7 and MMP9, the downregulation of
428 LAMB2 and LAMC1 may indirectly indicate renal fibrosis.

429 Matrix metalloproteinases (MMPs) and metalloproteinase inhibitors (TIMPs) maintain the
430 balance of fibrogenesis and fibrosis^{106,107}. In our dataset, we identified MMP2, MMP9, MMP14,
431 IMMP2L, MMP28, TIMP1,2 and 3. They are all identified upregulated over the different organs
432 (SI Figure 5). Fibrosis in pathological was only found in the lung, in which two kinds of inhibitors
433 were upregulated. It might indicate a positive feedback loop between MMPs and TIMPs.

434 The pulmonary fibrosis, which is associated with fibrous exudation, hyaline membrane
435 formation and alveolar space collapsed. We have identified the upregulation of lung fibrosis
436 biomarkers including Chitinase-3-like protein 1 (CHI3L1)¹⁰⁸ and pulmonary surfactant associated
437 protein B (SFTPB) (SI Figure 5). CHI3L1 was upregulated in the widest distributed among five
438 tissues including the lung, heart, liver, and kidney (SI Figure 5). SFTPB promotes the secreted
439 alveolar surfactant and sustains alveolar structure¹⁰⁹. The SFTPB was upregulated in the lung of
440 COVID-19 patients. FABP family is similar to the surfactant¹¹⁰. We found FABP3, FABP1 and
441 FABP5 were downregulated based in our dataset (SI Figure 5). The downregulated FABPs
442 indicated the potential of fibrosis.

443 Lipid metabolism is also associated with fibrosis. The fibrosis influenced by lipid metabolism
444 is the transformation between lipofibroblast and myofibroblast. TGF-beta can induce
445 lipofibroblast differentiation to myofibroblast which is the process of fibrosis generation¹¹¹. The
446 markers of lipofibroblast can be the potential markers for fibrosis, such as perilipin-2 (PLIN2). In
447 COVID-19 patients, PLIN2 upregulated in the lung, liver, heart, and spleen (SI Figure 5).

Supple Info



448

449 **SI Figure 5| Expression of fibrosis markers dysregulated between COVID-19 patients**
 450 **and the control group. The y-axis stands for the protein expression ratio by TMT-based**
 451 **quantitative proteomics. Pair-wise comparison of each protein between COVID-19 patients**

452 **and control groups was performed with Student's t Test. *, p < 0.05; **, p < 0.01; ***, p <**
453 **0.001; ****, p < 0.0001.**

454

455 **Fibrosis associated proteins**

456 Fibrosis could be divided into four stages⁶⁹. At the initiation stage, the cell and organ damage
457 would initiate a cascade of stress and immune responses. In response to the initial stress, multiple
458 inflammatory signaling pathways were activated, such as the chemokine signaling, complement
459 system, macrophage activation, NF- κ B signaling, interferon, platelet and neutrophil degranulation.
460 Thirdly, chronic inflammation would drive the differentiation or proliferation of fibroblasts and
461 wound-healing response. Fourthly, the extracellular matrix of immune cells and fibroblast cells
462 would be further modified. Here we compared the dysregulated proteins in our studies with
463 proteins in these pathways of the fibrosis and selected the top 20% dysregulated proteins with the
464 highest fold changes in a specific organ for discussion.

465

465 **Stage 1: Initiation**

466

466 In COVID-19 patients, alcohol dehydrogenase 1B (ADH1B) was downregulated in the
467 lung and liver, while it was upregulated in the white pulp of spleen, heart and thyroid. Alcohol
468 dehydrogenase 6 (ADH6) was downregulated in the lung and renal cortex. Aldehyde
469 dehydrogenase family 3 member A2 (ALDH3A2) was downregulated of in the liver, heart,
470 and renal cortex. Alcohol dehydrogenase 1C (ADH1C) was downregulated in the liver.
471 Alcohol dehydrogenase 4 (ADH4) was downregulated in the liver while it was upregulated in
472 the heart (SI Figure 6). They all belong to the alcohol dehydrogenase family and are involved
473 in the metabolic process of multiple substrates, such as ethanol, hydroxysteroids, and lipid
474 peroxidation products. It has been reported that lipid metabolism dysregulation can induce
475 hepatofibrosis in mouse model¹¹². The downregulation of these proteins in the liver of
476 COVID-19 patients might indicate the potential hepatic fibrosis. Moreover, the
477 downregulated ALDH3A2 in COVID-19 patients, may lead to the accumulation of lipid
478 precursors in the liver¹¹³. Besides, ADH1B, ADH6 are downregulated in the lung and kidney
479 of the COVID-19 patient, respectively.

480

480 In COVID-19 patients, fatty acid synthase (FASN) was upregulated in the lung, renal cortex
481 and thyroid, while it was downregulated in the liver and testis (SI Figure 6). It is a key lipogenic
482 enzyme in de novo biogenesis of fatty acids¹¹⁴ and FASN is required for profibrotic TGF- β
483 signaling¹¹⁵, which is a master regulator of fibrosis¹¹⁶. Compared with non-COVID-19 controls,
484 the upregulation of FASN in the lung, kidney and thyroid and the downregulation of FASN in the
485 liver and testis in COVID-19 patients suggest the initiation of fibrosis in lung, kidney and thyroid
486 along with the impairment of the fatty acid synthesis process in the liver and testis in COVID-19
487 patients.

488

488 Fructose-1,6-bisphosphatase (FBP1) was downregulated in the white pulp of spleen, liver and
489 renal cortex in COVID-19 patients (SI Figure 6). It is a tumor-suppressive function gene, which
490 encodes a rate-limiting gluconeogenic enzyme. Reduced expression of FBP1 was observed by
491 both quantitative real-time polymerase chain reaction(qRT-PCR) and Western Blot with increased
492 liver fibrosis score in mouse¹¹⁷. More dramatic fibrosis can be histologically detected in FBP1-
493 deficient liver¹¹⁸. The downregulation of FBP1 in spleen, liver and kidney of COVID-19 patients
494 compared with non-COVID-19 controls suggests dysfunction of glucose metabolism and fibrosis
495 potential in these tissues.

496 Lysosomal acid lipase (LIPA) was upregulated in the heart of COVID-19 patients (SI Figure
497 6). It is located in the lysosome to catalyze the hydrolysis of cholesteryl esters and triglycerides.
498 The deficiency of LIPA will lead to the accumulation of fat and cause cholesterol ester storage
499 disease (CESD). The accumulation of cholesteryl esters and triglycerides in hepatocytes result in
500 hepatomegaly with progressive fibrosis and liver cirrhosis¹¹⁹. Our data showed no significant
501 difference in LIPA expression in the liver but upregulation in the heart, which might indicate the
502 fibrosis initiation in the heart.


503 Phospholipid transfer protein (PLTP) was upregulated in the liver of COVID-19 patients (SI
504 Figure 6). It is responsible for lipid transfer and it can transfer phospholipids from triglyceride-
505 rich lipoprotein to high-density lipoprotein (HDL) and regulate lipid metabolism¹²⁰. The liver is
506 one of the main sites for the production and degradation of lipoprotein and the expression of
507 PLTP. Studies have shown that PLTP can amplify the pro-inflammatory effect of
508 lipopolysaccharide (LPS). In the mouse model, overexpression of PLTP can induce
509 atherosclerosis¹²¹. The overexpression of PLTP in COVID-19 liver tissue may be associated with
510 potential liver injury.

511 Acyl-CoA desaturase (SCD) was upregulated in the lung of COVID-19 patients (SI Figure 6).
512 It exists in the endoplasmic reticulum and is mainly involved in fatty acid biosynthesis. SCD is
513 involved in inflammation and stress regulation of different cell types, including adipocytes,
514 macrophages, endothelial cells, and muscle cells¹²². Upregulated SCD expression in the mouse
515 model promotes hepatic fibrosis through Wnt/ β -catenin signal and the lipid metabolism¹²³. Here,
516 the upregulated SCD in the lung tissue of COVID-19 patients may affect the pulmonary fibrosis
517 process by regulating metabolism reprogramming.

518 Protein transport protein Sec61 subunit beta (SEC61B) was upregulated in the lung, white
519 pulp of spleen and kidney of COVID-19 patients (SI Figure 6). It is one of the two subunits of
520 SEC61 complex which is the core component of the protein transport device in the endoplasmic
521 reticulum and is responsible for the transport of polypeptides across the endoplasmic
522 reticulum. SEC61B is associated with the cytosolic fibrosis through dysregulation of endoplasmic
523 reticulum¹²⁴. The upregulated SEC61B might indicate the fibrosis initiation in multiple COVID-19
524 organs.

525 Transforming Growth Factor Beta Receptor 2 (TGFBR2) was downregulated in the lung,
526 while it was upregulated in the heart of COVID-19 patients (SI Figure 6). It can form a
527 heterodimer with TGF- receptor type 1 and bind TGF to participate in the transcriptional
528 regulation of genes related to cell cycle, wound healing, immune suppression, and tumor
529 formation. TGF signaling mediates fibrosis after the inflammatory damage in the heart, kidney,
530 and intestines¹²⁵. TGFBR2 is also a potential target for inhibition of pulmonary fibrosis¹²⁶.

Supple Info



531

532

SI Figure 6| Expression of dysregulated proteins involved in initiation of fibrosis

533

process. The y-axis stands for the protein expression ratio by TMT-based quantitative proteomics.

534

Pair-wise comparison of each protein between COVID-19 patients and control groups was

535

performed with student's t test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

536

537

Stage 2: Inflammation

538

Aldo-keto reductase family 1 member B10 (AKR1B10) was upregulated in the renal

539

cortex of COVID-19 patients (SI Figure 7). It belongs to AKR family 1 subfamily B

540

(AKR1B)¹²⁷. Recent studies have shown that AKR1B10 is secreted into the stroma from liver

541

cells by binding to heat shock protein 90 and maybe a useful serum biomarker for advanced

542

fibrosis in nonalcoholic steatohepatitis (NASH)^{127,128}. The upregulation of AKR1B10 might

543

indicate the potential fibrosis in the renal cortex.

544

Delta-aminolevulinic acid dehydratase (ALAD) was downregulated in the lung, white

545

pulp of spleen, liver, renal cortex and thyroid of COVID-19 patients (SI Figure 7). It is the

546

principal lead binding protein in erythrocytes, which carry over 99% of the lead in blood¹²⁹. It

547

is involved in the biosynthesis of heme¹³⁰. Heme is a functional group of many heme proteins,

548

including cytochromes and hemoglobin (Hb), so it is essential for many different cellular

549

processes¹³¹. Excess free heme has been shown to exacerbate the pathogenesis of various

550

inflammatory diseases, such as sepsis, malaria, sickle cell disease, kidney disease, and

551 multiple organ failure¹³¹⁻¹³⁴. Chronic obstructive pulmonary disease (COPD) patients show
552 increased cell-free Hb, correlating with disease severity¹³⁵. However, we identified ALAD
553 was significantly downregulated in the multiple organs of COVID-19 patients.

554 Apolipoprotein was downregulated in COVID-19 patients compared with non-COVID-19
555 controls, mainly in liver, heart, kidney and thyroid (SI Figure 7). Based on the ability of
556 apolipoprotein to inhibit inflammation, oxidative stress, and tissue remodeling, as well as to
557 promote adaptive immunity and host defense, the emerging role of apolipoprotein in the
558 pathogenesis and treatment of lung diseases is increasingly recognized¹³⁶. Apolipoprotein A-I
559 (ApoA-I), apolipoprotein A-II (ApoA-II), and apolipoprotein B (ApoB) are important components
560 of lipoprotein particles that facilitate the transport of cholesterol, triglycerides, and phospholipids
561 between plasma and cells¹³⁷. Studies showed that an ApoA-I/ABCA1-dependent pathway
562 inhibited experimental ovalbumin-induced neutrophilic airway inflammation by reducing colony-
563 stimulating factor (G-CSF) production¹³⁸. ApoA-I was first proposed to play a role in the
564 pathogenesis of idiopathic pulmonary fibrosis (IPF). Based on proteomic analysis of
565 bronchoalveolar lavage fluid (BALF), the ApoA-I levels are reduced compared to healthy
566 subjects, while the treatment with ApoA-I would help to decrease the bleomycin-induced
567 inflammatory cells and collagen deposition, which reflects the negative correlation between
568 apolipoproteins and fibrosis¹³⁹. Based on our analysis, apolipoproteins were significantly
569 decreased in six tissues except for the testis to certain degrees, indicating a pro-fibrosis potential in
570 different organs in patients with COVID-19 infection. Furthermore, Apolipoprotein C-II (ApoC-
571 II) is a small exchangeable apolipoprotein found in triglyceride-rich lipoproteins (TRL), such as
572 chylomicrons (CM), very-low-density lipoproteins (VLDL), and in high-density lipoproteins
573 (HDL)^{140,141}. ApoC-II plays a critical role in TRL metabolism by acting as a cofactor of
574 lipoprotein lipase (LPL), the main enzyme that hydrolyzes plasma triglycerides (TG) on TRL¹⁴².
575 The reduction of ApoC-II based on our analysis further indicated the reduced metabolic level of
576 triglycerides-rich lipoproteins in patients with COVID-19 infection.

577 Antioxidant 1 (ATOX1) was downregulated in the white pulp of spleen, renal cortex and
578 thyroid of COVID-19 patients (SI Figure 7). It plays a crucial role as a copper chaperone¹⁴³⁻¹⁴⁵. It
579 is worth mentioning that ATOX1 was found to have a pivotal role in inflammation via inhibition
580 of inflammatory responses. The decrease of ATOX1 suggested the occurrence of prophase
581 inflammation¹⁴⁵, which might indicate an inflammation stage before fibrosis in these organs.

582 Complement component 3 (C3) was downregulated in the lung, heart and thyroid in COVID-
583 19 patients, but it was upregulated in the white pulp of spleen (SI Figure 7). The complement
584 system is a crucial part of the immune system that is involved in the pathogenesis of various
585 inflammatory lung conditions, including infectious disease and chronic obstructive pulmonary
586 disease¹⁴⁶⁻¹⁴⁹. Complement component 3 (C3) plays a central role in the activation of the
587 complement system¹⁴⁹⁻¹⁵¹. Additionally, C3-targeted intervention may provide broader therapeutic
588 control of complement-mediated inflammatory damage in COVID-19 patients¹⁵².

589 Catalase (CAT) was downregulated in the lung, white pulp of spleen, liver and renal
590 cortex of COVID-19 patients (SI Figure 7). It is an important antioxidant enzyme in the
591 process of defense against oxidative stress¹⁵³. It is preferentially expressed in the alveolar
592 epithelial cells. The downregulated CAT has been reported in the fibrotic lungs of human,
593 which may be associated with the protective role of CAT against inflammation and
594 subsequent fibrosis associated processes, such as TGF- β expression and collagen content¹⁵⁴.

595 The downregulated CAT may trigger the proinflammation state and contribute to the fibrosis
596 process in these organs.

597 Monocyte differentiation antigen (CD14) was upregulated in the white pulp of spleen and
598 renal cortex of COVID-19 patients (SI Figure 7). It is a surface antigen and preferentially
599 expressed on monocytes or macrophages, which plays multiple pivotal biological roles, such as
600 innate immune response to binding bacterial lipopolysaccharide¹⁵⁵. Additionally, it has been found
601 that CD14 was highly expressed in the lung, liver, spleen, and its expression was dynamically
602 changed in the course of inflammation¹⁵⁶. Another study showed that systematic inhibition of
603 CD14 could reduce organ inflammation, which was tested in lung, liver, spleen, and kidneys.
604 They also reported that ICAM-1 and VCAM-1 were significantly inhibited in the kidneys by
605 inhibiting CD14¹⁵⁷.

606 Chitinase-3-like protein 1 (CHI3L1) was upregulated in the lung, liver, heart, renal
607 cortex and medulla of COVID-19 patients (SI Figure 7). It is a member of chitinase family¹⁵⁸
608 and is highly expressed in the liver¹⁵⁹. In arthritic articular cartilage, CHI3L1 functions as a
609 growth-factor for fibroblasts¹⁶⁰. In the bleomycin-treated mice, it would decrease transiently
610 due to its protective role in the injury. Then it would increase and play a profibrotic role in
611 activating macrophages and inducing the fibroblast and matrix deposition¹⁰⁸. The upregulated
612 CHI3L1 in multiple organs of COVID-19 patients may indicate a profibrotic state.

613 C-reactive protein (CRP) was upregulated in six organs (except testis) of COVID-19
614 patients (SI Figure 7). Fibrosis is caused by scar tissue formation in internal organs. Two
615 closely related human serum proteins, serum amyloid P (SAP), and C-reactive protein (CRP),
616 strongly affect fibrosis¹⁶¹. In multiple animal models, and even Phase 1 and Phase 2 clinical
617 trials, CRP indicates the potential of fibrosis^{162,163}. It's worth noting that CRP was significantly
618 upregulated in almost all of organs based on our analysis. This prompts us that the follow of
619 CRP levels could potentially indicate the fibrogenesis status of COVID-19 patients.

620 FGB and FGG were upregulated in the lung but downregulated in the thyroid of
621 COVID-19 patients (SI Figure 7). They are both blood-borne glycoproteins and components
622 of fibrinogen, which play a role in vascular injury and dysregulated in thrombophilia¹⁶⁴, as
623 well as a proinflammatory role under several pathologic conditions including pulmonary and
624 kidney fibrosis¹⁶⁵. Fibrinogen was substantially higher in COVID-19 patients than those in
625 healthy controls¹⁶⁶. Meanwhile, in the process of acute phase response, interleukin-6 (IL-6)
626 could induce upregulation of the three fibrinogens, FGA, FGB and FGG, in liver and lung
627 epithelium¹⁶⁷. Consistent with fibrosis observed in the lung of COVID-19, FGB and FGG
628 were evaluated in lung but decreased in thyroid.

629 Glutathione Peroxidase 2 (GPX2) was found to be elevated in the liver of COVID-19
630 patients (SI Figure 7). GPX2 is a glutathione peroxidase, which catalyzes the reduction of
631 hydrogen peroxide (H₂O₂) by glutathione. Oxidative stress initiates epithelial cell injury and
632 fibrogenesis. Hence decreasing of glutathione results in hepatic fibrosis¹⁶⁸ and pulmonary
633 fibrosis¹⁶⁹. Elevated GPX2 in the liver predicts fibrogenesis in the liver of COVID-19 patients.

634 Intercellular adhesion molecule (ICAM)-1 was upregulated in the spleen, liver, heart, kidney
635 and thyroid of COVID-19 patients (SI Figure 7). ICAM1 is a member of the immunoglobulin
636 (Ig) superfamily expressed on fibroblasts and epithelial cells. ICAM deficiency suppresses
637 cytokine production, white cell infiltration and attenuates fibrogenesis¹⁷⁰. The upregulation of
638 ICAM1 indicates the occurrence of inflammation and fibrosis.

Supple Info


639 Protein tyrosine phosphatase non-receptor type 1 (PTPN1) was upregulated in five organs
640 (except the heart and testis) of COVID-19 patients (SI Figure 7). It is the founding member of
641 the protein tyrosine phosphatase (PTP) family. PTP1B was upregulated in the fibrotic liver, which
642 may be induced by TGF- β 1¹⁷¹. Based on our analysis, the elevated level of PTPN1 can be
643 observed in the lung, spleen, liver, kidney and thyroid, indicating a potential fibrosis status in
644 these organs.

645 Serum Amyloid A1(SAA1) was found to be significantly upregulated in the lung, liver, heart
646 and kidney of COVID-19 patients (SI Figure 7). SAA1 is a major acute phase protein that is
647 highly expressed in response to inflammation and tissue injury¹⁷². Significant upregulation of
648 SAA1 may indicate an inflammation status in these organs, which may contribute to fibrosis in the
649 end.

650 Superoxide dismutase 1(SOD1) was found to be down-regulated in the spleen, heart, kidney
651 and thyroid of COVID-19 patients (SI Figure 7). SOD1, a copper and zinc binding protein is an
652 enzyme for cleaning free superoxide radicals. Superoxide dismutase can act as a potential anti-
653 fibrotic drug for Hepatitis C related fibrosis¹⁷³. In our proteomics data, the downregulation of
654 SOD1 indicates a potential fibrosis status in these organs.

655 Vascular cell adhesion molecule 1(VCAM1) was upregulated in the kidney of COVID-19
656 patients (SI Figure 7). It is a cell surface sialoglycoprotein expressed by cytokine-activated
657 endothelium. VCAM1 is upregulated in IPF, which is responsive to TGF- β 1¹⁷⁴. The upregulation
658 of VCAM1 in the kidney may indicate the fibrosis potential in COVID-19.

Supple Info



659

660

SI Figure 7 | Expression of dysregulated proteins involved in inflammation of fibrosis

661 **process.** The y-axis stands for the protein expression ratio by TMT-based quantitative proteomics.
662 Pair-wise comparison of each protein between COVID-19 patients and control groups was
663 performed with student's t test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

664

665 **Stage 3: Proliferation**

666 β -arrestin1 (ARRB1) was downregulated in the lung, white pulp of spleen, liver and renal
667 medulla of COVID-19 patients (SI Figure 8). It has been demonstrated to function as a
668 molecular scaffold that regulates cellular function by interacting with other partner proteins, and
669 involved in multiple physiological processes including immune response, tumorigenesis and
670 inflammation¹⁷⁵. The β -arrestins are universally expressed, but the neural and immune systems
671 have a much higher expression level. Previous studies have reported that ARRB1 specifically
672 regulates the survival and homeostasis of CD4⁺ T cells and thus affects the adaptive immune
673 responses¹⁷⁶. The downregulation of ARRB1 in lung, spleen, liver and kidney in COVID-19
674 patients further suggests an end-stage immune response in COVID-19 patients. In addition,
675 ARRB1 has been reported to stimulate several signaling pathways involved in fibrosis, such as
676 TGF- β pathway. These pathways would affect cell growth, extracellular matrix deposition and
677 activation of inflammation¹⁷⁷. The dysregulated ARRB1 may participate in the fibrosis process in
678 COVID-19.

679 Cadherin 2 (CDH2) was downregulated in the renal cortex of COVID-19 patients (SI Figure
680 8). It can mediate the adhesion between homotypic cells by binding to the CDH2 chain on another
681 cell's membrane. In the process of IPF, CDH2 was transformed into CDH11, leading to the
682 aggravation of pulmonary fibrosis¹⁷⁸. Our data show that the expression of CDH2 in the kidney of
683 COVID-19 patients is decreased. However, the reduction of CDH2 in the renal cortex may be due
684 to the conversion of CDH2 to CDH11, which needs further investigation.

685 Stromal cell-derived factor 1 (CXCL12) was upregulated in the thyroid of COVID-19
686 patients (SI Figure 8). It has been reported as a pre-B cell growth factor and would contribute to
687 lymphopoiesis and embryogenesis homeostatic processes via regulating the migration of cells¹⁷⁹.
688 Moreover, exogenous CXCL12 would promote the migration and proliferation of human lung
689 fibroblasts and CXCR4/CXCL12 plays an important role in IPF¹⁸⁰. The upregulated CXCL12 in
690 the thyroid may be an underlying factor for fibrosis.

691 Hypoxia-inducible factor-1 (HIF-1) was upregulated in the renal cortex of COVID-19
692 patients (SI Figure 8). It regulates genes and processes in response to hypoxia. It was upregulated
693 in chronic kidney disease and could promote fibrogenesis¹⁸¹. The upregulated HIF1A protein in
694 COVID-19 patients may be an early fibrosis maker.

695 Insulin receptor (INSR) was upregulated in the white pulp of spleen, liver and thyroid of
696 COVID-19 patients (SI Figure 8). It binds with insulin or other ligands to activate the insulin
697 signaling pathway. In C57BL/6 mice, when insulin receptor (*InsR*) are haploinsufficient, the mice
698 showed impaired hepatic insulin signaling and promoted liver fibrosis accumulation, which
699 correlated with the induction of matrix stabilization protein Lysyl oxidase like 2 (Lox12)¹⁸². The
700 upregulated INSR may indicate the activated insulin signal and a more stabilized matrix.

701 Integrin alpha-1 (ITGA1) was downregulated in the lung of COVID-19 patients (SI Figure
702 8). It belongs to a subunit of integrin protein family. Together with the beta 1 subunit, ITGA1 is
703 the receptor for laminin and collagen. Integrins are involved in communicating with the
704 extracellular matrix, inflammatory cells, fibroblasts and parenchymal cells. Hence, they are

705 intimately involved in the processes of initiation and maintenance and resolution of tissue fibrosis.
706 Fibrosis models of multiple organs have demonstrated that integrins have profound effects in
707 fibrotic process. It is now known that integrins modulate the fibrotic process through activating
708 TGF- β ¹⁸³. Our results found a declined ITGA1 in the lung, suggesting a potential downregulated
709 activity of integrin in the lung.

710 Methyl-CpG-binding protein 2 (MECP2) was downregulated in the lung and liver of
711 COVID-19 patients (SI Figure 8). It is expressed by hepatic stellate cells (HSCs) and involves in
712 the liver fibrosis in mice by silencing the peroxisome proliferator-activated receptor gamma
713 (PPARgamma)¹⁸⁴. However, our data found downregulation of MECP2 in the liver.

714 Periostin (POSTN) was downregulated in the liver and heart of COVID-19 patients (SI
715 Figure 8). It is a secreted protein that exists in the extracellular matrix and could promote tissue
716 remodeling¹⁸⁵. Overexpression of POSTN was reported in the lungs of patients with IPF and
717 deficiency of POSTN would protect the lung from fibrogenesis induced by bleomycin¹⁸⁶. It was
718 upregulated after stimulation by TGF- β and would promote extracellular matrix deposition and
719 mesenchymal cell proliferation. The dysregulated POSTN may participate in the fibrosis process
720 in COVID-19.

721 Protein S100-A4 (S100A4) was downregulated in the spleen of COVID-19 patients (SI
722 Figure 8). It is a fibroblast specific protein and contains two EF-hand calcium-binding domains,
723 belonging to the S100 family of calcium-binding proteins. It has been studied in many kinds of
724 fibrosis¹⁸⁷.


725 Plasminogen activator inhibitor 1 (SERPINE1) was upregulated in the lung, liver, heart renal
726 cortex and medulla of COVID-19 patients (SI Figure 8). It inhibits the activities of urokinase-
727 type/tissue-type plasminogen activator (uPA/PLTA), plasmin and plasmin-dependent MMP¹⁸⁸,
728 which are all involved in the proteolytic degradation. In the fibrosis tissue, SERPINE1 is
729 significantly upregulated. Based on our analysis, elevated SERPINE1 may indicate a potential
730 fibrinolysis inhibition in these organs and result in fibrosis.

731 Signal transducer and activator of transcription 3 (STAT3) was upregulated in the white pulp
732 of spleen, liver, heart and renal cortex of COVID-19 patients (SI Figure 8). It is an important
733 regulator of inflammation which is the primary step of fibrosis. It is activated in the inflammatory
734 stage of tissue fibrosis and promotes fibrosis by inducing ECM¹⁸⁹. Based on our analysis,
735 overexpression of STAT3 may induce fibrosis in COVID-19 patients.

736 Thrombospondin 1 (THBS1) was upregulated in the liver, heart and kidney of COVID-19
737 patients (SI Figure 8). It is a glycoprotein that is released by platelet α -granules and mediates cell-
738 to-cell and cell-to-matrix interactions. THBS1 involves the fibrosis in TGF- β -dependent or -
739 independent mechanisms and its antagonist could reduce the fibrosis¹⁹⁰. The elevated level of
740 THBS1 in the liver, heart and kidney may suggest potential fibrosis in COVID-19 patients.

741 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta (YWHAB)
742 was downregulated in the white pulp of spleen, heart and renal cortex of COVID-19 patients (SI
743 Figure 8). It is a member of the 14-3-3 protein family, which mediates signal transduction by
744 binding to phosphoserine protein and participates in metabolism, apoptosis and cell cycle
745 regulation¹⁹¹.

Supple Info



746

747

SI Figure 8| Protein expression of dysregulated proteins involving in proliferation of fibrosis process. The y-axis stands for the protein expression ratio by TMT-based quantitative proteomics. Pair-wise comparison of each protein between COVID-19 patients and control groups was performed with Student's T-test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

751

752

Stage 4: Modification

753

Tyrosine-protein kinase receptor UFO (AXL) was downregulated in the white pulp of spleen while it was upregulated in the thyroid of COVID-19 patients (SI Figure 9). It belongs to the Tyro3-Axl-Mer (TAM) receptor tyrosine kinase subfamily. TAM recognizes growth factors and transduces extracellular signals into the cell, participating in cell survival and proliferation, migration, and differentiation. Studies on liver fibrosis indicate that the activation of AXL and ligand Gas6 is a necessary condition for hepatic stellate cell differentiation and targeting AXL can inhibit liver fibrosis levels¹⁹². Studies have shown that in the model of liver injury induced by

759

760 lipopolysaccharide, AXL binds to the ligand Gas6, activates macrophage autophagy, and inhibits
761 inflammasomes¹⁹³. These studies indicate that AXL is involved in multiple stages of the fibrosis
762 process after liver injury. However, there was no difference in the liver of COVID-19 patients. The
763 upregulated AXL in the thyroid tissue of COVID-19 patients may participate in the fibrosis
764 process.

765 BCL2 associated X (BAX) was downregulated in the white pulp of spleen, heart, renal
766 medulla and thyroid of COVID-19 patients (SI Figure 9). It is a member of BCL2 apoptosis
767 regulatory protein family. It can promote the release of Cytochrome C, the activation of caspase-3,
768 and then apoptosis. TGF- β induced inflammation and fibrosis is BAX dependent and null
769 mutation of BAX can influence the TGF- β stimulated TIMP and MMP expression¹⁹⁴.

770 Fibrosis is the accumulation of ECM components, or simply called collagen, in given
771 tissues¹⁹⁵. Four types of collagens were dysregulated in COVID-19 patients (SI Figure 9).
772 Collagen alpha-1(I) chain (COL1A1) was downregulated in the heart. It was identified as a
773 potential biomarker for heart failure progression, and its upregulation was related to the
774 percentage of heart fibrosis¹⁹⁶. The downregulation of COL1A1 may be associated with
775 myocardial hypertrophy in control groups. Collagen alpha-1(IV) chain (COL4A1) was found
776 upregulated in the spleen of COVID-19 patients. COL5A1 was found upregulated in the liver and
777 heart of COVID-19 patients (SI Figure 9). COLV is a minor component of the total hepatic
778 collagen (10–16%), but it could proliferate rapidly in active fibrogenesis in response to liver
779 injury¹⁹⁷. COLV binds TGF- β 1 in the ECM, thus controlling the availability of the pro-fibrotic
780 cytokine, which mediates fibrogenesis of neighboring cells. TGF- β 1 could stimulate COL5A1
781 mRNA expression in mouse HSC culture, which is followed by deposition of COLV in the culture
782 matrix with resultant COLI and III fibrillar assembly in the matrix¹⁹⁸. The upregulated COL5A1
783 may suggest damage and fibrogenesis in the liver and heart. COL6A3 was found upregulated in
784 the spleen and downregulated in the liver, heart and kidney of COVID-19 patients (SI Figure 9).
785 COL6, along with its derivatives are well-known biomarkers for hepatic fibrosis^{199,200}.

786 Cathepsin L (CTSL) was upregulated in the lung, white pulp of spleen and thyroid of
787 COVID-19 patients (SI Figure 9). Cathepsin D (CTSD) was observed upregulated in the lung,
788 liver, heart and thyroid of COVID-19 patients (SI Figure 9). Cathepsin is a lysosomal cysteine
789 proteinase that participates in a role of intracellular protein catabolism and has been implicated in
790 myofibril necrosis in myopathies and myocardial ischemia, and the renal tubular response to
791 proteinuria²⁰¹. CTSL was reported as a potential fibrosis marker in the liver, which would regulate
792 the extracellular matrix degradation and tissue remodeling²⁰². Hepatic stellate cells (HSCs) are
793 responsible for extensive synthesis and deposition of ECM during liver fibrosis. CTSD has
794 important functions outside lysosomes including degradation of ECM components when secreted
795 to the extracellular space²⁰³. CTSD was observed upregulated during the activation of rat HSCs
796 and liver fibrogenesis²⁰⁴. It was reported that CTSD can drive HSCs proliferation and promote
797 their fibrosis potential in an *in vivo* mice model²⁰⁵. The upregulated CTSD in COVID-19 patients
798 may indicate the fibrosis process.

799 Tumor necrosis factor receptor superfamily member 6 (FAS) was upregulated in the lung,
800 white pulp of spleen and thyroid of COVID-19 patients (SI Figure 9). It is a key member of the
801 TNF-receptor superfamily as a receptor of TNFSF6/FASLG²⁰⁶. It has been reported that it played
802 a central role in the programmed cell death, and has been implicated in the diseases of immune
803 system leading to inflammation²⁰⁷. The elevated FAS was known in cystic fibrosis lungs²⁰⁸ as

804 well induced inflammation and fibrosis in the liver by Hepatitis C virus²⁰⁹. The increased FAS
805 may indicate inflammation and fibrosis in fatal patients.

806 Kallikrein B (KLKB1) was downregulated in the lung, renal cortex and thyroid of COVID-19
807 patients (SI Figure 9). It is a plasma glycoprotein that participates in the surface-dependent
808 activation of blood coagulation, fibrinolysis, kinin generation and inflammation. The plasma
809 kallikrein has been reported to activate the TGF- β 1 signaling by depredeating the latency-
810 associated protein and is associated with liver fibrosis in patients²¹⁰. The declined KLKB1 may be
811 associated with dysregulated blood coagulation.


812 The transcription factor farnesoid X receptor (NR1H4) was upregulated in the renal cortex of
813 COVID-19 patients (SI Figure 9). It is ligand-activated and highly expressed in liver, kidney,
814 intestine and adrenal glands. NR1H4 can reduce liver cell damage and fibrosis by upregulating
815 small heterodimer companion (SHP), thereby inhibiting the production of Type I collagen and
816 TGF- β signaling²¹¹. The elevated expression of NR1H4 in COVID-19 patients may participate in
817 the fibrosis process.

818 Plasminogen (PLG) was downregulated in the heart and thyroid of COVID-19 patients (SI
819 Figure 9). Its main function is to degrade fibrin clots then bind and activate on fibrin clots. The
820 function of plasminogen activator inhibitor type-1 (PAI-1) is to regulate micro-environmental
821 homeostasis and wound healing by inhibiting plasmin-mediated MMP activation²¹². Plasminogen
822 is dramatically increased in adults with ARDS. It is reported that additional plasminogen may be
823 effective in the treatment of lung lesions and hypoxemia during COVID-19 infections²¹³.

824 Prostaglandin-endoperoxide synthase 2 (PTGS2) was upregulated in the liver of COVID-19
825 patients (SI Figure 9). It converts arachidonate to prostaglandin H2 (PGH2), a fundamental step in
826 prostanoid synthesis^{214,215}. Upregulation of PTGS2 results in an increased level of COX-2, which
827 potentially reduces Th2 immune responses and promotes neutrophil recruitment in hepatic
828 ischemia/reperfusion injury²¹⁶. The injury may be related to fibrogenesis²¹⁷. PTGS2 is
829 overexpressed in the bleomycin-induced pulmonary fibrosis, which was MMP-19 dependent²¹⁸.
830 The elevated PTGS2 may indicate that COVID-19 patients are suffering from liver fibrogenesis
831 by the activated immune system.

832 Metalloproteinase inhibitor 1 (TIMP1) was upregulated in the lung, liver, renal medulla and
833 thyroid of COVID-19 patients (SI Figure 9). It is a natural inhibitor of the matrix
834 metalloproteinases. TIMP-1 is related to the deposition of ECM, leading to fibrosis, which is
835 elevated in the profibrotic environments²¹⁹. While there is no difference in fibrosis severity
836 between wild type and *Timp1*^{-/-} mice, which may be due to the inhibition of inflammation by

837 TIMP1. The upregulated TIMP1 may be due to the fibrosis generation in these organs.



838

839

840 **SI Figure 9| Expression of dysregulated proteins involved in modification of fibrosis**
 841 **process.** The y-axis stands for the protein expression ratio by TMT-based quantitative proteomics.
 842 Pair-wise comparison of each protein between COVID-19 patients and control groups was
 843 performed with student's t test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

843

844

845 **Multi-organs proteomic changes (supple for Figures 6 and 7)**

846 **Lung and spleen**

847 The lung is the primary and the only positive organ of virus infection (Table S1). To
848 investigate the virus induced pathological features, we first focused on the lung proteome. The
849 most significant pathologic injury in the lung of COVID-19 patients is fibrosis, accompanying
850 with fibrosis associated fibrous exudation, hyaline membrane formation and alveolar space
851 collapsed²²⁰ (Figure S1).

852 As discussed above (Cluster1: Receptor), the expression of ACE2, the known receptor of
853 SARS-CoV-2, and the expression of CD209 and CLEC4M, two receptors of SARS, shown no
854 significant changes in COVID-19 patients (Figure 2C). However, a couple of proteins acting as
855 the cellular entry of other viruses, such as CTSL, CEACAM1 and NPC1, were found upregulated
856 in the COVID-19 patients (Figure 2C).

857 During virus replication, double-stranded RNA (dsRNA) and uncapped mRNA of virus,
858 known as viral pathogen-associated molecular patterns (PAMPs), could trigger the innate immune
859 response once recognized by the pattern recognition receptors (PRRs) in the cytoplasm²²¹.
860 According to the PRRs list²²¹, we found CGAS was upregulated in the lung of COVID-19 patients
861 (Figure 5A, SI Figure 10a). The upregulation of CGAS further induces downstream response
862 including Type I interferon secretion and the release of several other cytokines²²².

863 During the transcription and replication of coronavirus, host gene expression could be
864 blocked by mRNA suppression and translation shutoff. For example, the N protein has been
865 adapted to protect viral mRNA from degradation²²³. The lung is the only organ where SARS-CoV-
866 2 viral RNA was tested to be positive in our study. Therefore, we compared the virus associated
867 pathways in the lung with the ones in other organs (Figure 4C). The trend of EIF2 signaling and
868 tRNA charging showed a similar trend in the lung and liver (Figure 4A). We found an inhibition of
869 ARE-mediated mRNA degradation pathway in the lung and an activation trend in all the other
870 organs (Figure 4C). Eukaryotic translation initiation factor 4E (EIF4E) as the cap-binding protein
871 in the host cell only increased in the lung of COVID-19 patients (Figure 5A, SI Figure 10a), which
872 could be a potential target for human coronavirus 229E (HCoV-229E)²²⁴.

873 Once virus infected the host, viral pathogen-associated molecular patterns (PAMPs), such as
874 dsRNA, would trigger host immune cells for defense. The major pathology in immune is hyper
875 inflammation, such as C-reactive protein (CRP) increasing and lymphopenia in the peripheral
876 blood and spleen of these patients (Figures S1,2). The white pulp of spleen consists of T and B
877 lymphocytes while the marginal zone of white pulp and red pulp contains the APCs.
878 Pathologically, we observed that white pulp was atrophic while no pathological changes were
879 observed in the red pulp (Figure 1), the latter of which is consistent with our proteome data (Table
880 S4).

881 In the lung of COVID-19 patients, high affinity immunoglobulin gamma Fc receptor I
882 (FCGR1A) and low affinity immunoglobulin gamma Fc receptor II-a (FCGR2A) was upregulated
883 (Figure 5A). While in the spleen, high affinity immunoglobulin epsilon receptor subunit gamma
884 (FCER1G), FCGR1A and FCGR2A were all upregulated (Figure 5A). These receptors expressed
885 on the monocytes surface for antigen presentation. TNF receptor-associated factor 6 (TRAF6) was


886 upregulated in the spleen of COVID-19 patients, which plays a role in dendritic cell maturation
887 and stimulation of naïve T cell²²⁵. TYRO protein tyrosine kinase-binding protein (TYROBP) was
888 upregulated in the lung and spleen of COVID-19 patients, which is involved in NK cell anti-viral
889 function and inflammatory reactions²²⁶. All these proteins participating innate cell activity indicate
890 the activated antigen presenting process or anti-viral functions.

891 The activation of NK cells might also be negative feedback for the decreasing T-, B-
892 lymphocytes. Consistently, the adaptive immune associated pathways including B cell receptors
893 signaling, NFAT in regulation of the immune response were all inhibited (SI Figure 10b).
894 Tyrosine-protein kinase (LCK), which activates CD8 T cell combined with LR2R²²⁷, was
895 downregulated (Figure 5A). CEACAM1 as a negative regulator of adaptive immune also
896 upregulated (Figure 5A) which indicated the immunosuppression state in the COVID-19 patients
897 and might strengthen the proinflammatory cytokine secreted.

898 Except for the above proteins, a well-known immunosuppression molecular, CD274 (PD-L1),
899 is upregulated significantly (Figure 5A) and PD-1, PD-L1 pathway was activated (SI figure 10c)
900 in the spleen of COVID-19 patients. When mapping our data with an immune checkpoint database
901 including 21 immune checkpoint proteins²²⁸, we found three dysregulated proteins, including
902 CEACAM1, CD276 and CD274 (Figure 5A). Upregulation CEACAM1 and CD276 appeared in
903 the lung and upregulation of CD274 was in the spleen. The upregulation of these checkpoint
904 proteins may indicate the suppression of adaptive immune function.

905 The proinflammatory state including the excess cytokines would induce tissue injury. M2
906 macrophages mainly participate in the wound healing and tissue repair process. Sterol 26-
907 hydroxylase (CYP27A1) was upregulated in the COVID-19 patients (Figure 5A), which promotes
908 M2 conversion through increasing 27HC synthesis²²⁹. In addition, the maker of M2, CD163, was
909 upregulated in six organs (except testis), indicating that the wound healing and tissue repair have
910 been induced in the COVID-19 patients. Due to the excess export of lymphocytes to other injury
911 organs and increased apoptosis, exhausted lymphocytes and the white pulp may atrophy²³⁰.

912 In summary, these dysregulated proteins and enriched pathways suggest that the innate
913 immune was activated, the APCs were activated and increased with simultaneous wound healing,
914 while the adaptive immune was inhibited, which indicates the hyper inflammation state in the
915 COVID-19. To further validate the immune state in COVID-19, we performed the
916 immunohistochemical (IHC) staining for immune cells in the spleen and found that total T cell
917 (CD3), T helper cells (CD4), cytotoxicity T cells (CD8), and B cells (CD20) all decreased in the
918 spleen (Figure S6). On the contrary, macrophage (CD68), especially M2 (CD163) all increased
919 (Figure S6). These hyper inflammation state might further induce tissue over-repair and fibrosis.



920

921

SI Figure 10| Characteristic proteins in lung and spleen of COVID-19 patients. a.

922

Hypothetical crosstalk model between lung and spleen in COVID-19 patient. (a)

923

of four processes of the COVID-19 patients after SARS-CoV-2 infection including virus-host

924

interaction, immune microenvironment of COVID-19 patients, fibrosis and microthrombus

925

formation associated proteins. (1)-(4) in (a) shows four processes of virus infection the host cells

926

including virus entry, virus RNA release, dsRNA translation and virus replication. Red box with

927

black font is the upregulation protein and green box with black font is the downregulation protein.

928

Upregulation pathway (or biological process) is red box with white font and downregulation

929

pathway (or biological process) is green box with white font. Blue box represents the pathology of

930

lung. **b.** Pathways enriched by IPA for 1606 pulmonary dysregulation proteins. **c.** Pathways

931

enriched by IPA for 1726 splenic dysregulation proteins.

932

933 Liver

934 In the COVID-19 group, the main pathological changes in the liver are the steatosis and
935 coagulative necrosis (Figure S1). Pathway analysis of 1,969 significant dysregulated proteins in
936 the liver shown the acute phase response signaling, eIF2 signaling, fatty acid α and β -oxidation,
937 necroptosis signaling pathway, apoptosis signaling and stearate biosynthesis were activated while
938 the xenobiotic metabolism was inhibited (SI Figure 11a). Several key proteins related to
939 necroptosis were shown in SI Figure 11b. The steatosis and necrosis processes are always
940 accompanied by inflammation^{231,232}. Thereby, we mapped our differentially expressed proteins in
941 the liver with the immunological proteins from GSEA-immunologic gene sets and then employed
942 IPA for pathway analysis for the overlapping proteins (SI Figure 11c). The key proteins
943 participating in these pathways are shown in Figure 5B. The proinflammatory state in the liver
944 was reflected with activated IL-6, IL-8 signaling and NF- κ B signaling. Remarkably, we found that
945 hepatic fibrosis signaling (SI Figure 11c) was activated and hepatic fibrosis markers including
946 metalloproteinase inhibitor 1 (TIMP1) and plasminogen activator inhibitor 1 (SERPINE1)²³³ were
947 upregulated (SI Figure 11b). These dysregulated proteins might indicate that the chronic
948 inflammation and fibrosis process have initiated at molecular level though no obvious pathological
949 changes were observed. This phenomenon might be clinically meaningful for patients who have
950 recovered to take special care for the potential to develop fibrosis.

951 We hence propose a hypothetical model in the liver of COVID-19 patients according to the
952 main pathological changes and the enriched pathways (SI Figure 11d). Firstly, the inflammation
953 biomarkers, such as C reactive protein (CRP), serum ferritin, IL-6 were significantly elevated in
954 COVID-19 patients (Figure S2), which might be stimulated by the inflammatory response derived
955 from the lung through cytokines and immune cells. The upstream regulator, STAT3, and pathway
956 analysis, NF- κ B signaling pathways were enriched, which were induced by cycling IL-1, IL-6 and
957 IL-8. As a result, the acute phase response was activated and the expression of CRP
958 upregulated²³⁴. Due to the activated NF- κ B signaling, the two related catalytic subunits of IKK
959 kinase complex and its regulatory subunit, IKBKG, NEMO and IKKG, were all upregulated. The
960 IKK kinase complex induced the degradation of I κ B inhibitory molecules and lead to the nuclear
961 translocation of the NF- κ B dimers, which would activate transcription of genes participating in the
962 immune and inflammatory response²³⁵. Besides, the NF- κ B could also activate IL-8 signaling and
963 TNF signaling, which may contribute to hepatic fibrosis process^{236,237}.

964 Secondly, among the significantly dysregulated transcription factors (Table S5), we noticed
965 the downregulated hepatocyte nuclear factor 4-alpha (HNF4A) (SI Figure 11b), which regulates
966 lipid homeostasis in the liver²³⁸. The hypoxia state and upregulated STAT3 would reduce the
967 expression of HNF4A^{239,240}. Following its downregulation, very low-density lipoprotein (VLDL)
968 mediated lipids exporting was reduced by downregulated microsomal triglyceride transfer protein
969 large subunit (MTTP) and apolipoprotein B-100 (ApoB). Meanwhile, the hepatic uptake of fatty
970 acids was enhanced by upregulated scavenger receptor class B member 1 (SCARB1) (SI Figure
971 11b). Both reduced lipids exporting and enhanced fatty acids uptake would contribute to the
972 hepatic steatosis²⁴¹.

973 The hepatic steatosis is always associated with insulin resistance, which may be induced by
974 excess ROS leakage by upregulated fatty acid oxidation and mitochondrial dysfunction²⁴². In
975 COVID-19 patients, the enzymes and transporters involved in fatty acid oxidation, such as
976 ACSL3, CPT2, SLC27A4, TMLHE, EC11, HADHA/B, IVD and SCP2, were significantly


Supple Info

977 upregulated, leading to the generation of reduced NADH. Moreover, the upregulated ATP synthase
978 (ATP5F1A/B/C/D/E, ATP5MC1/E/F/B/D/F/O), NADH dehydrogenase and its oxidase involving
979 oxidative phosphorylation catalyze more energy production, which is benefit for the translation of
980 acute phase proteins and coagulation factors. Besides, it would lead to the excess generation of
981 reactive oxygen species (ROS), which induce necrosis²⁴³ and insulin resistance. Moreover, the
982 upregulated voltage-dependent anion-selective channel proteins (VDAC1/2/3), mitochondrial
983 import receptor (TOMM22/40/40L/5/70) and mitochondrial import inner membrane translocase
984 (TIMM9) induced the mitochondrial membrane permeabilization²⁴⁴, could all lead to the release
985 of proapoptotic proteins such as DIABLO, AIFM1 and CYCS and activate apoptosis²⁴³.

986 Thirdly, the xenobiotic metabolism-PXR signaling pathway was downregulated in the liver of
987 COVID-19 patients. The downregulation of its related enzymes, such as Cytochrome P450 2C9
988 (CYP2C9), Glutathione S-transferase A1 (GSTA1), UDP-glucuronosyltransferase 2B7 (UGT2B7),
989 S-formylglutathione hydrolase (ESD) and Sulfotransferase 1E1 (SULT1E1), could be reasoned by
990 antibiotics, antivirals and steroids treatment, the widely used therapies of COVID-19²⁴⁵.

991 In summary, we speculate the pathological damage in the liver of COVID-19 patients is
992 mainly caused by the severe inflammatory response and the hypoxia status by the viral infection in
993 the lung, as well as the drug-induced hepatotoxicity during therapy (SI Figure 11d).

Supple Info



994

995 **SI Figure 11| Characteristic proteins in the liver of COVID-19 patients. a.** Pathways
 996 enriched by IPA for 1969 hepatic dysregulation proteins. **b.** Dysregulated proteins related to the
 997 pathological changes in the liver of COVID-19 patients. **c.** Pathways enriched by IPA for
 998 dysregulated immunological proteins enriched from GSEA immunologic gene sets. **d.**
 999 Hypothetical model of the liver in COVID-19 patient. Red box with black font indicates the
 1000 upregulation of the protein in the COVID-19 patients and green box with black font indicates the
 1001 downregulation of protein. Upregulation pathway (or biological process) is shown in red box with
 1002 white font and downregulation pathway (or biological process) is green box with white font. Blue
 1003 box represents the pathology of liver. GC, glucocorticoid; ROS, reactive oxygen species; ATP,
 1004 adenosine triphosphate; NADH, nicotinamide adenine dinucleotide.

1005


1006 **Heart**

1007 Two kinds of pathological changes were observed in the heart of COVID-19 patients. One is
1008 vasogenic edema with mild infiltration of inflammatory cells, and the other is myocardial cell
1009 edema (Figure S1).

1010 Vasogenic edema is mainly caused by the change of vascular permeability, which induces the
1011 serum fluids to flow into interstitium. The increase of vascular permeability is usually caused by
1012 inflammation^{246,247}. Several inflammatory mediators were elevated in the heart tissue of COVID-
1013 19 patients, including matrix metalloproteinases 9 (MMP9), C5a anaphylatoxin chemotactic
1014 receptor 1(C5AR1), interferon gamma receptor 1 (IFNGR1) and several other cytokines (Figure
1015 S7A, SI Figure 12a). Importantly, histamine N-methyltransferase (HNMT), which catabolizes
1016 histamine, was significantly downregulated and may lead to histamine accumulation and vascular
1017 hyperpermeability²⁴⁷. The accumulation of inflammatory mediators, such as C5a and histamine,
1018 could induce the P-selectin expression and result in leukocyte extravasation²⁴⁸ (SI Figure 12b).
1019 The above findings were also supported by the upregulation of intercellular adhesion molecule 1
1020 (ICAM-1), which involves in leukocyte adhesion and trans-endothelial migration²⁴⁹ and MMP9,
1021 which facilitates matrix degradation and is believed to contribute to inflammatory cell
1022 invasion²⁵⁰. Physiologically consistent, we observed inflammatory cell infiltration by
1023 hematoxylin-eosin staining sections (Figure S1).

1024 Myocardial cell edema is caused by the movement of osmotically active molecules from the
1025 extracellular to the intracellular space including sodium, chloride and water. One of the underlying
1026 pathological mechanisms was the reduced ATP availability in the mitochondria due to dysfunction
1027 of sodium (Na⁺), potassium (K⁺) ATPase²⁵¹ under hypoxia, inflammation and other conditions²⁵².
1028 These observations strongly indicated a hypoxia situation in COVID-19 patients, and we also
1029 observed consistent molecular changes under hypoxia (SI Figure 12 c). Under aerobic conditions,
1030 the hypoxia-inducible factor 1-alpha (HIF-1 α) can be ubiquitinated by ubiquitin-activating
1031 enzyme (E1), ubiquitin-conjugating enzymes E2 (E2), and a substrate-specific ubiquitin-protein
1032 ligase (E3) and then degraded by hypoxia-inducible factor 1-alpha inhibitor (HIF1AN)²⁵³. In
1033 COVID-19 patients, we identified a decreased expression of HIF1AN, ubiquitin-conjugating
1034 enzyme E2 G1 (UBE2G1) and ubiquitin-conjugating enzyme E2 H (UBE2H) (Figure S7A),
1035 suggesting the stabilization of HIF-1 α under hypoxic conditions. Besides, the heme protein
1036 myoglobin (Mb) specializing in oxygen transport and storage was downregulated. These
1037 observations strongly indicated a hypoxia situation in COVID-19 patients. What's more,
1038 thioredoxin-2 (TXN2), a redox protein, which is essential for mitochondrial reactive oxygen
1039 species (ROS) homeostasis, is downregulated in our analysis. It is reported that TXN2 deficiency
1040 could lead to increased reactive oxygen species (ROS) levels and impaired mitochondrial
1041 function^{254,255}.

1042 In conclusion, the molecular changes in the heart of COVID-19 patients were consistent with
1043 the HE staining result of vasogenic edema and cytotoxic edema. It's worth noting that the control
1044 samples were collected from dilated cardiomyopathy (DCM) patients. Therefore, the molecular
1045 changes involved in DCM patients, such as pathways related to ATP generation²⁵⁶ should be
1046 considered carefully.



1047

1048

1049

1050

1051

1052

1053

1054

1055

SI Figure 12| Characteristic proteins in the heart of COVID-19 patients (a), (b) The stimulated inflammatory mediators and dysregulated endothelial cells would cause vascular hyperpermeability. (c) Hypoxia related protein alteration. (d) ATP generation in mitochondria. (e) NA⁺/K⁻ ATPase dysfunction. Red box with black font is the upregulation protein and green box with black font is the downregulation protein. Upregulation pathway (or biological process) is present by red box with white font and downregulation pathway (or biological process) is green box with white font. Blue box represents the pathology of heart.

1056

Kidney

1057

1058

1059

1060

1061

All COVID-19 patients in our study showed a varying degree of acute kidney injury (AKI) (Table S1). Diffuse proximal tubule injury, brush border lost and microthrombus were observed in the pathological sections of the cortex, while occasional cellular swelling and atrophy were also observed in the medulla (Figure S1). Generally, more damage was observed in pathological sections in the renal cortex than in the renal medulla.

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076


Notably, according to the 2016 Third International Consensus Definition for Sepsis and Septic Shock²⁵⁷ (Table S1), sepsis was observed in the most COVID-19 patients as a complication (Table S1), with a decrease of platelet, an increase of D-dimer and neutrophil (Figure S2, Table S1). At the molecular level, we identified a total of 9,544 proteins in the kidney with 1,585 dysregulated proteins in the renal cortex and 642 in the renal medulla (Figure 1). By IPA analysis, the LPS/IL-1 mediated inhibition of RXR function, acute phase response, IL-8 signaling, necroptosis and neuroinflammation signaling pathways were found to be upregulated in both cortex and medulla (SI Figure 13a). Meanwhile, the activated status of the enriched pathways in the renal cortex are more drastic than in the renal medulla (SI Figure 13a). Besides, the upregulated pathways including signaling by Rho Family GTPase, Toll-like receptor signaling, IL-6 signaling and NF- κ B signaling and the downregulation pathways including fatty acid beta-oxidation I, glycolysis and gluconeogenesis were also specifically enriched in the renal cortex. Thus, at both pathological and molecular levels, SARS-COV-2 has a greater impact on the cortex than the medulla (SI Figure 13a, Figure S1).

In COVID-19 patients, lipopolysaccharide-binding protein (LBP), interleukin-1 receptor 1

1077 (IL1R1) and vWF were upregulated in renal cortex (Figure S2). LBP could bind to the pathogen
1078 lipopolysaccharides (LPS) and enhance CD14 and Toll-like receptors, which may be the cause of
1079 pathogenic infection and sepsis in these COVID-19 patients²⁵⁸. Another inflammatory cytokine,
1080 Interleukin-1 (IL1) could also induce sepsis²⁵⁹. The IL1R1 was found to be upregulated in
1081 COVID-19 patients, as well as sepsis^{259,260}. Upregulation of the downstream NF- κ B complexes
1082 and CCAAT enhancer binding protein beta (CEBPB) were also observed, leading to activation of
1083 IL-6, IL-8, iNOS and TNFR1 signaling pathways²⁶¹. Besides, activated signal transducer and
1084 activator of transcription 1 (STAT1) and receptor interacting serine/threonine kinase 1 (RIPK1)
1085 could play a role in apoptosis and tissue damage²⁶²⁻²⁶⁴.

1086 In addition to inflammatory and infection-related proteins, we also detected the upregulation
1087 of hypoxia inducible factor 1 subunit alpha (HIF1A) in the cortex, which could promote TLR2,
1088 vWF overexpression and nitric oxide (NO) generation. These could lead to insulin resistance²⁶⁵.
1089 Furthermore, HIF1A could suppress energy metabolism-related pathways including fatty acid β -
1090 oxidation and gluconeogenesis to exacerbate insulin resistance²⁶⁶. As the main ATP provider in the
1091 renal proximal tubular cells, the inhibition of fatty acid β -oxidation would block energy supply
1092 and lead to aggravate kidney injury²⁶⁶. Interestingly, among seven organs, kidney is the only one
1093 in which ACE2 was downregulated (Figure 2C), ACE2 not only acts as the receptor of SARS-
1094 CoV-2 but could also catalyze the cleavage of angiotensin II (Ang II) into vasodilator angiotensin
1095 1-7 (Ang 1-7). The downregulation of ACE2 could mediate Ang II accumulation and induce the
1096 upregulation of vascular cell adhesion molecule 1 (VCAM1)²⁶⁷, a marker for sepsis and kidney
1097 injury^{268,269}. Likewise, Ang II regulates RhoGTPase via G Protein-Coupled Receptor (GPCR),
1098 indeed the G α , G β and RhoGTPase including RHO and CDC42 were all upregulated in COVID-
1099 19 patients. ROCK1, a downstream molecular of RHO, was upregulated as well, which could lead
1100 to renal tubular injury, inflammation and fibrogenesis^{270,271}. CDC42 induced CDC42EP4 is an
1101 upstream regulator of SEPTIN family and the upregulated SEPTIN6, SEPTIN7, SEPTIN8 and
1102 SEPTIN9 could induce fibrogenesis in kidney as well, which means SARS-CoV2 infection may
1103 cause chronic injury and affect prognosis in COVID-19 patients²⁷². Meanwhile, the use of non-
1104 steroidal anti-inflammatory drugs and β -lactam antibiotics are also possible precipitating factors of
1105 kidney injury²⁷³ (Table S1).

1106 In conclusion, renal tissue damage is more severe in renal cortex than in the medulla of
1107 COVID-19 patients, and the AKI may be caused by the combinational effects of hypoxia, bacterial
1108 infection, sepsis induced cytokine storm and drug-induced nephrotoxicity.



1109

1110

SI Figure 13| Characteristic proteins in the kidney of COVID-19 patients. **a.** Pathways enriched by IPA for 1585 dysregulated proteins in renal cortex (right) and 642 dysregulated proteins in renal medulla (left). **b.** Hypothetical model of kidney in COVID-19 patient. Red box with black font is the upregulation protein and green box with black font is the downregulation protein. Upregulation pathway (or biological process) is red box with white font and downregulation pathway (or biological process) is green box with white font. Blue box represents the pathology of kidney.

1117

1118

Thyroid

1119

Lymphoid infiltration was found in some interfollicular regions in the thyroid of COVID-19. In our study, 1,297 proteins in the thyroid were dysregulated ((Figure 1) and the top ten pathways are enriched for these proteins (SI Figure 14a).

1122

Among these enriched pathways, eIF2 and mTOR upregulation might be associated with protein synthesis and indicate the dysregulation of thyroid function at molecular level. IL-8 and NF- κ B signaling are associated with inflammatory response physically. The pathology associated pathways including angiogenesis (VEGF signaling), coagulation and thrombin signaling, cardiac hypertrophy signaling and renin-angiotensin signaling were also enriched (SI Figure 14A). The key dysregulated proteins in these pathways are listed in the Figure S7D. We proposed a hypothetical model for thyroid pathology by these key proteins and pathways (SI Figure 14B). The thyroid is adjacent to the superior respiratory system, thereby would be easily influenced by the inflammation. Some cytokines and their receptors, such as CXCL12, IL1R1 and IL6ST, were dysregulated, which could stimulate the NF- κ B or mTOR signaling and then induce a series of downstream cascade reactions. CXCL12 is involved in promoting cell growth and angiogenesis²⁷⁴, which is associated with mTOR signaling²⁷⁵. In thyroid of COVID-19 patients, mTOR and CXCL12 were both upregulated (Figure S7D). IL-1 and IL-6 are associated with a variety of


1134

1135 chronic inflammatory response, such as coagulation²⁷⁶ and insulin resistance²⁷⁷, through
 1136 activating NF-κB signaling.

1137 In the thyroid of COVID-19 patients, Cell division control protein 42 (CDC42) and G protein
 1138 subunit alpha Q (GNAQ) were both upregulated. CDC42 belongs to GTPase family involved in
 1139 the thrombin formulation process²⁷⁸ and GNAQ also belongs to G proteins and is involved in
 1140 thrombin signaling²⁷⁹. The upregulated CDC42 and GNAQ may indicate the coagulation response
 1141 in the thyroid. Besides, two kinds of coagulation associated protease inhibitors, serine protease
 1142 inhibitors (SERPINs) family²⁸⁰ and alpha-2-macroglobulin (A2M), were all downregulated in the
 1143 thyroid of COVID-19 patients (Figure S7D), which could suppress plasmin and kallikrein⁵³.
 1144 Kininogen-1 (KNG1), an alpha-2-thiol protease inhibitor, was also downregulated in the thyroid
 1145 of COVID-19 patients (Figure S7D), which could disturb kinin-kallikrein system²⁸¹.

1146 Neuroendocrine convertase 2 (PCSK2), insulin receptor (INSR) and carboxypeptidase E
 1147 (CPE) all participate the insulin processing and their secretion is regulated by mTOR in insulin
 1148 resistance²⁸², which also matched with our data (Figure S7D).

1149 Altogether, the thyroid is mainly affected by the inflammatory response after virus infection,
 1150 in which the activated NF-κB and mTOR signaling could have an association with coagulation,
 1151 insulin resistance and VEGF involved angiogenesis.



1152

1153 **SI Figure 14| Characteristic proteins in the thyroid of COVID-19 patients. a.** Pathways
 1154 enriched by IPA for 1297 dysregulated proteins. **b.** Hypothetical model of the response of thyroid
 1155 in COVID-19 patient. Red box with black font is the upregulation protein and green box with
 1156 black font is the downregulation protein. Upregulation pathway (or biological process) is red box
 1157 with white font and downregulation pathway (or biological process) is green box with white font.

1158 Testis

1159 Because of one of the dysregulated proteins in the testis do not have GO annotation, nine
 1160 differential expressed proteins in the testis are discussed in this part (SI Figure 15). We performed
 1161 a functional enrichment of the 9 downregulated proteins by STRING, and found that 5 out of 9
 1162 proteins are enriched in cholesterol biosynthetic process (GO:0006695, FDR=9.19e-07) and
 1163 cholesterol metabolic regulation (GO:0090181, FDR=9.19e-07), including Squalene synthase
 1164 (FDFT1), ATP-citrate lyase (ACLY), squalene monooxygenase (SQLE), FASN, and Delta(14)-

1165 sterol reductase *TM7SF2* (*TM7SF2*).

1166 Although those proteins are unrelated to the virus directly, the cholesterol synthesis is
1167 associated with steroid hormones such as testosterone. The low intracellular concentration of
1168 sterols would induce the cleavage of membrane bound sterol response element-binding protein
1169 (SREBP) by SREBP cleavage-activation protein (SCAP), then cleaved SREBP in the cytosol
1170 would enter the nucleus to activate expression of proteins participated in cholesterol biosynthesis
1171 and uptake process²⁸³.

1172 Delta (14)-sterol reductase is encoded by *TM7SF2*, which can be activated in response to low
1173 cell sterol levels mediated by SREBP²⁸⁴. *TM7SF2* is detected in Leydig cells specifically by
1174 antibody staining²⁸⁵, the decrease of which suggested impaired Leydig cell population or function.
1175 We also found a Leydig cell biomarker, INSL3, was decreased (SI Figure 15). INSL3 was first
1176 isolated from the boar testis cDNA library and is expressed uniquely in fetal and postnatal Leydig
1177 cell²⁸⁶. INSL3 is mainly produced in gonadal tissues in male and female²⁸⁷ and is known to be
1178 associated with testicular descent^{288,289}. Three independent studies reported the association of
1179 INSL3 gene mutation with human cryptorchidism, which is a common congenital abnormality in
1180 testis²⁹⁰⁻²⁹². INSL3 seems to function within the testis as an important supplementary downstream
1181 effector of the hypothalamic–pituitary–gonadal (HPG) axis²⁸⁷. Free from acute regulation of HPG
1182 axis, it can reflect the differentiation status and the number of the Leydig cells present²⁹³. The
1183 unique INSL3 receptor, RXFP2, has been identified at mRNA and protein levels on both Leydig
1184 cells themselves²⁹⁴ and also on germ cells within the seminiferous compartment²⁹⁵. The most
1185 significantly decreased proteins in the testis is INSL3, which indicates Leydig cell reduction and
1186 might associates with diabetes²⁹⁶ as well.

1187 The hypothalamic–pituitary–gonadal (HPG) axis comprises of pulsatile GnRH from the
1188 hypothalamus. It will impact on the anterior pituitary to induce expression and release of both LH
1189 and FSH into the circulation. These will, in turn, stimulate receptors on testicular Leydig and
1190 Sertoli cells, respectively, to promote steroidogenesis and spermatogenesis. Both Leydig and
1191 Sertoli cells exhibit negative feedback to the pituitary and/or hypothalamus via their products
1192 testosterone and inhibin B, respectively, thereby allowing tight regulation of the HPG axis. In
1193 particular, LH exerts both acute control on Leydig cells by influencing steroidogenic enzyme
1194 activity, as well as chronic control by impacting on Leydig cell differentiation and gene
1195 expression²⁸⁷.

1196 Significantly decreased INSL3 indicates the decreased number of mature Leydig cells in the
1197 patients with COVID-19, which is consistent with the HE staining images (Figure 7B, C).
1198 Interestingly, Ma et al observed significantly elevated serum luteinizing hormone (LH) and
1199 dramatically decrease in the ratio of testosterone (T) to LH and the ratio of follicle stimulating
1200 hormone (FSH) to LH, while no statistical difference in serum T ($p=0.0945$) or FSH
1201 ($p=0.5783$)²⁹⁷. We inferred the change on LH might be caused by the reduced number of mature
1202 Leydig cells, which would cause the decreased serum T. Weakened negative feedback from
1203 Leydig cells might promote the secretion of LH.

1204 FASN, ACLY, SQLE and FDFT1 all participate in lipid synthesis directly. Fatty acid synthase
1205 is a key enzyme in de novo lipogenesis. FASN is markedly inactivated under conditions of insulin
1206 resistance and is a potential biomarker for insulin resistance²⁹⁸. Reduced FASN suggested the
1207 progression of insulin resistance in COVID-19 patients. This protein has been discussed in the
1208 fibrosis process associated proteins.

Supple Info


1209 ACLY is the enzyme primarily responsible for the production of extramitochondrial acetyl-
1210 CoA and is thus strategically positioned at the intersection of glycolytic and lipidic metabolism²⁹⁹,
1211 which make it a potential target for lipid lowering³⁰⁰. FDFT1 and SQLE play an important role in
1212 the cholesterol biosynthesis pathway, and both of them are effective targets in the treatment of
1213 hypercholesterolemia^{301,302}. ACLY, SQLE and FDFT1 were observed downregulated in the testis
1214 tissue of COVID-19 patients compared with non-COVID-19 controls (SI Figure 15), which was
1215 consistent with a previous study discovering lower levels of low-density lipoprotein cholesterol
1216 and total cholesterol levels in COVID-19 patients as compared with normal subjects³⁰³.

1217 There are two dysregulated proteins associated with sperm generation. RNF216 is essential
1218 for spermatogenesis and male fertility³⁰⁴. The deletion of *Drc7* leads to aberrant tail formation in
1219 mouse spermatozoa that phenocopies patients with multiple morphological abnormalities of the
1220 sperm flagella (MMAF)³⁰⁵. These two proteins were reduced in COVID-19 patients (SI Figure
1221 15), suggesting the impairment of spermatogenesis and sperm motility caused by SARS-CoV-2
1222 infection.

1223 Store-operated calcium entry-associated regulatory factor (SARAF) was downregulated in
1224 the testis of COVID-19 patients (SI Figure 15), which inactivates the store operated calcium entry
1225 machinery to prevent excess calcium refilling³⁰⁶.

1226 In conclusion, reduced INSL3 and five cholesterol biosynthesis related proteins suggests
1227 damage to Leydig cells and their steroidogenic functions (Figure 7D). Decrease of DRC7 indicates
1228 impaired sperm mobility. Future investigations of Leydig cell functions and sperm mobility of
1229 alive COVID-19 patients are needed since our observations are based on autopsies.
1230

1230



1231

1232 **SI Figure 15| Expression of dysregulated proteins in the testis of COVID-19 patients.**

1233 The y-axis stands for the protein expression ratio by TMT-based quantitative proteomics. Pair-
1234 wise comparison of each protein between COVID-19 patients and control groups was performed
1235 with student's t test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.
1236

1237 **References**

- 1238 1 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
1239 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278,
1240 doi:10.1016/j.cell.2020.02.052 (2020).
- 1241 2 Jeffers, S. A. *et al.* CD209L (L-SIGN) is a receptor for severe acute respiratory
1242 syndrome coronavirus. *Proc Natl Acad Sci U S A* **101**, 15748-15753,
1243 doi:10.1073/pnas.0403812101 (2004).
- 1244 3 Chan, V. S. *et al.* Homozygous L-SIGN (CLEC4M) plays a protective role in SARS
1245 coronavirus infection. *Nat Genet* **38**, 38-46, doi:10.1038/ng1698 (2006).
- 1246 4 Zheng, Y. Y., Ma, Y. T., Zhang, J. Y. & Xie, X. COVID-19 and the cardiovascular
1247 system. *Nat Rev Cardiol* **17**, 259-260, doi:10.1038/s41569-020-0360-5 (2020).
- 1248 5 Liu, P. P., Blet, A., Smyth, D. & Li, H. The Science Underlying COVID-19: Implications
1249 for the Cardiovascular System. *Circulation* **142**, 68-78,
1250 doi:10.1161/CIRCULATIONAHA.120.047549 (2020).
- 1251 6 Vaduganathan, M. *et al.* Renin-Angiotensin-Aldosterone System Inhibitors in
1252 Patients with Covid-19. *N Engl J Med* **382**, 1653-1659, doi:10.1056/NEJMSr2005760
1253 (2020).
- 1254 7 Donoghue, M. *et al.* A novel angiotensin-converting enzyme-related
1255 carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ Res* **87**, E1-9,
1256 doi:10.1161/01.res.87.5.e1 (2000).
- 1257 8 Bashirova, A. A. *et al.* A dendritic cell-specific intercellular adhesion molecule 3-
1258 grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver
1259 sinusoidal endothelial cells and promotes HIV-1 infection. *J Exp Med* **193**, 671-678,
1260 doi:10.1084/jem.193.6.671 (2001).
- 1261 9 Rydz, N. *et al.* The C-type lectin receptor CLEC4M binds, internalizes, and clears
1262 von Willebrand factor and contributes to the variation in plasma von Willebrand factor
1263 levels. *Blood* **121**, 5228-5237, doi:10.1182/blood-2012-10-457507 (2013).
- 1264 10 Cormier, E. G. *et al.* L-SIGN (CD209L) and DC-SIGN (CD209) mediate
1265 transinfection of liver cells by hepatitis C virus. *Proc Natl Acad Sci U S A* **101**, 14067-14072,
1266 doi:10.1073/pnas.0405695101 (2004).
- 1267 11 Liu, T., Luo, S., Libby, P. & Shi, G. P. Cathepsin L-selective inhibitors: A
1268 potentially promising treatment for COVID-19 patients. *Pharmacol Ther*, 107587,
1269 doi:10.1016/j.pharmthera.2020.107587 (2020).
- 1270 12 Fung, T. S. & Liu, D. X. Human Coronavirus: Host-Pathogen Interaction. *Annu*
1271 *Rev Microbiol* **73**, 529-557, doi:10.1146/annurev-micro-020518-115759 (2019).
- 1272 13 Cote, M. *et al.* Small molecule inhibitors reveal Niemann-Pick C1 is essential
1273 for Ebola virus infection. *Nature* **477**, 344-348, doi:10.1038/nature10380 (2011).

Supple Info

- 1274 14 Abu-Farha, M. *et al.* The Role of Lipid Metabolism in COVID-19 Virus Infection
1275 and as a Drug Target. *Int J Mol Sci* **21**, doi:10.3390/ijms21103544 (2020).
- 1276 15 Tsai, J. C., Zelus, B. D., Holmes, K. V. & Weiss, S. R. The N-terminal domain of
1277 the murine coronavirus spike glycoprotein determines the CEACAM1 receptor specificity
1278 of the virus strain. *J Virol* **77**, 841-850, doi:10.1128/jvi.77.2.841-850.2003 (2003).
- 1279 16 Huang, Y. H. *et al.* CEACAM1 regulates TIM-3-mediated tolerance and
1280 exhaustion. *Nature* **517**, 386-390, doi:10.1038/nature13848 (2015).
- 1281 17 Poy, M. N. *et al.* CEACAM1 regulates insulin clearance in liver. *Nat Genet* **30**,
1282 270-276, doi:10.1038/ng840 (2002).
- 1283 18 Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. *Cold*
1284 *Spring Harb Perspect Biol* **1**, a001651, doi:10.1101/cshperspect.a001651 (2009).
- 1285 19 Carmody, R. J. & Chen, Y. H. Nuclear factor-kappaB: activation and regulation
1286 during toll-like receptor signaling. *Cell Mol Immunol* **4**, 31-41 (2007).
- 1287 20 Chen, K. *et al.* Germline mutations in NFKB2 implicate the noncanonical NF-
1288 kappaB pathway in the pathogenesis of common variable immunodeficiency. *Am J Hum*
1289 *Genet* **93**, 812-824, doi:10.1016/j.ajhg.2013.09.009 (2013).
- 1290 21 Rayet, B. & Gelinas, C. Aberrant rel/nfkb genes and activity in human cancer.
1291 *Oncogene* **18**, 6938-6947, doi:10.1038/sj.onc.1203221 (1999).
- 1292 22 Greenbaum, L. E. *et al.* CCAAT enhancer- binding protein beta is required for
1293 normal hepatocyte proliferation in mice after partial hepatectomy. *J Clin Invest* **102**, 996-
1294 1007, doi:10.1172/JCI3135 (1998).
- 1295 23 Tanaka, T. *et al.* Targeted disruption of the NF-IL6 gene discloses its essential
1296 role in bacteria killing and tumor cytotoxicity by macrophages. *Cell* **80**, 353-361,
1297 doi:10.1016/0092-8674(95)90418-2 (1995).
- 1298 24 Leaman, D. W., Leung, S., Li, X. & Stark, G. R. Regulation of STAT-dependent
1299 pathways by growth factors and cytokines. *FASEB J* **10**, 1578-1588 (1996).
- 1300 25 Battle, T. E. & Frank, D. A. The role of STATs in apoptosis. *Curr Mol Med* **2**,
1301 381-392, doi:10.2174/1566524023362456 (2002).
- 1302 26 Madamanchi, N. R., Li, S., Patterson, C. & Runge, M. S. Thrombin regulates
1303 vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway. *J*
1304 *Biol Chem* **276**, 18915-18924, doi:10.1074/jbc.M008802200 (2001).
- 1305 27 Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a
1306 leading role for STAT3. *Nat Rev Cancer* **9**, 798-809, doi:10.1038/nrc2734 (2009).
- 1307 28 Hess, J., Angel, P. & Schorpp-Kistner, M. AP-1 subunits: quarrel and harmony
1308 among siblings. *J Cell Sci* **117**, 5965-5973, doi:10.1242/jcs.01589 (2004).
- 1309 29 Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. *Nat Cell Biol*
1310 **4**, E131-136, doi:10.1038/ncb0502-e131 (2002).
- 1311 30 Dyson, N. J. RB1: a prototype tumor suppressor and an enigma. *Genes Dev* **30**,
1312 1492-1502, doi:10.1101/gad.282145.116 (2016).
- 1313 31 Hilgendorf, K. I. *et al.* The retinoblastoma protein induces apoptosis directly at
1314 the mitochondria. *Genes Dev* **27**, 1003-1015, doi:10.1101/gad.211326.112 (2013).
- 1315 32 Tcherkezian, J. *et al.* Proteomic analysis of cap-dependent translation identifies
1316 LARP1 as a key regulator of 5'TOP mRNA translation. *Genes Dev* **28**, 357-371,
1317 doi:10.1101/gad.231407.113 (2014).

Supple Info

- 1318 33 Gordon, D. E. *et al.* A SARS-CoV-2 protein interaction map reveals targets for
1319 drug repurposing. *Nature* **583**, 459-468, doi:10.1038/s41586-020-2286-9 (2020).
- 1320 34 Lee, J. W., Ko, J., Ju, C. & Eltzschig, H. K. Hypoxia signaling in human diseases
1321 and therapeutic targets. *Exp Mol Med* **51**, 1-13, doi:10.1038/s12276-019-0235-1 (2019).
- 1322 35 Babeu, J. P. & Boudreau, F. Hepatocyte nuclear factor 4-alpha involvement in
1323 liver and intestinal inflammatory networks. *World J Gastroenterol* **20**, 22-30,
1324 doi:10.3748/wjg.v20.i1.22 (2014).
- 1325 36 Palta, S., Saroa, R. & Palta, A. Overview of the coagulation system. *Indian J*
1326 *Anaesth* **58**, 515-523, doi:10.4103/0019-5049.144643 (2014).
- 1327 37 Iba, T. & Levy, J. H. Inflammation and thrombosis: roles of neutrophils, platelets
1328 and endothelial cells and their interactions in thrombus formation during sepsis. *J Thromb*
1329 *Haemost* **16**, 231-241, doi:10.1111/jth.13911 (2018).
- 1330 38 Subramaniam, S. *et al.* Distinct contributions of complement factors to platelet
1331 activation and fibrin formation in venous thrombus development. *Blood* **129**, 2291-2302,
1332 doi:10.1182/blood-2016-11-749879 (2017).
- 1333 39 Broze, G. J., Jr. Tissue factor pathway inhibitor and the revised theory of
1334 coagulation. *Annu Rev Med* **46**, 103-112, doi:10.1146/annurev.med.46.1.103 (1995).
- 1335 40 Colman, R. W. & Schmaier, A. H. Contact system: a vascular biology modulator
1336 with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. *Blood*
1337 **90**, 3819-3843 (1997).
- 1338 41 Muszbek, L., Bereczky, Z., Bagoly, Z., Komaromi, I. & Katona, E. Factor XIII: a
1339 coagulation factor with multiple plasmatic and cellular functions. *Physiol Rev* **91**, 931-972,
1340 doi:10.1152/physrev.00016.2010 (2011).
- 1341 42 Peyvandi, F., Garagiola, I. & Baronciani, L. Role of von Willebrand factor in the
1342 haemostasis. *Blood Transfus* **9 Suppl 2**, s3-8, doi:10.2450/2011.002S (2011).
- 1343 43 Gobel, K. *et al.* The Coagulation Factors Fibrinogen, Thrombin, and Factor XII
1344 in Inflammatory Disorders-A Systematic Review. *Front Immunol* **9**, 1731,
1345 doi:10.3389/fimmu.2018.01731 (2018).
- 1346 44 Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Protein C anticoagulant and
1347 cytoprotective pathways. *Int J Hematol* **95**, 333-345, doi:10.1007/s12185-012-1059-0
1348 (2012).
- 1349 45 Heeb, M. J. & Griffin, J. H. Physiologic inhibition of human activated protein C
1350 by alpha 1-antitrypsin. *J Biol Chem* **263**, 11613-11616 (1988).
- 1351 46 Elisen, M. G., von dem Borne, P. A., Bouma, B. N. & Meijers, J. C. Protein C
1352 inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of
1353 protein C in human plasma. *Blood* **91**, 1542-1547 (1998).
- 1354 47 Fourrier, F. *et al.* Septic shock, multiple organ failure, and disseminated
1355 intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein
1356 S deficiencies. *Chest* **101**, 816-823, doi:10.1378/chest.101.3.816 (1992).
- 1357 48 Okamoto, T., Tanigami, H., Suzuki, K. & Shimaoka, M. Thrombomodulin: a
1358 bifunctional modulator of inflammation and coagulation in sepsis. *Crit Care Res Pract*
1359 **2012**, 614545, doi:10.1155/2012/614545 (2012).
- 1360 49 He, L., Vicente, C. P., Westrick, R. J., Eitzman, D. T. & Tollefsen, D. M. Heparin
1361 cofactor II inhibits arterial thrombosis after endothelial injury. *J Clin Invest* **109**, 213-219,

Supple Info

- 1362 doi:10.1172/JCI13432 (2002).
- 1363 50 Chapin, J. C. & Hajjar, K. A. Fibrinolysis and the control of blood coagulation.
- 1364 *Blood Rev* **29**, 17-24, doi:10.1016/j.blre.2014.09.003 (2015).
- 1365 51 Carpenter, S. L. & Mathew, P. Alpha2-antiplasmin and its deficiency:
- 1366 fibrinolysis out of balance. *Haemophilia* **14**, 1250-1254, doi:10.1111/j.1365-
- 1367 2516.2008.01766.x (2008).
- 1368 52 Vaughan, D. E. PAI-1 and atherothrombosis. *J Thromb Haemost* **3**, 1879-1883,
- 1369 doi:10.1111/j.1538-7836.2005.01420.x (2005).
- 1370 53 de Boer, J. P. *et al.* Alpha-2-macroglobulin functions as an inhibitor of
- 1371 fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.
- 1372 *Infect Immun* **61**, 5035-5043 (1993).
- 1373 54 Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. *N Engl J Med* **364**,
- 1374 656-665, doi:10.1056/NEJMra0910283 (2011).
- 1375 55 Rongvaux, A. *et al.* Nicotinamide phosphoribosyl transferase/pre-B cell
- 1376 colony-enhancing factor/visfatin is required for lymphocyte development and cellular
- 1377 resistance to genotoxic stress. *J Immunol* **181**, 4685-4695,
- 1378 doi:10.4049/jimmunol.181.7.4685 (2008).
- 1379 56 Samal, B. *et al.* Cloning and characterization of the cDNA encoding a novel
- 1380 human pre-B-cell colony-enhancing factor. *Mol Cell Biol* **14**, 1431-1437,
- 1381 doi:10.1128/mcb.14.2.1431 (1994).
- 1382 57 Skokowa, J. *et al.* NAMPT is essential for the G-CSF-induced myeloid
- 1383 differentiation via a NAD(+)-sirtuin-1-dependent pathway. *Nat Med* **15**, 151-158,
- 1384 doi:10.1038/nm.1913 (2009).
- 1385 58 Jia, S. H. *et al.* Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis
- 1386 in experimental inflammation and clinical sepsis. *J Clin Invest* **113**, 1318-1327,
- 1387 doi:10.1172/JCI19930 (2004).
- 1388 59 Escoter-Torres, L. *et al.* Fighting the Fire: Mechanisms of Inflammatory Gene
- 1389 Regulation by the Glucocorticoid Receptor. *Front Immunol* **10**, 1859,
- 1390 doi:10.3389/fimmu.2019.01859 (2019).
- 1391 60 Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and
- 1392 disease. *Cold Spring Harb Perspect Biol* **6**, a016295, doi:10.1101/cshperspect.a016295
- 1393 (2014).
- 1394 61 Heinrich, P. C. *et al.* Principles of interleukin (IL)-6-type cytokine signalling and
- 1395 its regulation. *Biochem J* **374**, 1-20, doi:10.1042/BJ20030407 (2003).
- 1396 62 Chen, G. *et al.* Clinical and immunological features of severe and moderate
- 1397 coronavirus disease 2019. *J Clin Invest* **130**, 2620-2629, doi:10.1172/jci137244 (2020).
- 1398 63 Carbone, C. *et al.* Angiopoietin-Like Proteins in Angiogenesis, Inflammation
- 1399 and Cancer. *Int J Mol Sci* **19**, doi:10.3390/ijms19020431 (2018).
- 1400 64 Oike, Y. *et al.* Angiopoietin-related growth factor antagonizes obesity and
- 1401 insulin resistance. *Nat Med* **11**, 400-408, doi:10.1038/nm1214 (2005).
- 1402 65 Holtwick, R. *et al.* Pressure-independent cardiac hypertrophy in mice with
- 1403 cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl
- 1404 cyclase-A. *J Clin Invest* **111**, 1399-1407, doi:10.1172/JCI17061 (2003).
- 1405 66 Song, W., Wang, H. & Wu, Q. Atrial natriuretic peptide in cardiovascular

Supple Info

- 1406 biology and disease (NPPA). *Gene* **569**, 1-6, doi:10.1016/j.gene.2015.06.029 (2015).
- 1407 67 Yun, Y. R. *et al.* Fibroblast growth factors: biology, function, and application for
- 1408 tissue regeneration. *J Tissue Eng* **2010**, 218142, doi:10.4061/2010/218142 (2010).
- 1409 68 Mori, S. *et al.* The integrin-binding defective FGF2 mutants potently suppress
- 1410 FGF2 signalling and angiogenesis. *Biosci Rep* **37**, doi:10.1042/bsr20170173 (2017).
- 1411 69 Wynn, T. A. IL-13 effector functions. *Annu Rev Immunol* **21**, 425-456,
- 1412 doi:10.1146/annurev.immunol.21.120601.141142 (2003).
- 1413 70 Ramalingam, T. R. *et al.* Unique functions of the type II interleukin 4 receptor
- 1414 identified in mice lacking the interleukin 13 receptor alpha1 chain. *Nat Immunol* **9**, 25-33,
- 1415 doi:10.1038/ni1544 (2008).
- 1416 71 Thiel, D. J. *et al.* Observation of an unexpected third receptor molecule in the
- 1417 crystal structure of human interferon-gamma receptor complex. *Structure* **8**, 927-936,
- 1418 doi:10.1016/s0969-2126(00)00184-2 (2000).
- 1419 72 Xia, C., Anderson, P. & Hahm, B. Viral dedication to vigorous destruction of
- 1420 interferon receptors. *Virology* **522**, 19-26, doi:10.1016/j.virol.2018.06.017 (2018).
- 1421 73 Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an
- 1422 overview of signals, mechanisms and functions. *J Leukoc Biol* **75**, 163-189,
- 1423 doi:10.1189/jlb.0603252 (2004).
- 1424 74 Smits, S. L. *et al.* Exacerbated innate host response to SARS-CoV in aged non-
- 1425 human primates. *PLoS Pathog* **6**, e1000756, doi:10.1371/journal.ppat.1000756 (2010).
- 1426 75 Yang, D. *et al.* Eosinophil-derived neurotoxin (EDN), an antimicrobial protein
- 1427 with chemotactic activities for dendritic cells. *Blood* **102**, 3396-3403, doi:10.1182/blood-
- 1428 2003-01-0151 (2003).
- 1429 76 Domachowske, J. B., Bonville, C. A., Dyer, K. D. & Rosenberg, H. F. Evolution of
- 1430 antiviral activity in the ribonuclease A gene superfamily: evidence for a specific interaction
- 1431 between eosinophil-derived neurotoxin (EDN/RNase 2) and respiratory syncytial virus.
- 1432 *Nucleic Acids Res* **26**, 5327-5332, doi:10.1093/nar/26.23.5327 (1998).
- 1433 77 Baietti, M. F. *et al.* Syndecan-syntenin-ALIX regulates the biogenesis of
- 1434 exosomes. *Nat Cell Biol* **14**, 677-685, doi:10.1038/ncb2502 (2012).
- 1435 78 Legler, D. F. *et al.* B cell-attracting chemokine 1, a human CXC chemokine
- 1436 expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. *J Exp*
- 1437 *Med* **187**, 655-660, doi:10.1084/jem.187.4.655 (1998).
- 1438 79 Saez de Guinoa, J., Barrio, L., Mellado, M. & Carrasco, Y. R. CXCL13/CXCR5
- 1439 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. *Blood* **118**,
- 1440 1560-1569, doi:10.1182/blood-2011-01-332106 (2011).
- 1441 80 Zanetti, M. Cathelicidins, multifunctional peptides of the innate immunity. *J*
- 1442 *Leukoc Biol* **75**, 39-48, doi:10.1189/jlb.0403147 (2004).
- 1443 81 Mangelsdorf, D. J., Ong, E. S., Dyck, J. A. & Evans, R. M. Nuclear receptor that
- 1444 identifies a novel retinoic acid response pathway. *Nature* **345**, 224-229,
- 1445 doi:10.1038/345224a0 (1990).
- 1446 82 Nagy, L., Szanto, A., Szatmari, I. & Szeles, L. Nuclear hormone receptors enable
- 1447 macrophages and dendritic cells to sense their lipid environment and shape their immune
- 1448 response. *Physiol Rev* **92**, 739-789, doi:10.1152/physrev.00004.2011 (2012).
- 1449 83 Ma, F. *et al.* Retinoid X receptor alpha attenuates host antiviral response by

Supple Info

- 1450 suppressing type I interferon. *Nat Commun* **5**, 5494, doi:10.1038/ncomms6494 (2014).
1451 84 Risau, W. Mechanisms of angiogenesis. *Nature* **386**, 671-674,
1452 doi:10.1038/386671a0 (1997).
1453 85 Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the
1454 HIF system. *Nat Med* **9**, 677-684, doi:10.1038/nm0603-677 (2003).
1455 86 Byrne, A. M., Bouchier-Hayes, D. J. & Harmey, J. H. Angiogenic and cell survival
1456 functions of vascular endothelial growth factor (VEGF). *J Cell Mol Med* **9**, 777-794,
1457 doi:10.1111/j.1582-4934.2005.tb00379.x (2005).
1458 87 Munk, V. C. *et al.* Angiotensin II induces angiogenesis in the hypoxic adult
1459 mouse heart in vitro through an AT2-B2 receptor pathway. *Hypertension* **49**, 1178-1185,
1460 doi:10.1161/HYPERTENSIONAHA.106.080242 (2007).
1461 88 Koch, A. E., Halloran, M. M., Haskell, C. J., Shah, M. R. & Poverini, P. J.
1462 Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion
1463 molecule-1. *Nature* **376**, 517-519, doi:10.1038/376517a0 (1995).
1464 89 Pepper, M. S. Transforming growth factor-beta: vasculogenesis, angiogenesis,
1465 and vessel wall integrity. *Cytokine Growth Factor Rev* **8**, 21-43, doi:10.1016/s1359-
1466 6101(96)00048-2 (1997).
1467 90 Hadanny, A. *et al.* Hyperbaric oxygen can induce angiogenesis and recover
1468 erectile function. *Int J Impot Res* **30**, 292-299, doi:10.1038/s41443-018-0023-9 (2018).
1469 91 Ackermann, M. *et al.* Pulmonary Vascular Endothelialitis, Thrombosis, and
1470 Angiogenesis in Covid-19. *N Engl J Med* **383**, 120-128, doi:10.1056/NEJMoa2015432
1471 (2020).
1472 92 Stupack, D. G. & Chersesh, D. A. Integrins and angiogenesis. *Curr Top Dev Biol*
1473 **64**, 207-238, doi:10.1016/s0070-2153(04)64009-9 (2004).
1474 93 Zhang, J. *et al.* The role of CX(3)CL1/CX(3)CR1 in pulmonary angiogenesis and
1475 intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome. *J*
1476 *Hepatol* **57**, 752-758, doi:10.1016/j.jhep.2012.05.014 (2012).
1477 94 Shellenberger, T. D. *et al.* Headpin: a serpin with endogenous and exogenous
1478 suppression of angiogenesis. *Cancer Res* **65**, 11501-11509, doi:10.1158/0008-5472.Can-
1479 05-2262 (2005).
1480 95 Somekawa, S. *et al.* Tmem100, an ALK1 receptor signaling-dependent gene
1481 essential for arterial endothelium differentiation and vascular morphogenesis. *Proc Natl*
1482 *Acad Sci U S A* **109**, 12064-12069, doi:10.1073/pnas.1207210109 (2012).
1483 96 Moon, E. H. *et al.* Essential role for TMEM100 in vascular integrity but limited
1484 contributions to the pathogenesis of hereditary haemorrhagic telangiectasia. *Cardiovasc*
1485 *Res* **105**, 353-360, doi:10.1093/cvr/cvu260 (2015).
1486 97 Wynn, T. A. Cellular and molecular mechanisms of fibrosis. *J Pathol* **214**, 199-
1487 210, doi:10.1002/path.2277 (2008).
1488 98 Karsdal, M. A. *et al.* The good and the bad collagens of fibrosis - Their role in
1489 signaling and organ function. *Adv Drug Deliv Rev* **121**, 43-56,
1490 doi:10.1016/j.addr.2017.07.014 (2017).
1491 99 Kong, P., Christia, P. & Frangogiannis, N. G. The pathogenesis of cardiac
1492 fibrosis. *Cell Mol Life Sci* **71**, 549-574, doi:10.1007/s00018-013-1349-6 (2014).
1493 100 Dilated cardiomyopathy. *Nat Rev Dis Primers* **5**, 33, doi:10.1038/s41572-019-

Supple Info

- 1494 0088-x (2019).
- 1495 101 Marijianowski, M. M., Teeling, P., Mann, J. & Becker, A. E. Dilated
1496 cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a
1497 quantitative assessment. *J Am Coll Cardiol* **25**, 1263-1272, doi:10.1016/0735-
1498 1097(94)00557-7 (1995).
- 1499 102 Korner, T., Kropf, J. & Gressner, A. M. Serum laminin and hyaluronan in liver
1500 cirrhosis: markers of progression with high prognostic value. *J Hepatol* **25**, 684-688,
1501 doi:10.1016/s0168-8278(96)80239-x (1996).
- 1502 103 Mak, K. M. & Mei, R. Basement Membrane Type IV Collagen and Laminin: An
1503 Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease. *Anat Rec*
1504 (*Hoboken*) **300**, 1371-1390, doi:10.1002/ar.23567 (2017).
- 1505 104 Tan, R. J. & Liu, Y. Matrix metalloproteinases in kidney homeostasis and
1506 diseases. *Am J Physiol Renal Physiol* **302**, F1351-1361, doi:10.1152/ajprenal.00037.2012
1507 (2012).
- 1508 105 Catania, J. M., Chen, G. & Parrish, A. R. Role of matrix metalloproteinases in
1509 renal pathophysiologies. *Am J Physiol Renal Physiol* **292**, F905-911,
1510 doi:10.1152/ajprenal.00421.2006 (2007).
- 1511 106 Hemmann, S., Graf, J., Roderfeld, M. & Roeb, E. Expression of MMPs and TIMPs
1512 in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. *J*
1513 *Hepatol* **46**, 955-975, doi:10.1016/j.jhep.2007.02.003 (2007).
- 1514 107 Giannandrea, M. & Parks, W. C. Diverse functions of matrix metalloproteinases
1515 during fibrosis. *Dis Model Mech* **7**, 193-203, doi:10.1242/dmm.012062 (2014).
- 1516 108 Zhou, Y. *et al.* Chitinase 3-like 1 suppresses injury and promotes
1517 fibroproliferative responses in Mammalian lung fibrosis. *Sci Transl Med* **6**, 240ra276,
1518 doi:10.1126/scitranslmed.3007096 (2014).
- 1519 109 Greene, K. E. *et al.* Serum surfactant proteins-A and -D as biomarkers in
1520 idiopathic pulmonary fibrosis. *Eur Respir J* **19**, 439-446,
1521 doi:10.1183/09031936.02.00081102 (2002).
- 1522 110 Guthmann, F. *et al.* Expression of fatty-acid-binding proteins in cells involved
1523 in lung-specific lipid metabolism. *Eur J Biochem* **253**, 430-436, doi:10.1046/j.1432-
1524 1327.1998.2530430.x (1998).
- 1525 111 El Agha, E. *et al.* Two-Way Conversion between Lipogenic and Myogenic
1526 Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. *Cell Stem*
1527 *Cell* **20**, 261-273 e263, doi:10.1016/j.stem.2016.10.004 (2017).
- 1528 112 Moustafa, T. *et al.* Alterations in lipid metabolism mediate inflammation,
1529 fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
1530 *Gastroenterology* **142**, 140-151.e112, doi:10.1053/j.gastro.2011.09.051 (2012).
- 1531 113 Kelson, T. L., Secor McVoy, J. R. & Rizzo, W. B. Human liver fatty aldehyde
1532 dehydrogenase: microsomal localization, purification, and biochemical characterization.
1533 *Biochim Biophys Acta* **1335**, 99-110, doi:10.1016/s0304-4165(96)00126-2 (1997).
- 1534 114 Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype
1535 in cancer pathogenesis. *Nat Rev Cancer* **7**, 763-777, doi:10.1038/nrc2222 (2007).
- 1536 115 Jung, M. Y. *et al.* Fatty acid synthase is required for profibrotic TGF- β signaling.
1537 *Faseb j* **32**, 3803-3815, doi:10.1096/fj.201701187R (2018).

Supple Info

- 1538 116 Meng, X.-m., Nikolic-Paterson, D. J. & Lan, H. Y. TGF- β : the master regulator
1539 of fibrosis. *Nature Reviews Nephrology* **12**, 325-338, doi:10.1038/nrneph.2016.48 (2016).
- 1540 117 Zhang, Y. *et al.* Pokeweed antiviral protein attenuates liver fibrosis in mice
1541 through regulating Wnt/Jnk mediated glucose metabolism. *Saudi journal of*
1542 *gastroenterology : official journal of the Saudi Gastroenterology Association* **24**, 157-164,
1543 doi:10.4103/sjg.SJG_470_17 (2018).
- 1544 118 Li, F. *et al.* FBP1 loss disrupts liver metabolism and promotes tumorigenesis
1545 through a hepatic stellate cell senescence secretome. *Nature Cell Biology* **22**, 728-739,
1546 doi:10.1038/s41556-020-0511-2 (2020).
- 1547 119 Reiner, Ž. *et al.* Lysosomal acid lipase deficiency--an under-recognized cause
1548 of dyslipidaemia and liver dysfunction. *Atherosclerosis* **235**, 21-30,
1549 doi:10.1016/j.atherosclerosis.2014.04.003 (2014).
- 1550 120 Rao, R., Albers, J. J., Wolfbauer, G. & Pownall, H. J. Molecular and
1551 macromolecular specificity of human plasma phospholipid transfer protein. *Biochemistry*
1552 **36**, 3645-3653, doi:10.1021/bi962776b (1997).
- 1553 121 Jiang, X. C., Jin, W. & Hussain, M. M. The impact of phospholipid transfer
1554 protein (PLTP) on lipoprotein metabolism. *Nutr Metab (Lond)* **9**, 75, doi:10.1186/1743-
1555 7075-9-75 (2012).
- 1556 122 Igal, R. A. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms
1557 of cell proliferation, programmed cell death and transformation to cancer. *Carcinogenesis*
1558 **31**, 1509-1515, doi:10.1093/carcin/bgq131 (2010).
- 1559 123 Lai, K. K. Y. *et al.* Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor
1560 Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density
1561 Lipoprotein-Receptor-Related Proteins 5 and 6. *Gastroenterology* **152**, 1477-1491,
1562 doi:10.1053/j.gastro.2017.01.021 (2017).
- 1563 124 Bebok, Z., Mazzochi, C., King, S. A., Hong, J. S. & Sorscher, E. J. The mechanism
1564 underlying cystic fibrosis transmembrane conductance regulator transport from the
1565 endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic,
1566 deglycosylated intermediary. *J Biol Chem* **273**, 29873-29878,
1567 doi:10.1074/jbc.273.45.29873 (1998).
- 1568 125 Pohlers, D. *et al.* TGF-beta and fibrosis in different organs - molecular pathway
1569 imprints. *Biochim Biophys Acta* **1792**, 746-756, doi:10.1016/j.bbadis.2009.06.004 (2009).
- 1570 126 Liang, C. *et al.* The anti-fibrotic effects of microRNA-153 by targeting TGFBR-
1571 2 in pulmonary fibrosis. *Exp Mol Pathol* **99**, 279-285, doi:10.1016/j.yexmp.2015.07.011
1572 (2015).
- 1573 127 Cao, D., Fan, S. T. & Chung, S. S. Identification and characterization of a novel
1574 human aldose reductase-like gene. *J Biol Chem* **273**, 11429-11435,
1575 doi:10.1074/jbc.273.19.11429 (1998).
- 1576 128 Kanno, M. *et al.* Serum aldo-keto reductase family 1 member B10 predicts
1577 advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. *J*
1578 *Gastroenterol* **54**, 549-557, doi:10.1007/s00535-019-01551-3 (2019).
- 1579 129 Bergdahl, I. A. *et al.* Lead binding to delta-aminolevulinic acid dehydratase
1580 (ALAD) in human erythrocytes. *Pharmacol Toxicol* **81**, 153-158, doi:10.1111/j.1600-
1581 0773.1997.tb02061.x (1997).

Supple Info

- 1582 130 Warren, M. J., Cooper, J. B., Wood, S. P. & Shoolingin-Jordan, P. M. Lead
1583 poisoning, haem synthesis and 5-aminolaevulinic acid dehydratase. *Trends Biochem Sci*
1584 **23**, 217-221, doi:10.1016/s0968-0004(98)01219-5 (1998).
- 1585 131 Wagener, F. A. *et al.* Different faces of the heme-heme oxygenase system in
1586 inflammation. *Pharmacol Rev* **55**, 551-571, doi:10.1124/pr.55.3.5 (2003).
- 1587 132 Larsen, R. *et al.* A central role for free heme in the pathogenesis of severe
1588 sepsis. *Sci Transl Med* **2**, 51ra71, doi:10.1126/scitranslmed.3001118 (2010).
- 1589 133 Wagener, F. A., Abraham, N. G., van Kooyk, Y., de Witte, T. & Figdor, C. G.
1590 Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation.
1591 *Trends Pharmacol Sci* **22**, 52-54, doi:10.1016/s0165-6147(00)01609-6 (2001).
- 1592 134 Nath, K. A., Balla, J., Croatt, A. J. & Vercellotti, G. M. Heme protein-mediated
1593 renal injury: a protective role for 21-aminosteroids in vitro and in vivo. *Kidney Int* **47**, 592-
1594 602, doi:10.1038/ki.1995.75 (1995).
- 1595 135 Aggarwal, S. *et al.* Heme scavenging reduces pulmonary endoplasmic
1596 reticulum stress, fibrosis, and emphysema. *JCI Insight* **3**, doi:10.1172/jci.insight.120694
1597 (2018).
- 1598 136 Leman, L. J., Maryanoff, B. E. & Ghadiri, M. R. Molecules that mimic
1599 apolipoprotein A-I: potential agents for treating atherosclerosis. *J Med Chem* **57**, 2169-
1600 2196, doi:10.1021/jm4005847 (2014).
- 1601 137 Provost, P. R., Boucher, E. & Tremblay, Y. Apolipoprotein A-I, A-II, C-II, and H
1602 expression in the developing lung and sex difference in surfactant lipids. *J Endocrinol* **200**,
1603 321-330, doi:10.1677/JOE-08-0238 (2009).
- 1604 138 Gauthier, M., Ray, A. & Wenzel, S. E. Evolving Concepts of Asthma. *Am J Respir*
1605 *Crit Care Med* **192**, 660-668, doi:10.1164/rccm.201504-0763PP (2015).
- 1606 139 Kim, T. H. *et al.* Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis:
1607 antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. *Am J*
1608 *Respir Crit Care Med* **182**, 633-642, doi:10.1164/rccm.200905-0659OC (2010).
- 1609 140 Toth, P. P. Triglyceride-rich lipoproteins as a causal factor for cardiovascular
1610 disease. *Vasc Health Risk Manag* **12**, 171-183, doi:10.2147/VHRM.S104369 (2016).
- 1611 141 Nordestgaard, B. G. & Varbo, A. Triglycerides and cardiovascular disease.
1612 *Lancet* **384**, 626-635, doi:10.1016/S0140-6736(14)61177-6 (2014).
- 1613 142 Wolska, A. *et al.* Apolipoprotein C-II: New findings related to genetics,
1614 biochemistry, and role in triglyceride metabolism. *Atherosclerosis* **267**, 49-60,
1615 doi:10.1016/j.atherosclerosis.2017.10.025 (2017).
- 1616 143 Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L. & Rios, C.
1617 Copper and copper proteins in Parkinson's disease. *Oxid Med Cell Longev* **2014**, 147251,
1618 doi:10.1155/2014/147251 (2014).
- 1619 144 Hung, I. H., Casareno, R. L., Labesse, G., Mathews, F. S. & Gitlin, J. D. HAH1 is a
1620 copper-binding protein with distinct amino acid residues mediating copper homeostasis
1621 and antioxidant defense. *J Biol Chem* **273**, 1749-1754, doi:10.1074/jbc.273.3.1749 (1998).
- 1622 145 Kim, D. W. *et al.* Tat-ATOX1 inhibits inflammatory responses via regulation of
1623 MAPK and NF-kappaB pathways. *BMB Rep* **51**, 654-659 (2018).
- 1624 146 Pandya, P. H. & Wilkes, D. S. Complement system in lung disease. *Am J Respir*
1625 *Cell Mol Biol* **51**, 467-473, doi:10.1165/rcmb.2013-0485TR (2014).

Supple Info

- 1626 147 Kerr, A. R., Paterson, G. K., Riboldi-Tunncliffe, A. & Mitchell, T. J. Innate
1627 immune defense against pneumococcal pneumonia requires pulmonary complement
1628 component C3. *Infect Immun* **73**, 4245-4252, doi:10.1128/IAI.73.7.4245-4252.2005 (2005).
- 1629 148 Marc, M. M. *et al.* Complement factors c3a, c4a, and c5a in chronic obstructive
1630 pulmonary disease and asthma. *Am J Respir Cell Mol Biol* **31**, 216-219,
1631 doi:10.1165/rcmb.2003-0394OC (2004).
- 1632 149 Liu, Y. *et al.* Complement C3 Produced by Macrophages Promotes Renal
1633 Fibrosis via IL-17A Secretion. *Front Immunol* **9**, 2385, doi:10.3389/fimmu.2018.02385
1634 (2018).
- 1635 150 Passwell, J., Schreiner, G. F., Nonaka, M., Beuscher, H. U. & Colten, H. R. Local
1636 extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in
1637 murine lupus nephritis. *J Clin Invest* **82**, 1676-1684, doi:10.1172/JCI113780 (1988).
- 1638 151 Natoli, R. *et al.* Retinal Macrophages Synthesize C3 and Activate Complement
1639 in AMD and in Models of Focal Retinal Degeneration. *Invest Ophthalmol Vis Sci* **58**, 2977-
1640 2990, doi:10.1167/iovs.17-21672 (2017).
- 1641 152 Mastaglio, S. *et al.* The first case of COVID-19 treated with the complement
1642 C3 inhibitor AMY-101. *Clin Immunol* **215**, 108450, doi:10.1016/j.clim.2020.108450 (2020).
- 1643 153 Goyal, M. M. & Basak, A. Human catalase: looking for complete identity.
1644 *Protein Cell* **1**, 888-897, doi:10.1007/s13238-010-0113-z (2010).
- 1645 154 Odajima, N. *et al.* The role of catalase in pulmonary fibrosis. *Respir Res* **11**, 183,
1646 doi:10.1186/1465-9921-11-183 (2010).
- 1647 155 Wu, Z., Zhang, Z., Lei, Z. & Lei, P. CD14: Biology and role in the pathogenesis
1648 of disease. *Cytokine Growth Factor Rev* **48**, 24-31, doi:10.1016/j.cytogfr.2019.06.003
1649 (2019).
- 1650 156 Ramaiah, S. K., Gunthner, R., Lech, M. & Anders, H. J. Toll-like receptor and
1651 accessory molecule mRNA expression in humans and mice as well as in murine
1652 autoimmunity, transient inflammation, and progressive fibrosis. *Int J Mol Sci* **14**, 13213-
1653 13230, doi:10.3390/ijms140713213 (2013).
- 1654 157 Thorgersen, E. B. *et al.* Systemic CD14 inhibition attenuates organ
1655 inflammation in porcine Escherichia coli sepsis. *Infect Immun* **81**, 3173-3181,
1656 doi:10.1128/IAI.00390-13 (2013).
- 1657 158 Berres, M. L. *et al.* A functional variation in CHI3L1 is associated with severity
1658 of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. *J Hepatol* **50**,
1659 370-376, doi:10.1016/j.jhep.2008.09.016 (2009).
- 1660 159 Kamal, S. M. *et al.* Progression of fibrosis in hepatitis C with and without
1661 schistosomiasis: correlation with serum markers of fibrosis. *Hepatology* **43**, 771-779,
1662 doi:10.1002/hep.21117 (2006).
- 1663 160 Hu, B., Trinh, K., Figueira, W. F. & Price, P. A. Isolation and sequence of a novel
1664 human chondrocyte protein related to mammalian members of the chitinase protein
1665 family. *J Biol Chem* **271**, 19415-19420, doi:10.1074/jbc.271.32.19415 (1996).
- 1666 161 Cox, N., Pilling, D. & Gomer, R. H. DC-SIGN activation mediates the differential
1667 effects of SAP and CRP on the innate immune system and inhibits fibrosis in mice. *Proc
1668 Natl Acad Sci U S A* **112**, 8385-8390, doi:10.1073/pnas.1500956112 (2015).
- 1669 162 Du Clos, T. W. Pentraxins: structure, function, and role in inflammation. *ISRN*

Supple Info

- 1670 *Inflamm* **2013**, 379040, doi:10.1155/2013/379040 (2013).
- 1671 163 Devaraj, S. & Jialal, I. C-reactive protein polarizes human macrophages to an
1672 M1 phenotype and inhibits transformation to the M2 phenotype. *Arterioscler Thromb*
1673 *Vasc Biol* **31**, 1397-1402, doi:10.1161/ATVBAHA.111.225508 (2011).
- 1674 164 Weisel, J. W. & Litvinov, R. I. Fibrin Formation, Structure and Properties. *Subcell*
1675 *Biochem* **82**, 405-456, doi:10.1007/978-3-319-49674-0_13 (2017).
- 1676 165 Davalos, D. & Akassoglou, K. Fibrinogen as a key regulator of inflammation in
1677 disease. *Semin Immunopathol* **34**, 43-62, doi:10.1007/s00281-011-0290-8 (2012).
- 1678 166 Helms, J. *et al.* High risk of thrombosis in patients with severe SARS-CoV-2
1679 infection: a multicenter prospective cohort study. *Intensive Care Med* **46**, 1089-1098,
1680 doi:10.1007/s00134-020-06062-x (2020).
- 1681 167 Duan, H. O. & Simpson-Haidaris, P. J. Cell type-specific differential induction
1682 of the human gamma-fibrinogen promoter by interleukin-6. *J Biol Chem* **281**, 12451-
1683 12457, doi:10.1074/jbc.M600294200 (2006).
- 1684 168 Yang, H. *et al.* Induction of avian musculoaponeurotic fibrosarcoma proteins
1685 by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to
1686 cholestatic liver injury in mice. *Hepatology* **51**, 1291-1301, doi:10.1002/hep.23471 (2010).
- 1687 169 Lu, S. C. Regulation of glutathione synthesis. *Mol Aspects Med* **30**, 42-59,
1688 doi:10.1016/j.mam.2008.05.005 (2009).
- 1689 170 Yoshizaki, A. *et al.* Cell adhesion molecules regulate fibrotic process via
1690 Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. *J Immunol* **185**,
1691 2502-2515, doi:10.4049/jimmunol.0901778 (2010).
- 1692 171 Chen, P. J. *et al.* PTP1B confers liver fibrosis by regulating the activation of
1693 hepatic stellate cells. *Toxicol Appl Pharmacol* **292**, 8-18, doi:10.1016/j.taap.2015.12.021
1694 (2016).
- 1695 172 Thorn, C. F., Lu, Z. Y. & Whitehead, A. S. Tissue-specific regulation of the
1696 human acute-phase serum amyloid A genes, SAA1 and SAA2, by glucocorticoids in
1697 hepatic and epithelial cells. *Eur J Immunol* **33**, 2630-2639, doi:10.1002/eji.200323985
1698 (2003).
- 1699 173 Emerit, J., Samuel, D. & Pavio, N. Cu-Zn super oxide dismutase as a potential
1700 antifibrotic drug for hepatitis C related fibrosis. *Biomed Pharmacother* **60**, 1-4,
1701 doi:10.1016/j.biopha.2005.09.002 (2006).
- 1702 174 Agassandian, M. *et al.* VCAM-1 is a TGF-beta1 inducible gene upregulated in
1703 idiopathic pulmonary fibrosis. *Cell Signal* **27**, 2467-2473, doi:10.1016/j.cellsig.2015.09.003
1704 (2015).
- 1705 175 DeWire, S. M., Ahn, S., Lefkowitz, R. J. & Shenoy, S. K. Beta-arrestins and cell
1706 signaling. *Annu Rev Physiol* **69**, 483-510, doi:10.1146/annurev.physiol.69.022405.154749
1707 (2007).
- 1708 176 Shi, Y. *et al.* Critical regulation of CD4+ T cell survival and autoimmunity by
1709 beta-arrestin 1. *Nat Immunol* **8**, 817-824, doi:10.1038/ni1489 (2007).
- 1710 177 Gu, Y. J., Sun, W. Y., Zhang, S., Wu, J. J. & Wei, W. The emerging roles of beta-
1711 arrestins in fibrotic diseases. *Acta Pharmacol Sin* **36**, 1277-1287, doi:10.1038/aps.2015.74
1712 (2015).
- 1713 178 Black, M. *et al.* FOXF1 Inhibits Pulmonary Fibrosis by Preventing CDH2-CDH11

Supple Info

- 1714 Cadherin Switch in Myofibroblasts. *Cell Rep* **23**, 442-458, doi:10.1016/j.celrep.2018.03.067
1715 (2018).
- 1716 179 Nagasawa, T. *et al.* Defects of B-cell lymphopoiesis and bone-marrow
1717 myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* **382**, 635-638,
1718 doi:10.1038/382635a0 (1996).
- 1719 180 Li, F., Xu, X., Geng, J., Wan, X. & Dai, H. The autocrine CXCR4/CXCL12 axis
1720 contributes to lung fibrosis through modulation of lung fibroblast activity. *Exp Ther Med*
1721 **19**, 1844-1854, doi:10.3892/etm.2020.8433 (2020).
- 1722 181 Higgins, D. F. *et al.* Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation
1723 of epithelial-to-mesenchymal transition. *J Clin Invest* **117**, 3810-3820,
1724 doi:10.1172/JCI30487 (2007).
- 1725 182 Dongiovanni, P. *et al.* Insulin resistance promotes Lysyl Oxidase Like 2
1726 induction and fibrosis accumulation in non-alcoholic fatty liver disease. *Clin Sci (Lond)*
1727 **131**, 1301-1315, doi:10.1042/cs20170175 (2017).
- 1728 183 Henderson, N. C. & Sheppard, D. Integrin-mediated regulation of TGF β in
1729 fibrosis. *Biochim Biophys Acta* **1832**, 891-896, doi:10.1016/j.bbadis.2012.10.005 (2013).
- 1730 184 Mann, J. *et al.* MeCP2 controls an epigenetic pathway that promotes
1731 myofibroblast transdifferentiation and fibrosis. *Gastroenterology* **138**, 705-714,
1732 714.e701-704, doi:10.1053/j.gastro.2009.10.002 (2010).
- 1733 185 Liu, A. Y., Zheng, H. & Ouyang, G. Periostin, a multifunctional matricellular
1734 protein in inflammatory and tumor microenvironments. *Matrix Biol* **37**, 150-156,
1735 doi:10.1016/j.matbio.2014.04.007 (2014).
- 1736 186 Naik, P. K. *et al.* Periostin promotes fibrosis and predicts progression in patients
1737 with idiopathic pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* **303**, L1046-1056,
1738 doi:10.1152/ajplung.00139.2012 (2012).
- 1739 187 Schneider, M., Hansen, J. L. & Sheikh, S. P. S100A4: a common mediator of
1740 epithelial-mesenchymal transition, fibrosis and regeneration in diseases? *J Mol Med (Berl)*
1741 **86**, 507-522, doi:10.1007/s00109-007-0301-3 (2008).
- 1742 188 Ghosh, A. K. & Vaughan, D. E. PAI-1 in tissue fibrosis. *J Cell Physiol* **227**, 493-
1743 507, doi:10.1002/jcp.22783 (2012).
- 1744 189 Kasembeli, M. M., Bharadwaj, U., Robinson, P. & Twardy, D. J. Contribution of
1745 STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment.
1746 *Int J Mol Sci* **19**, doi:10.3390/ijms19082299 (2018).
- 1747 190 Sweetwyne, M. T. & Murphy-Ullrich, J. E. Thrombospondin1 in tissue repair
1748 and fibrosis: TGF-beta-dependent and independent mechanisms. *Matrix Biol* **31**, 178-
1749 186, doi:10.1016/j.matbio.2012.01.006 (2012).
- 1750 191 Noutsios, G. T., Ghattas, P., Bennett, S. & Floros, J. 14-3-3 isoforms bind
1751 directly exon B of the 5'-UTR of human surfactant protein A2 mRNA. *Am J Physiol Lung*
1752 *Cell Mol Physiol* **309**, L147-157, doi:10.1152/ajplung.00088.2015 (2015).
- 1753 192 Bárcena, C. *et al.* Gas6/Axl pathway is activated in chronic liver disease and its
1754 targeting reduces fibrosis via hepatic stellate cell inactivation. *J Hepatol* **63**, 670-678,
1755 doi:10.1016/j.jhep.2015.04.013 (2015).
- 1756 193 Han, J. *et al.* Autophagy induced by AXL receptor tyrosine kinase alleviates
1757 acute liver injury via inhibition of NLRP3 inflammasome activation in mice. *Autophagy* **12**,

Supple Info

- 1758 2326-2343, doi:10.1080/15548627.2016.1235124 (2016).
- 1759 194 Kang, H. R., Cho, S. J., Lee, C. G., Homer, R. J. & Elias, J. A. Transforming growth
1760 factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent,
1761 bid-activated pathway that involves matrix metalloproteinase-12. *J Biol Chem* **282**, 7723-
1762 7732, doi:10.1074/jbc.M610764200 (2007).
- 1763 195 Roberts, A. B. *et al.* Transforming growth factor type beta: rapid induction of
1764 fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. *Proc Natl*
1765 *Acad Sci U S A* **83**, 4167-4171, doi:10.1073/pnas.83.12.4167 (1986).
- 1766 196 Hua, X. *et al.* Multi-level transcriptome sequencing identifies COL1A1 as a
1767 candidate marker in human heart failure progression. *BMC Medicine* **18**, 2,
1768 doi:10.1186/s12916-019-1469-4 (2020).
- 1769 197 Takai, K. K., Hattori, S. & Irie, S. Type V collagen distribution in liver is
1770 reconstructed in coculture system of hepatocytes and stellate cells; the possible functions
1771 of type V collagen in liver under normal and pathological conditions. *Cell structure and*
1772 *function* **26**, 289-302, doi:10.1247/csf.26.289 (2001).
- 1773 198 Moriya, K. *et al.* A fibronectin-independent mechanism of collagen
1774 fibrillogenesis in adult liver remodeling. *Gastroenterology* **140**, 1653-1663,
1775 doi:10.1053/j.gastro.2011.02.005 (2011).
- 1776 199 Kim, M. I. N. & Park, J. Collagen VI-Derived Endotrophin Promotes Hepatic
1777 Apoptosis, Inflammation, and Fibrosis in Chronic Liver Disease. *Diabetes* **67**, 254-LB,
1778 doi:10.2337/db18-254-LB (2018).
- 1779 200 Gerling, B., Becker, M., Staab, D. & Schuppan, D. Prediction of liver fibrosis
1780 according to serum collagen VI level in children with cystic fibrosis. *N Engl J Med* **336**,
1781 1611-1612, doi:10.1056/nejm199705293362217 (1997).
- 1782 201 Smieszek, S. P., Przychodzen, B. P. & Polymeropoulos, M. H. Amantadine
1783 disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. *Int J Antimicrob*
1784 *Agents* **55**, 106004, doi:10.1016/j.ijantimicag.2020.106004 (2020).
- 1785 202 Manchanda, M. *et al.* Cathepsin L and B as Potential Markers for Liver Fibrosis:
1786 Insights From Patients and Experimental Models. *Clin Transl Gastroenterol* **8**, e99,
1787 doi:10.1038/ctg.2017.25 (2017).
- 1788 203 Khalkhali-Ellis, Z. & Hendrix, M. J. Elucidating the function of secreted maspin:
1789 inhibiting cathepsin D-mediated matrix degradation. *Cancer Res* **67**, 3535-3539,
1790 doi:10.1158/0008-5472.Can-06-4767 (2007).
- 1791 204 Kristensen, D. B. *et al.* Proteome analysis of rat hepatic stellate cells.
1792 *Hepatology* **32**, 268-277, doi:10.1053/jhep.2000.9322 (2000).
- 1793 205 Moles, A., Tarrats, N., Fernández-Checa, J. C. & Marí, M. Cathepsins B and D
1794 drive hepatic stellate cell proliferation and promote their fibrogenic potential. *Hepatology*
1795 **49**, 1297-1307, doi:10.1002/hep.22753 (2009).
- 1796 206 Cascino, I., Fiucci, G., Papoff, G. & Ruberti, G. Three functional soluble forms of
1797 the human apoptosis-inducing Fas molecule are produced by alternative splicing. *J*
1798 *Immunol* **154**, 2706-2713 (1995).
- 1799 207 Guegan, J. P. & Legembre, P. Nonapoptotic functions of Fas/CD95 in the
1800 immune response. *FEBS J* **285**, 809-827, doi:10.1111/febs.14292 (2018).
- 1801 208 Chen, Q. *et al.* Cystic fibrosis epithelial cells are primed for apoptosis as a result

Supple Info

- 1802 of increased Fas (CD95). *J Cyst Fibros* **17**, 616-623, doi:10.1016/j.jcf.2018.01.010 (2018).
- 1803 209 Panasiuk, A., Parfieniuk, A., Zak, J. & Flisiak, R. Association among Fas
- 1804 expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic
- 1805 inflammation and fibrosis in chronic hepatitis C. *Liver Int* **30**, 472-478, doi:10.1111/j.1478-
- 1806 3231.2009.02159.x (2010).
- 1807 210 Hara, M. *et al.* LAP degradation product reflects plasma kallikrein-dependent
- 1808 TGF-beta activation in patients with hepatic fibrosis. *Springerplus* **3**, 221,
- 1809 doi:10.1186/2193-1801-3-221 (2014).
- 1810 211 Fiorucci, S. *et al.* The nuclear receptor SHP mediates inhibition of hepatic
- 1811 stellate cells by FXR and protects against liver fibrosis. *Gastroenterology* **127**, 1497-1512,
- 1812 doi:10.1053/j.gastro.2004.08.001 (2004).
- 1813 212 Flevaris, P. & Vaughan, D. The Role of Plasminogen Activator Inhibitor Type-1
- 1814 in Fibrosis. *Semin Thromb Hemost* **43**, 169-177, doi:10.1055/s-0036-1586228 (2017).
- 1815 213 Wu, Y. *et al.* Plasminogen improves lung lesions and hypoxemia in patients
- 1816 with COVID-19. *Qjm*, doi:10.1093/qjmed/hcaa121 (2020).
- 1817 214 Lucido, M. J., Orlando, B. J., Vecchio, A. J. & Malkowski, M. G. Crystal Structure
- 1818 of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products
- 1819 with Reversed Stereochemistry. *Biochemistry* **55**, 1226-1238,
- 1820 doi:10.1021/acs.biochem.5b01378 (2016).
- 1821 215 Orlando, B. J. & Malkowski, M. G. Substrate-selective Inhibition of
- 1822 Cyclooxygenase-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone. *J Biol*
- 1823 *Chem* **291**, 15069-15081, doi:10.1074/jbc.M116.725713 (2016).
- 1824 216 Hamada, T. *et al.* Cyclooxygenase-2 deficiency enhances Th2 immune
- 1825 responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. *J*
- 1826 *Immunol* **180**, 1843-1853, doi:10.4049/jimmunol.180.3.1843 (2008).
- 1827 217 Bonner, J. C. *et al.* Susceptibility of cyclooxygenase-2-deficient mice to
- 1828 pulmonary fibrogenesis. *Am J Pathol* **161**, 459-470, doi:10.1016/S0002-9440(10)64202-
- 1829 2 (2002).
- 1830 218 Yu, G. *et al.* Matrix metalloproteinase-19 is a key regulator of lung fibrosis in
- 1831 mice and humans. *Am J Respir Crit Care Med* **186**, 752-762, doi:10.1164/rccm.201202-
- 1832 0302OC (2012).
- 1833 219 Arpino, V., Brock, M. & Gill, S. E. The role of TIMPs in regulation of extracellular
- 1834 matrix proteolysis. *Matrix Biol* **44-46**, 247-254, doi:10.1016/j.matbio.2015.03.005 (2015).
- 1835 220 Strieter, R. M. & Mehrad, B. New mechanisms of pulmonary fibrosis. *Chest* **136**,
- 1836 1364-1370, doi:10.1378/chest.09-0510 (2009).
- 1837 221 Lin, H. & Cao, X. Nuclear innate sensors for nucleic acids in immunity and
- 1838 inflammation. *Immunol Rev*, doi:10.1111/imr.12893 (2020).
- 1839 222 Li, X. D. *et al.* Pivotal roles of cGAS-cGAMP signaling in antiviral defense and
- 1840 immune adjuvant effects. *Science* **341**, 1390-1394, doi:10.1126/science.1244040 (2013).
- 1841 223 Tanaka, T., Kamitani, W., DeDiego, M. L., Enjuanes, L. & Matsuura, Y. Severe
- 1842 acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells
- 1843 through a specific translational shutoff of host mRNA. *J Virol* **86**, 11128-11137,
- 1844 doi:10.1128/JVI.01700-12 (2012).
- 1845 224 Cencic, R. *et al.* Blocking eIF4E-eIF4G interaction as a strategy to impair

Supple Info

- 1846 coronavirus replication. *J Virol* **85**, 6381-6389, doi:10.1128/JVI.00078-11 (2011).
- 1847 225 Kobayashi, T. *et al.* TRAF6 is a critical factor for dendritic cell maturation and
1848 development. *Immunity* **19**, 353-363, doi:10.1016/s1074-7613(03)00230-9 (2003).
- 1849 226 Tomasello, E. & Vivier, E. KARAP/DAP12/TYROBP: three names and a
1850 multiplicity of biological functions. *Eur J Immunol* **35**, 1670-1677,
1851 doi:10.1002/eji.200425932 (2005).
- 1852 227 Kim, P. W., Sun, Z. Y., Blacklow, S. C., Wagner, G. & Eck, M. J. A zinc clasp
1853 structure tethers Lck to T cell coreceptors CD4 and CD8. *Science* **301**, 1725-1728,
1854 doi:10.1126/science.1085643 (2003).
- 1855 228 Liu, Y. *et al.* HisgAtlas 1.0: a human immunosuppression gene database.
1856 *Database (Oxford)* **2017**, doi:10.1093/database/bax094 (2017).
- 1857 229 Yin, K. *et al.* Vitamin D Protects Against Atherosclerosis via Regulation of
1858 Cholesterol Efflux and Macrophage Polarization in Hypercholesterolemic Swine.
1859 *Arterioscler Thromb Vasc Biol* **35**, 2432-2442, doi:10.1161/ATVBAHA.115.306132 (2015).
- 1860 230 Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion.
1861 *Nat Rev Immunol* **15**, 486-499, doi:10.1038/nri3862 (2015).
- 1862 231 Chalasani, N. *et al.* The diagnosis and management of nonalcoholic fatty liver
1863 disease: Practice guidance from the American Association for the Study of Liver Diseases.
1864 *Hepatology* **67**, 328-357, doi:10.1002/hep.29367 (2018).
- 1865 232 Hijona, E., Hijona, L., Arenas, J. I. & Bujanda, L. Inflammatory mediators of
1866 hepatic steatosis. *Mediators Inflamm* **2010**, 837419, doi:10.1155/2010/837419 (2010).
- 1867 233 Liu, T., Wang, X., Karsdal, M. A., Leeming, D. J. & Genovese, F. Molecular serum
1868 markers of liver fibrosis. *Biomark Insights* **7**, 105-117, doi:10.4137/BMI.S10009 (2012).
- 1869 234 Alonzi, T. *et al.* Essential role of STAT3 in the control of the acute-phase
1870 response as revealed by inducible gene inactivation [correction of activation] in the liver.
1871 *Mol Cell Biol* **21**, 1621-1632, doi:10.1128/MCB.21.5.1621-1632.2001 (2001).
- 1872 235 Israel, A. The IKK complex, a central regulator of NF-kappaB activation. *Cold
1873 Spring Harb Perspect Biol* **2**, a000158, doi:10.1101/cshperspect.a000158 (2010).
- 1874 236 Zimmermann, H. W. *et al.* Interleukin-8 is activated in patients with chronic
1875 liver diseases and associated with hepatic macrophage accumulation in human liver
1876 fibrosis. *PLoS One* **6**, e21381, doi:10.1371/journal.pone.0021381 (2011).
- 1877 237 Yang, Y. M. & Seki, E. TNFalpha in liver fibrosis. *Curr Pathobiol Rep* **3**, 253-261,
1878 doi:10.1007/s40139-015-0093-z (2015).
- 1879 238 Yin, L., Ma, H., Ge, X., Edwards, P. A. & Zhang, Y. Hepatic hepatocyte nuclear
1880 factor 4alpha is essential for maintaining triglyceride and cholesterol homeostasis.
1881 *Arterioscler Thromb Vasc Biol* **31**, 328-336, doi:10.1161/ATVBAHA.110.217828 (2011).
- 1882 239 Cairo, S. & Buendia, M. A. How transient becomes stable: an epigenetic switch
1883 linking liver inflammation and tumorigenesis. *J Hepatol* **57**, 910-912,
1884 doi:10.1016/j.jhep.2012.05.017 (2012).
- 1885 240 Mazure, N. M., Nguyen, T. L. & Danan, J. L. Severe hypoxia specifically
1886 downregulates hepatocyte nuclear factor-4 gene expression in HepG2 human hepatoma
1887 cells. *Tumour Biol* **22**, 310-317, doi:10.1159/000050632 (2001).
- 1888 241 Hayhurst, G. P., Lee, Y. H., Lambert, G., Ward, J. M. & Gonzalez, F. J. Hepatocyte
1889 nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene

Supple Info

- 1890 expression and lipid homeostasis. *Mol Cell Biol* **21**, 1393-1403,
1891 doi:10.1128/MCB.21.4.1393-1403.2001 (2001).
- 1892 242 Capeau, J. Insulin resistance and steatosis in humans. *Diabetes Metab* **34**, 649-
1893 657, doi:10.1016/S1262-3636(08)74600-7 (2008).
- 1894 243 Festjens, N., Vanden Berghe, T. & Vandenabeele, P. Necrosis, a well-
1895 orchestrated form of cell demise: signalling cascades, important mediators and
1896 concomitant immune response. *Biochim Biophys Acta* **1757**, 1371-1387,
1897 doi:10.1016/j.bbabi.2006.06.014 (2006).
- 1898 244 Zamzami, N., Larochette, N. & Kroemer, G. Mitochondrial permeability
1899 transition in apoptosis and necrosis. *Cell Death & Differentiation* **12**, 1478-1480,
1900 doi:10.1038/sj.cdd.4401682 (2005).
- 1901 245 Fan, Z. *et al.* Clinical Features of COVID-19-Related Liver Functional
1902 Abnormality. *Clin Gastroenterol Hepatol* **18**, 1561-1566, doi:10.1016/j.cgh.2020.04.002
1903 (2020).
- 1904 246 Sprague, A. H. & Khalil, R. A. Inflammatory cytokines in vascular dysfunction
1905 and vascular disease. *Biochem Pharmacol* **78**, 539-552, doi:10.1016/j.bcp.2009.04.029
1906 (2009).
- 1907 247 Nagy, J. A., Benjamin, L., Zeng, H., Dvorak, A. M. & Dvorak, H. F. Vascular
1908 permeability, vascular hyperpermeability and angiogenesis. *Angiogenesis* **11**, 109-119,
1909 doi:10.1007/s10456-008-9099-z (2008).
- 1910 248 Muller, W. A. Getting leukocytes to the site of inflammation. *Vet Pathol* **50**, 7-
1911 22, doi:10.1177/0300985812469883 (2013).
- 1912 249 Barreiro, O. *et al.* Dynamic interaction of VCAM-1 and ICAM-1 with moesin
1913 and ezrin in a novel endothelial docking structure for adherent leukocytes. *J Cell Biol* **157**,
1914 1233-1245, doi:10.1083/jcb.200112126 (2002).
- 1915 250 Hidalgo, A. & Frenette, P. S. Leukocyte podosomes sense their way through
1916 the endothelium. *Immunity* **26**, 753-755, doi:10.1016/j.immuni.2007.06.002 (2007).
- 1917 251 Liang, D., Bhatta, S., Gerzanich, V. & Simard, J. M. Cytotoxic edema:
1918 mechanisms of pathological cell swelling. *Neurosurg Focus* **22**, E2,
1919 doi:10.3171/foc.2007.22.5.3 (2007).
- 1920 252 Benarroch, E. E. Na⁺, K⁺-ATPase: functions in the nervous system and
1921 involvement in neurologic disease. *Neurology* **76**, 287-293,
1922 doi:10.1212/WNL.0b013e3182074c2f (2011).
- 1923 253 Koh, M. Y., Darnay, B. G. & Powis, G. Hypoxia-associated factor, a novel E3-
1924 ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its
1925 oxygen-independent degradation. *Mol Cell Biol* **28**, 7081-7095, doi:10.1128/MCB.00773-
1926 08 (2008).
- 1927 254 Holzerova, E. *et al.* Human thioredoxin 2 deficiency impairs mitochondrial
1928 redox homeostasis and causes early-onset neurodegeneration. *Brain* **139**, 346-354,
1929 doi:10.1093/brain/awv350 (2016).
- 1930 255 Perez, V. I. *et al.* Thioredoxin 2 haploinsufficiency in mice results in impaired
1931 mitochondrial function and increased oxidative stress. *Free Radic Biol Med* **44**, 882-892,
1932 doi:10.1016/j.freeradbiomed.2007.11.018 (2008).
- 1933 256 Schultheiss, H. P. Disturbance of the myocardial energy metabolism in dilated

Supple Info

- 1934 cardiomyopathy due to autoimmunological mechanisms. *Circulation* **87**, IV43-48 (1993).
- 1935 257 Singer, M. *et al.* The Third International Consensus Definitions for Sepsis and
- 1936 Septic Shock (Sepsis-3). *JAMA* **315**, 801-810, doi:10.1001/jama.2016.0287 (2016).
- 1937 258 Iovine, N., Eastvold, J., Elsbach, P., Weiss, J. P. & Gioannini, T. L. The carboxyl-
- 1938 terminal domain of closely related endotoxin-binding proteins determines the target of
- 1939 protein-lipopolysaccharide complexes. *J Biol Chem* **277**, 7970-7978,
- 1940 doi:10.1074/jbc.M109622200 (2002).
- 1941 259 Shakoory, B. *et al.* Interleukin-1 Receptor Blockade Is Associated With Reduced
- 1942 Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis
- 1943 of a Prior Phase III Trial. *Crit Care Med* **44**, 275-281, doi:10.1097/CCM.0000000000001402
- 1944 (2016).
- 1945 260 Hultgren, O. H., Svensson, L. & Tarkowski, A. Critical role of signaling through
- 1946 IL-1 receptor for development of arthritis and sepsis during *Staphylococcus aureus*
- 1947 infection. *J Immunol* **168**, 5207-5212, doi:10.4049/jimmunol.168.10.5207 (2002).
- 1948 261 Brydon, E. W., Morris, S. J. & Sweet, C. Role of apoptosis and cytokines in
- 1949 influenza virus morbidity. *FEMS Microbiol Rev* **29**, 837-850,
- 1950 doi:10.1016/j.femsre.2004.12.003 (2005).
- 1951 262 Chen, D., Li, X., Zhai, Z. & Shu, H. B. A novel zinc finger protein interacts with
- 1952 receptor-interacting protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-
- 1953 induced NF-kappa B activation. *J Biol Chem* **277**, 15985-15991,
- 1954 doi:10.1074/jbc.M108675200 (2002).
- 1955 263 Strilic, B. *et al.* Tumour-cell-induced endothelial cell necroptosis via death
- 1956 receptor 6 promotes metastasis. *Nature* **536**, 215-218, doi:10.1038/nature19076 (2016).
- 1957 264 Stephanou, A. *et al.* Ischemia-induced STAT-1 expression and activation play
- 1958 a critical role in cardiomyocyte apoptosis. *J Biol Chem* **275**, 10002-10008,
- 1959 doi:10.1074/jbc.275.14.10002 (2000).
- 1960 265 Singh, B., Biswas, I., Bhagat, S., Surya Kumari, S. & Khan, G. A. HMGB1 facilitates
- 1961 hypoxia-induced vWF upregulation through TLR2-MYD88-SP1 pathway. *Eur J Immunol*
- 1962 **46**, 2388-2400, doi:10.1002/eji.201646386 (2016).
- 1963 266 Simon, N. & Hertig, A. Alteration of Fatty Acid Oxidation in Tubular Epithelial
- 1964 Cells: From Acute Kidney Injury to Renal Fibrogenesis. *Front Med (Lausanne)* **2**, 52,
- 1965 doi:10.3389/fmed.2015.00052 (2015).
- 1966 267 Imhof, B. A. & Aurrand-Lions, M. Angiogenesis and inflammation face off. *Nat*
- 1967 *Med* **12**, 171-172, doi:10.1038/nm0206-171 (2006).
- 1968 268 Kaminska, J. *et al.* IL 6 but not TNF is linked to coronary artery calcification in
- 1969 patients with chronic kidney disease. *Cytokine* **120**, 9-14, doi:10.1016/j.cyto.2019.04.002
- 1970 (2019).
- 1971 269 Su, C. M. *et al.* Elevated serum vascular cell adhesion molecule-1 is associated
- 1972 with septic encephalopathy in adult community-onset severe sepsis patients. *Biomed Res*
- 1973 *Int* **2014**, 598762, doi:10.1155/2014/598762 (2014).
- 1974 270 Prakash, J. *et al.* Inhibition of renal rho kinase attenuates ischemia/reperfusion-
- 1975 induced injury. *J Am Soc Nephrol* **19**, 2086-2097, doi:10.1681/ASN.2007070794 (2008).
- 1976 271 Seccia, T. M., Rigato, M., Ravarotto, V. & Calo, L. A. ROCK (RhoA/Rho Kinase)
- 1977 in Cardiovascular-Renal Pathophysiology: A Review of New Advancements. *J Clin Med* **9**,

Supple Info

- 1978 doi:10.3390/jcm9051328 (2020).
- 1979 272 Neubauer, K., Neubauer, B., Seidl, M. & Zieger, B. Characterization of septin
1980 expression in normal and fibrotic kidneys. *Cytoskeleton (Hoboken)* **76**, 143-153,
1981 doi:10.1002/cm.21473 (2019).
- 1982 273 Bellomo, R., Kellum, J. A. & Ronco, C. Acute kidney injury. *Lancet* **380**, 756-766,
1983 doi:10.1016/S0140-6736(11)61454-2 (2012).
- 1984 274 Kryczek, I., Wei, S., Keller, E., Liu, R. & Zou, W. Stroma-derived factor (SDF-
1985 1/CXCL12) and human tumor pathogenesis. *Am J Physiol Cell Physiol* **292**, C987-995,
1986 doi:10.1152/ajpcell.00406.2006 (2007).
- 1987 275 Hashimoto, I. *et al.* Blocking on the CXCR4/mTOR signalling pathway induces
1988 the anti-metastatic properties and autophagic cell death in peritoneal disseminated
1989 gastric cancer cells. *Eur J Cancer* **44**, 1022-1029, doi:10.1016/j.ejca.2008.02.043 (2008).
- 1990 276 van Deventer, S. J. *et al.* Experimental endotoxemia in humans: analysis of
1991 cytokine release and coagulation, fibrinolytic, and complement pathways. *Blood* **76**, 2520-
1992 2526 (1990).
- 1993 277 Senn, J. J., Klover, P. J., Nowak, I. A. & Mooney, R. A. Interleukin-6 induces
1994 cellular insulin resistance in hepatocytes. *Diabetes* **51**, 3391-3399,
1995 doi:10.2337/diabetes.51.12.3391 (2002).
- 1996 278 Ridley, A. J. Rho GTPases and actin dynamics in membrane protrusions and
1997 vesicle trafficking. *Trends Cell Biol* **16**, 522-529, doi:10.1016/j.tcb.2006.08.006 (2006).
- 1998 279 Gutkind, J. S. Cell growth control by G protein-coupled receptors: from signal
1999 transduction to signal integration. *Oncogene* **17**, 1331-1342, doi:10.1038/sj.onc.1202186
2000 (1998).
- 2001 280 Rau, J. C., Beaulieu, L. M., Huntington, J. A. & Church, F. C. Serpins in
2002 thrombosis, hemostasis and fibrinolysis. *J Thromb Haemost* **5 Suppl 1**, 102-115,
2003 doi:10.1111/j.1538-7836.2007.02516.x (2007).
- 2004 281 Morange, P. E. *et al.* KNG1 Ile581Thr and susceptibility to venous thrombosis.
2005 *Blood* **117**, 3692-3694, doi:10.1182/blood-2010-11-319053 (2011).
- 2006 282 Rovira, J. *et al.* mTOR Inhibition: Reduced Insulin Secretion and Sensitivity in a
2007 Rat Model of Metabolic Syndrome. *Transplant Direct* **2**, e65,
2008 doi:10.1097/TXD.0000000000000576 (2016).
- 2009 283 Brown, M. S. & Goldstein, J. L. A proteolytic pathway that controls the
2010 cholesterol content of membranes, cells, and blood. *Proc Natl Acad Sci U S A* **96**, 11041-
2011 11048, doi:10.1073/pnas.96.20.11041 (1999).
- 2012 284 Bennati, A. M. *et al.* Sterol dependent regulation of human TM7SF2 gene
2013 expression: role of the encoded 3beta-hydroxysterol Delta14-reductase in human
2014 cholesterol biosynthesis. *Biochim Biophys Acta* **1761**, 677-685,
2015 doi:10.1016/j.bbailip.2006.05.004 (2006).
- 2016 285 Uhlen, M. *et al.* Proteomics. Tissue-based map of the human proteome.
2017 *Science* **347**, 1260419, doi:10.1126/science.1260419 (2015).
- 2018 286 Adham, I. M., Burkhardt, E., Benahmed, M. & Engel, W. Cloning of a cDNA for
2019 a novel insulin-like peptide of the testicular Leydig cells. *J Biol Chem* **268**, 26668-26672
2020 (1993).
- 2021 287 Ivell, R., Heng, K. & Anand-Ivell, R. Insulin-Like Factor 3 and the HPG Axis in

Supple Info

- 2022 the Male. *Front Endocrinol (Lausanne)* **5**, 6, doi:10.3389/fendo.2014.00006 (2014).
- 2023 288 Nef, S. & Parada, L. F. Cryptorchidism in mice mutant for Insl3. *Nat Genet* **22**,
- 2024 295-299, doi:10.1038/10364 (1999).
- 2025 289 Zimmermann, S. *et al.* Targeted disruption of the Insl3 gene causes bilateral
- 2026 cryptorchidism. *Mol Endocrinol* **13**, 681-691, doi:10.1210/mend.13.5.0272 (1999).
- 2027 290 Tomboc, M. *et al.* Insulin-like 3/relaxin-like factor gene mutations are
- 2028 associated with cryptorchidism. *J Clin Endocrinol Metab* **85**, 4013-4018,
- 2029 doi:10.1210/jcem.85.11.6935 (2000).
- 2030 291 Marin, P. *et al.* Novel insulin-like 3 (INSL3) gene mutation associated with
- 2031 human cryptorchidism. *Am J Med Genet* **103**, 348-349 (2001).
- 2032 292 Canto, P. *et al.* A novel mutation of the insulin-like 3 gene in patients with
- 2033 cryptorchidism. *J Hum Genet* **48**, 86-90, doi:10.1007/s100380300012 (2003).
- 2034 293 Ivell, R., Wade, J. D. & Anand-Ivell, R. INSL3 as a biomarker of Leydig cell
- 2035 functionality. *Biol Reprod* **88**, 147, doi:10.1095/biolreprod.113.108969 (2013).
- 2036 294 Anand-Ivell, R. J. *et al.* Expression of the insulin-like peptide 3 (INSL3)
- 2037 hormone-receptor (LGR8) system in the testis. *Biol Reprod* **74**, 945-953,
- 2038 doi:10.1095/biolreprod.105.048165 (2006).
- 2039 295 Filonzi, M. *et al.* Relaxin family peptide receptors Rxfp1 and Rxfp2: mapping of
- 2040 the mRNA and protein distribution in the reproductive tract of the male rat. *Reprod Biol*
- 2041 *Endocrinol* **5**, 29, doi:10.1186/1477-7827-5-29 (2007).
- 2042 296 Gambineri, A. *et al.* Basal insulin-like factor 3 levels predict functional ovarian
- 2043 hyperandrogenism in the polycystic ovary syndrome. *J Endocrinol Invest* **34**, 685-691,
- 2044 doi:10.3275/7726 (2011).
- 2045 297 Ling Ma, W. X., Danyang Li, Lei Shi, Yanhong Mao, Yao Xiong, Yuanzhen Zhang,
- 2046 Ming Zhang. Effect of SARS-CoV-2 infection upon male gonadal function: A single
- 2047 center-based study. *medRxiv*, doi:10.1101/2020.03.21.20037267 (2020).
- 2048 298 Fernandez-Real, J. M. *et al.* Extracellular fatty acid synthase: a possible
- 2049 surrogate biomarker of insulin resistance. *Diabetes* **59**, 1506-1511, doi:10.2337/db09-
- 2050 1756 (2010).
- 2051 299 Granchi, C. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the
- 2052 crossroads of glucose and lipid metabolism. *Eur J Med Chem* **157**, 1276-1291,
- 2053 doi:10.1016/j.ejmech.2018.09.001 (2018).
- 2054 300 Pinkosky, S. L., Groot, P. H. E., Lalwani, N. D. & Steinberg, G. R. Targeting ATP-
- 2055 Citrate Lyase in Hyperlipidemia and Metabolic Disorders. *Trends Mol Med* **23**, 1047-1063,
- 2056 doi:10.1016/j.molmed.2017.09.001 (2017).
- 2057 301 Do, R., Kiss, R. S., Gaudet, D. & Engert, J. C. Squalene synthase: a critical enzyme
- 2058 in the cholesterol biosynthesis pathway. *Clin Genet* **75**, 19-29, doi:10.1111/j.1399-
- 2059 0004.2008.01099.x (2009).
- 2060 302 Belter, A. *et al.* Squalene monooxygenase - a target for hypercholesterolemic
- 2061 therapy. *Biol Chem* **392**, 1053-1075, doi:10.1515/BC.2011.195 (2011).
- 2062 303 Wei, X. *et al.* Hypolipidemia is associated with the severity of COVID-19. *J Clin*
- 2063 *Lipidol* **14**, 297-304, doi:10.1016/j.jacl.2020.04.008 (2020).
- 2064 304 Melnick, A. F. *et al.* RNF216 is essential for spermatogenesis and male
- 2065 fertilitydagger. *Biol Reprod* **100**, 1132-1134, doi:10.1093/biolre/ioz006 (2019).

Supple Info

2066 305 Morohoshi, A. *et al.* Nexin-Dynein regulatory complex component DRC7 but
2067 not FBXL13 is required for sperm flagellum formation and male fertility in mice. *PLoS*
2068 *Genet* **16**, e1008585, doi:10.1371/journal.pgen.1008585 (2020).
2069 306 Palty, R., Raveh, A., Kaminsky, I., Meller, R. & Reuveny, E. SARAF inactivates the
2070 store operated calcium entry machinery to prevent excess calcium refilling. *Cell* **149**, 425-
2071 438, doi:10.1016/j.cell.2012.01.055 (2012).
2072